Method for producing alkyl acetate compounds
By providing an enzyme with acetyltransferase activity to catalyze the production of alkyl acetate in an aqueous environment, the problem of difficult production of alkyl acetate in the prior art is solved, and high efficiency in the biosynthesis pathway is achieved Production and suitable reaction conditions.
Patent Information
- Application Number
- CN201980064843.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-15
- Filing Date
- 2019-10-14
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-10-14
AI Technical Summary
The prior art is difficult to effectively catalyze the production of alkyl acetate in aqueous environments, especially in biosynthesis pathways, and the acetylation reaction conditions are not suitable for the physiological environment.
Provides enzymes with acetyltransferase activity, using acetyl-CoA as an acetyl donor to produce alkyl acetate esters such as lepharole acetate or lepharole acetate, suitable for Perform in an aqueous environment.
The efficient production of alkyl acetate in an aqueous environment is achieved, providing easier-to-treat derivatives, simplifying the processing process of alkyl alcohols, and meeting physiological conditions.
Smart Images

Figure BDA0003001695420000141 
Figure BDA0003001695420000151 
Figure BDA0003001695420000251
Abstract
Description
Technical Field
[0001] The present invention provides novel methods for the in vitro or in vivo acetylation of a corresponding drimanyl alcohol source for the acetyltransferase-catalyzed production of drimanyl acetate compounds. The present invention also relates to the identification of enzymes having corresponding acetyltransferase activity from various microbial and plant sources. The present invention also relates to the provision of enzyme mutants derived from the newly identified enzymes. Another aspect of the present invention relates to the provision of corresponding coding sequences, recombinant vectors, and recombinant host cells for producing such enzymes and mutants, which are suitable for producing such acetyltransferases and mutants and for use in the novel methods for producing drimanyl acetate compounds. Another aspect of the present invention relates to the use of such drimanyl acetates obtained according to the present invention as intermediates for the production of odorants, flavorings, fragrances, or insect / pest control ingredients. Background Art
[0002] Terpenes are present in most organisms (microorganisms, animals and plants). These compounds are composed of five carbon units called isoprene units and are classified by the number of these units present in their structure. Therefore, monoterpenes, sesquiterpenes and diterpenes are terpenes containing 10, 15 and 20 carbon atoms respectively. For example, sesquiterpenes are widely present in the plant kingdom. Many sesquiterpenoid molecules are well known for their flavor and aromatic properties and their beauty, medical and antibacterial effects. Many sesquiterpenoid hydrocarbons and sesquiterpenoid compounds have been identified. Chemical synthesis routes have been developed, but are still very complicated and not always cost-effective.
[0003] The biosynthesis of terpenes involves enzymes called terpene synthases. There are multiple sesquiterpene synthases in the plant kingdom, all of which use the same substrate (farnesyl diphosphate, FPP) but have different product structures. Genes and cDNAs encoding sesquiterpene synthases have been cloned, and the corresponding recombinant enzymes have been characterized.
[0004] Sesquiterpenes are compounds with drimane structures, for example drimane alcohols, particularly many main sources of albicanol or drimenol are plants or microorganisms that naturally contain sesquiterpenes. However, the content of sesquiterpenes in these natural sources may be lower. Even if available, such drimane alcohols are difficult to handle during their further processing, mainly because they are solid at ambient temperature. Providing a derivative that is easier to handle would be an improved method and simplify the further processing of drimane alcohols.
[0005] Akita, H. et al., Tetrahedron: Asymmetry 11 (2000), 1375-1388, describe the lipase-catalyzed asymmetric synthesis of (+)-zolidine acetate. This prior art method requires at least eight chemical synthesis steps and two sequential reactions catalyzed by lipases to obtain enantiomerically pure zolidine acetate. In addition, the acetylation reaction occurs at 33°C in the presence of diisopropyl ether and isopropenyl acetate, conditions that are incompatible with the physiological conditions required for the biosynthetic pathway. Moreover, under physiological conditions, to the best of our knowledge, lipases are unable to catalyze the desired transesterification reaction. Although ester formation by lipases is possible, this activity is strongly dependent on the amount of water present. Therefore, in aqueous environments such as the in vivo environment of the present invention, lipases catalyze the hydrolysis of ester bonds rather than acetylation (Jaeger K. et al.; FEMS Microbiology Reviews, 1994, 15:1 pp29-63).
[0006] There remains a need to provide new methods for producing alkyl acetate compounds, particularly methods that can be used for the complete biochemical synthesis of alkyl acetates in an aqueous environment, such as in host cell-based processes that provide alkyl alcohol precursors through metabolism of sugar substrates. Summary of the Invention
[0007] The above problems can be solved by providing a new class of enzymes that exhibit acetyltransferase activity and produce hydroxyalkyl acetates, such as hydroxyalkyl acetate or drimenyl acetate, from corresponding hydroxyalkyl alcohol precursors (such as hydroxyalkyl alcohol or hydroxyalkyl alcohol) by acetylation using acetyl-CoA as an acetyl donor. Due to their physicochemical properties, in particular, because they are liquid at ambient temperature, acetylated derivatives of hydroxyalkyl alcohols can be used as more suitable materials. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1a : The structures of (+)-zheliol, (-)-buminol and bicyclic farnesol, and their comparison Figure 1c The structure of the thiazane is more specifically the thiazane portion.
[0009] Figure 1b : Reaction scheme illustrating the cell biological production of fennel acetate via the acyclic sesquiterpene precursor FPP and fennel alcohol.
[0010] Figure 1c : A more generalized "ammonium structure" with the potential position of the C=C-double bond indicated.
[0011] Figure 2(A / B) GC-FID analysis of zygomycetin acetate produced using a modified Saccharomyces cerevisiae strain YST069 that co-expresses zygomycetin synthase XP_007369631.1 with either the acetyltransferase CrDAT (A) or the acetyltransferase FgaAT (B). The MS spectrum of zygomycetin acetate produced by the acetyltransferase CrDAT in (A) is shown in (C) and is identical to the MS spectrum of a zygomycetin acetate standard.
[0012] Figure 3 : Relative amounts of zygomycetin acetate produced by nine acetyltransferases (CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6 and CfACT1-8) found to be active on zygomycetin (as described in Example 2).
[0013] Figure 4 : Relative amounts of fenvalerate acetate produced by nine acetyltransferases (CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6 and CfACT1-8) found to be active on fennel (as described in Example 2).
[0014] Figure 5 : Relative amounts of zeyl acetate produced by Saccharomyces cerevisiae cells expressing each of the following acetyltransferases: CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6, CfACT1-8, ERR364415-1_contig_8546, and DfATC13.
[0015] Figure 6 : Relative amounts of thiazolyl acetate produced by Saccharomyces cerevisiae cells expressing each of the following acetyltransferases: CrDAT, FgaAT, OAH94415.1, TcTAT, GAO81666.1, CfACT1-6, CfACT1-8, XP_001258079.1, ERR364415-1_contig_8546, and DfATC13.
[0016] Figure 7 : The MS spectrum of fenvalerate acetate produced by the acetyltransferase CrDAT is shown in (A), which is the same as the MS spectrum from the fenvalerate acetate standard shown in (B).
[0017] Figure 8: The MS spectrum of bicyclic farnesyl acetate produced by acetyltransferase CrDAT is shown in (A), which is identical to the MS spectrum from a bicyclic farnesyl acetate standard (B).
[0018] Figure 9 : Relative amounts of bicyclofarnesyl acetate produced by Saccharomyces cerevisiae cells expressing each of the following acetyltransferases: CrDAT, FgaAT, TcTAT, CrMAT, GAO81666.1, CfACT1-6, CfACT1-8, BAU61551.1, PsSalAT, XP_001217250.1, ERR364415-1_contig_8546, PYI04555.1, and DfACT13. DETAILED DESCRIPTION
[0019] Abbreviations used
[0020] bp base pair
[0021] kb kilobase
[0022] CoA Coenzyme A
[0023] DNA deoxyribonucleic acid
[0024] cDNA complementary DNA
[0025] DTT dithiothreitol
[0026] FPP farnesyl diphosphate
[0027] GC gas chromatography
[0028] MS Mass Spectrometer / Mass Spectrometry
[0029] MVA mevalonic acid
[0030] PCR polymerase chain reaction
[0031] RNA ribonucleic acid
[0032] mRNA messenger ribonucleic acid
[0033] miRNA
[0034] siRNA Small interfering RNA
[0035] rRNA ribosomal RNA
[0036] tRNA transfer RNA
[0037] definition
[0038] Unless otherwise stated, the following definitions of technical terms apply:
[0039] For the purposes of this application, "acetyltransferase" or "polypeptide having acetyltransferase activity" or "polypeptide capable of transferring an acetyl group" refers more generally to an enzyme of the class of acyltransferases EC 2.3.1, in particular, acetyl-CoA:alcohol O-acetyltransferase EC 2.3.1.84. It exhibits the ability to acetylate at least one thiazolinol selected from thiazolinol, thiazolinol, and bicyclofarnesyl alcohol using acetyl-CoA as an acetyl donor. The thiazolinol acetate can be produced in the form of any stereoisomer or as a mixture thereof. If the corresponding alcohol precursor is present as a single acetyl acceptor, thiazolinol, thiazolinol, or bicyclofarnesyl acetate may be the sole product, or, if a mixture of two or more thiazolinols is provided and the acetyltransferase is not substrate-specific, may be part of a mixture of two or more thiazolinol acetates. In cases of increased selectivity, the acetyltransferase may predominantly form a single thiazolinol acetate. As described herein, acetyltransferases can exhibit the same or different preferences or specificities for different sulphanols as substrates. For example, a first type of acetyltransferase may primarily acetylize sulphanol, a second type of acetyltransferase may primarily acetylize sulphanol, and a third type of acetyltransferase may primarily acetylize bicyclic farnesol. In this case, if a mixture of such sulphanols is used as a substrate, sulphanol acetate, sulphanol acetate, or bicyclic farnesyl acetate will be formed. In the case of substrate specificity, the acetyltransferase can selectively form a single sulphanol acetate, even if a mixture of such sulphanols is used as a substrate. In particular, the acetylation is carried out while retaining the corresponding stereochemical configuration of the sulphanol substrate.
[0040] "Acetyl donor" refers to a chemical entity or molecule that serves as a source of an acetyl group to be enzymatically transferred from the donor to an acceptor molecule, such as a molecule having a functional hydroxyl group that can then react with the acetyl group to form the corresponding acetate. One specific acetyl donor is acetyl-coenzyme A (acetyl-CoA).
[0041] The term "tebucone sesquiterpenes" or "tebucone" refers to terpenes having Figure 1a The cyclic terpenes having the thiamidine-like carbon skeleton structure shown, or more specifically, Figure 1c The higher order structure of Λ / ...
[0042] The term "buminanol" refers to a hydroxylated derivative of a "buminane sesquiterpene" or "buminane." Examples are zephyranthenol, zephyranthenol, and bicyclic farnesol in any stereoisomeric form.
[0043] The term "aminoalkyl acetate" refers to acetyl ester derivatives of such aminoalkyl acetates, such as fenvalerate acetate, fenvalerate acetate and bicyclofarnesyl acetate.
[0044] For the purposes of the present application, "ellipticol" relates in particular to (+)-ellipticol (CAS: 54632-04-1).
[0045] For the purposes of the present application, "buminol" relates in particular to (-)-buminol (CAS: 468-68-8).
[0046] For the purposes of the present application, "bicyclic farnesol" relates in particular to (+)-bicyclic farnesol or [(4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydro-1-naphthyl]methanol (IUPAC name
[0047] "Farnesyl diphosphate" refers to (2E,6E)-3,7,11-trimethyldodeca-2,6,10-triene-1-pyrophosphate (FPP).
[0048] For the purposes of this application, "Ambrox" relates to the IUPAC name: (-)-(3aR,5aS,9aS,9bR)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan (CAS: 6790-58-5).
[0049] The terms "terpene synthase" or "sesquiterpene synthase" or "tetramethylene sesquiterpene synthase" are used interchangeably herein.
[0050] The term "bifunctional terpene synthase" or "polypeptide having bifunctional terpene synthase activity" relates to a polypeptide as further defined in PCT / EP2018 / 064344 filed on May 31, 2018.
[0051] The term "farnesyl diphosphate synthase" or "polypeptide having terpenyl diphosphate synthase activity" or "terpenyl diphosphate synthase protein" or "having the ability to produce terpenyl diphosphate" relates to a polypeptide that is capable of catalyzing the synthesis of terpenyl diphosphate in the form of any stereoisomer or a mixture thereof starting from an acyclic terpene pyrophosphate, in particular farnesyl diphosphate (FPP). Terpenyl diphosphate may be the sole product or may be part of a mixture of sesquiterpenes. The mixture may comprise terpenyl monophosphate and / or terpenol. Such polypeptides are described, for example, in PCT / CN2018 / 088902 filed on May 29, 2018.
[0052] As described in PCT / CN2018 / 088902, "Cyclodextrin-1-phosphate synthase activity" was determined under "standard conditions".
[0053] The term "zhaochol synthase" or "polypeptide having zhaochol synthase activity" or "zhaochol synthase protein" refers to a polypeptide that is capable of catalyzing the synthesis of zhaochol in the form of any stereoisomer or a mixture thereof starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP). Zhaochol may be the sole product or may be part of a mixture of two or more sesquiterpenes.
[0054] The term "buminol synthase" or "polypeptide having buminol synthase activity" or "buminol synthase protein" refers to a polypeptide that is capable of catalyzing the synthesis of buminol in the form of any stereoisomer or a mixture thereof starting from an acyclic terpene pyrophosphate, particularly farnesyl diphosphate (FPP). Buminol may be the sole product or may be part of a mixture of two or more sesquiterpenes.
[0055] “Zhimenol synthase activity” and bumitol synthase activity are determined as described, for example, in PCT / EP2018 / 064344, WO 2015 / 169871 or WO 2015 / 176959.
[0056] The enzyme "phosphatase" as used in the present invention has the ability to convert orthophosphate into the corresponding alcohol and orthophosphate radical under the condition of consuming water. It includes acid phosphatase (EC.3.1.3.2 with optimal acidic reaction) and alkaline phosphatase (EC.3.1.3.1 with optimal alkaline reaction).
[0057] The terms "biological function", "function", "biological activity" or "activity" refer to the ability of a terpene synthase as described herein to: a) catalyze the formation of hydrazine diphosphate and / or hydrazine alcohol, or a mixture of compounds comprising hydrazine diphosphate, and / or hydrazine monophosphate and / or hydrazine alcohol and / or one or more other terpenes, in particular hydrazine diphosphate; or b) catalyze the formation of salalkyl alcohol or a mixture of two or more salalkyl alcohols and optionally one or more other terpenes.
[0058] The terms "biological function," "function," "biological activity," or "activity" refer to the ability of an acetyltransferase as described herein to catalyze the formation of an aminoalkyl acetate or a mixture of two or more aminoalkyl acetates and optionally one or more other acetylated compounds.
[0059] The term "mixture of terpenes" or "mixture of sesquiterpenes" refers to a mixture of terpenes or sesquiterpenes comprising at least one of ziziphiol, bucatinol and bicyclic farnesol, and may further comprise one or more additional terpenes and / or one or more additional sesquiterpenes.
[0060] The "mevalonate pathway," also known as the "isoprene pathway" or "HMG-CoA reductase pathway," is an essential metabolic pathway in eukaryotes, archaea, and some bacteria. The mevalonate pathway begins with acetyl-CoA and produces two five-carbon building blocks, called isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). The key enzymes are acetoacetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase, and isopentenyl pyrophosphate isomerase. Combining the mevalonate pathway with enzyme activities to produce the terpene precursors GPP, FPP, or GGPP, particularly FPP synthase, allows recombinant cells to produce terpenes.
[0061] As used herein, the term "host cell" or "transformed cell" refers to a cell (or organism) that has been modified to harbor at least one nucleic acid molecule, for example, a recombinant gene encoding a desired protein or nucleic acid sequence, which, when transcribed, produces at least one functional polypeptide of the present invention required for performing the biocatalytic method or other recombinant method described herein. In particular, such host cells or transformed cells provide an acetyltransferase that can be used to prepare at least one benzoyl acetate from the corresponding benzoyl alcohol. They can also provide other enzymes, such as benzoyl diphosphate synthase proteins, which can be used to produce benzoyl diphosphate and / or benzoyl monophosphate and / or benzoyl alcohol, or a corresponding mixture of terpenes containing benzoyl diphosphate and / or benzoyl monophosphate and / or benzoyl alcohol. They can also provide a terpene synthase for preparing at least one benzoyl alcohol. The host cell is in particular a bacterial cell, a fungal cell or a plant cell or plant. The host cell may contain a recombinant gene that has been integrated into the nuclear or organelle genome of the host cell. Alternatively, the host may contain the recombinant gene extrachromosomally.
[0062] The term "organism" refers to any non-human multicellular or unicellular organism, such as a plant or a microorganism. In particular, the microorganism is a bacterium, yeast, algae or fungus.
[0063] The term "plant" is used interchangeably to include plant cells, including plant protoplasts, plant tissues, plant cell tissue cultures to produce regenerated plants or plant parts, or plant organs such as roots, stems, leaves, flowers, pollen, ovules, embryos, fruits, etc. Any plant can be used to practice the methods of the embodiments herein.
[0064] "Capable of producing FPP" is meant when a particular organism or cell naturally produces FPP or when it does not naturally produce FPP but is transformed with a nucleic acid as described herein to produce FPP. Organisms or cells that have been transformed to produce higher amounts of FPP than naturally occurring organisms or cells are also encompassed as "organisms or cells capable of producing FPP."
[0065] "Capable of producing amyl acetate" is meant when a particular organism or cell naturally produces amyl acetate or when it does not naturally produce amyl acetate but is transformed with the nucleic acids described herein to produce amyl acetate. Organisms or cells that have been transformed to produce amyl acetate in higher amounts than naturally occurring organisms or cells are also encompassed as "organisms or cells capable of producing amyl acetate."
[0066] "Capable of producing bumilk alcohol" is meant when a particular organism or cell naturally produces bumilk alcohol or when it does not naturally produce bumilk alcohol but is transformed to produce bumilk diphosphate and, if necessary, further transformed with a nucleic acid to produce an enzyme activity that converts bumilk diphosphate to bumilk alcohol. Organisms or cells that have been transformed to produce higher amounts of bumilk alcohol than naturally occurring organisms or cells are also encompassed as "organisms or cells capable of producing bumilk alcohol."
[0067] For purposes of this specification and the appended claims, the use of "or" means "and / or" unless stated otherwise. Similarly, the various tenses of "including," "comprising," "comprising," and "comprising" are interchangeable and not limiting.
[0068] It should be further understood that while the term "comprising" is used in the description of various embodiments, those skilled in the art will understand that in some specific cases, the language "consisting essentially of" or "consisting of" may be used alternatively to describe the embodiment.
[0069] As used herein, the terms "purified," "substantially purified," and "isolated" refer to a state free from other, different compounds with which the compounds of the invention are normally associated in their natural state, such that "purified," "substantially purified," and "isolated" articles comprise at least 0.5%, 1%, 5%, 10%, or 20%, or at least 50% or 75%, by weight of a given sample. In one embodiment, these terms refer to at least 95%, 96%, 97%, 98%, 99%, or 100% by weight of a compound of the invention. As used herein, when referring to nucleic acids or proteins, the terms "purified," "substantially purified," and "isolated" of nucleic acids or proteins also refer to a purified or concentrated state that is different from the state in which they naturally exist, for example, in a prokaryotic or eukaryotic environment, such as in bacterial or fungal cells, or in mammals, particularly humans. Any degree of purification or concentration greater than that found in nature, including (1) purification from other related structures or compounds, or (2) association with structures or compounds with which they are not normally associated in the prokaryotic or eukaryotic environment, is within the meaning of "isolated." The nucleic acids, proteins, or classes of nucleic acids or proteins described herein can be isolated or otherwise associated with structures or compounds with which they are not normally associated in nature according to various methods and procedures known to those skilled in the art.
[0070] The term "about" indicates a possible variation of ±25%, in particular ±15%, ±10%, more in particular ±5%, ±2% or ±1% of the stated value.
[0071] The term "substantially" describes a value range of about 80 to 100%, such as 85 to 99.9%, particularly 90 to 99.9%, more particularly 95 to 99.9%, or 98 to 99.9%, especially 99 to 99.9%.
[0072] “Predominantly” means a proportion in the range of greater than 50%, for example in the range of 51% to 100%, in particular in the range of 75% to 99.9%; especially 85 to 98.5%, for example 95 to 99%.
[0073] In the context of the present invention, "primary product" means a single compound or a group of at least two compounds, for example two, three, four, five or more, in particular two or three compounds, which is "primarily" produced by the reaction described herein and is contained in the reaction in a major proportion based on the total amount of the components of the products formed by the reaction. The proportion can be a molar ratio, a weight ratio or, preferably, an area ratio calculated from the corresponding chromatogram of the reaction products based on chromatographic analysis.
[0074] In the context of the present invention, "by-product" means a single compound or a group of at least two compounds, such as 2, 3, 4, 5 or more, in particular 2 or 3 compounds, which single compound or group of compounds is not "primarily" prepared by the reaction described herein.
[0075] Due to the reversible nature of enzymatic reactions, unless otherwise stated, the present invention relates to the enzymatic or biocatalytic reactions described herein in both reaction directions.
[0076] "Functional mutants" of the polypeptides described herein include "functional equivalents" of such polypeptides as defined below.
[0077] The term "stereoisomer" specifically includes conformational isomers.
[0078] The present invention generally encompasses all "stereoisomeric forms" of the compounds described herein, such as structural isomers, in particular stereoisomers, and mixtures thereof, such as optical isomers or geometric isomers, such as E and Z isomers, and combinations thereof. If several asymmetric centers are present in a molecule, the present invention encompasses all combinations of different conformations of these asymmetric centers, such as enantiomeric pairs.
[0079] "Stereoselectivity" describes the ability to produce a specific stereoisomer of a compound in stereomerically pure form or the ability to specifically convert a specific stereoisomer from multiple stereoisomers using the enzymatic methods described herein. More specifically, this means that the product of the invention is enriched with respect to a specific stereoisomer, or that the educt is depleted with respect to a specific stereoisomer. This can be quantified by the purity parameter, %ee, calculated according to the following formula:
[0080] %ee=[X A -X B ] / [X A +X B ]*100,
[0081] where X A and X B represents the molar ratio of stereoisomers A and B (Molenbruch).
[0082] The term "selectively convert" or "increase selectivity" generally means that during the entire course of the reaction (i.e., between the start and end of the reaction), at a certain point in time in the reaction, or during a "period" of the reaction, a specific stereoisomeric form, such as the E-form of an unsaturated hydrocarbon, is converted in a higher proportion or amount (compared on a molar basis) than the corresponding other stereoisomeric forms, such as the Z-form. In particular, the selectivity can be observed during a "period" corresponding to a conversion rate of 1 to 99%, 2 to 95%, 3 to 90%, 5 to 85%, 10 to 80%, 15 to 75%, 20 to 70%, 25 to 65%, 30 to 60%, or 40 to 50% of the initial amount of substrate. The higher proportion or amount can be expressed, for example, in the following manner:
[0083] - a higher maximum isomer yield observed during the entire reaction process or during said portion thereof;
[0084] - a higher relative content of an isomer at a determined percentage substrate conversion value; and / or
[0085] - The same relative content of isomers at higher percentage conversion values;
[0086] Each of these is preferably viewed relative to a reference method performed under otherwise identical conditions using a known chemical or biochemical method.
[0087] The present invention generally encompasses all "isomeric forms" of the compounds described herein, such as structural isomers, especially stereoisomers, and mixtures thereof, such as optical isomers or geometric isomers, such as E and Z isomers, and combinations thereof. If several asymmetric centers are present in a molecule, the present invention encompasses all combinations of different conformations of these asymmetric centers, such as enantiomeric pairs, or any mixture of stereoisomeric forms.
[0088] The "yield" and / or "conversion" of the reaction according to the invention is determined over a defined period of time, for example 4, 6, 8, 10, 12, 16, 20, 24, 36 or 48 hours, during which the reaction is carried out. In particular, the reaction is carried out under precisely defined conditions, for example "standard conditions" as defined herein.
[0089] The different yield parameters ("yield" or YP / S; "specific productivity yield"; or space-time yield (STY)) are well known in the art and are determined as described in the literature.
[0090] "Yield" and "YP / S" (both expressed as mass of product produced / mass of material consumed) are used as synonyms herein.
[0091] The specific productivity yield describes the amount of product produced per gram of biomass per liter of fermentation broth per hour. The wet cell weight expressed as WCW describes the number of biologically active microorganisms in the biochemical reaction. This value is given as g of product per g WCW per hour (i.e. g / g WCW). -1 h -1 Alternatively, the amount of biomass can also be expressed as the amount of dry cell weight, expressed as DCW. In addition, by measuring the 600nm (OD 600 ) and using experimentally determined correlation factors to estimate the corresponding wet or dry cell weights, respectively, can more easily determine biomass concentration.
[0092] The terms "fermentative production" or "fermentation" refer to the ability of a microorganism (aided by enzyme activities contained in or produced by the microorganism) to produce a compound in a cell culture using at least one carbon source added to the incubation.
[0093] The term "fermentation broth" is understood to mean a liquid, in particular an aqueous solution or an aqueous / organic solution, which is based on a fermentation process and which has been subjected to or has been subjected to a work-up such as described herein.
[0094] "Enzymatic" or "biocatalytic" methods are methods that are performed under the catalytic action of an enzyme (including enzyme mutants as defined herein). Thus, the method can be performed in the presence of the enzyme in isolated (purified, enriched) or crude form, or in the presence of a cell system, in particular a natural or recombinant microbial cell comprising the enzyme in active form and having the ability to catalyze the transformation reaction as disclosed herein.
[0095] If the present disclosure relates to features, parameters and ranges thereof with varying degrees of preference (including generic, non-explicitly preferred features, parameters and ranges thereof), then, unless otherwise stated, any combination of two or more of these features, parameters and ranges is encompassed within the disclosure of the present invention regardless of their respective degrees of preference.
[0096] Detailed description
[0097] a. Specific Embodiments of the Invention
[0098] 1. A biocatalytic process for producing at least one, in particular one, two or three, in particular one or two, aminoalkyl acetate compounds,
[0099] The following steps are involved:
[0100] (1) contacting at least one, in particular one, thiazolyl alcohol in stereoisomerically pure form or in the form of a mixture of stereoisomers with at least one, in particular one, polypeptide having an acetyltransferase activity capable of transferring an acetyl group from said acetyl donor to said at least one, in particular one, thiazolyl alcohol in the presence of an acetyl donor, thereby obtaining at least one, in particular one, thiazolyl acetate as the main product; and
[0101] (2) Optionally, the at least one, particularly one, ammonium alkyl acetate compound is separated from the reaction product of step (1).
[0102] If more than one alkyl acetate is formed, the mixture can be further separated and the individual acetates can be purified.
[0103] 2. The method according to embodiment 1, wherein the alkyl acetate compound is selected from the group consisting of fennel acetate, fennel acetate, and bicyclofarnesyl acetate, each of which is in stereoisomerically pure form or as a mixture of at least two of its stereoisomers, or a combination thereof comprising at least two members of said group. In a particular embodiment, only one alkyl alcohol is used as a substrate, and only one alkyl acetate is obtained in stereoisomerically pure form or as a mixture of at least two of its stereoisomers, in particular as a product in stereoisomerically pure form.
[0104] 3. The method according to embodiment 1 or 2, wherein the busanalkyl alcohol is selected from the group consisting of zirconia, in particular (+)-zirconia, busanol, in particular (-)-busanol, and bicyclic farnesol, in particular (+)-bicyclic farnesol, each in stereoisomerically pure form or as a mixture of at least two of its stereoisomers, or a combination thereof comprising at least two members of said group. In a particular embodiment, only one busanalkyl alcohol, in particular in stereoisomerically pure form, is used as the substrate.
[0105] 4. The method according to any one of the preceding embodiments, wherein the acetyl donor is acetyl-CoA (acetyl-CoA). The donor can be added exogenously to the reaction mixture, such as in an in vitro process using an isolated, enriched or purified enzyme, or more specifically, endogenously present, such as in an in vivo process using a host cell system that produces the acetyl-CoA system as a metabolite and expresses the desired polypeptide or polypeptides to carry out the desired acetylation or a more complex multi-step process that includes the acetylation as a step.
[0106] 5. The method according to any one of the preceding embodiments, wherein the acetyltransferase is selected from the group consisting of:
[0107] a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 118, 121, 124, 127, 130, 133, 136, 143 and 144, and
[0108] b) a polypeptide having acetyltransferase activity and comprising an amino acid sequence that exhibits at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to at least one of the amino acid sequences of SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 118, 121, 124, 127, 130, 133, 136, 143, and 144.
[0109] The following list illustrates the ability of specific acetyltransferases of the present invention to produce one or more alkyl acetate compounds selected from the group consisting of fenvalerate acetate, fenvalerate acetate, and bicyclofarnesyl acetate:
[0110]
[0111]
[0112] 6. The method according to any one of the preceding embodiments, further comprising, before step 1), the biocatalytic formation of the at least one, in particular one, amyl alcohol compound.
[0113] 7. A method according to embodiment 6, wherein the bupropionate compound can be present endogenously in the reaction mixture, for example in an in vivo process using a host cell system that produces the bupropionate compound as a metabolite and expresses the desired polypeptide(s) for carrying out the synthesis of the desired bupropionate or a more complex multi-step process that includes the synthesis of the bupropionate as a step, whereby the bupropionate is enzymatically synthesized from an acyclic sesquiterpene precursor.
[0114] Alternatively, the alkylol compound is produced chemically or enzymatically and added exogenously to the reaction mixture, for example in an in vitro process using an isolated, enriched or purified synthase as defined below required for its formation.
[0115] 8. The method of embodiment 7, wherein the acyclic sesquiterpene precursor is farnesyl pyrophosphate (FPP).
[0116] 9. The method according to any one of embodiments 7 to 8, wherein the enzymatic synthesis of the bupropion is catalyzed by one or more polypeptides having the ability to convert the acyclic sesquiterpene precursor into at least one bupropion, particularly one bupropion, particularly as the main product, in one or more enzymatic steps.
[0117] 10. The method according to any one of embodiments 6 to 9, wherein the at least one alkyl alcohol is produced from FPP in a single or multiple, in particular two, enzymatic steps.
[0118] 11. The method according to embodiment 10, wherein the at least one alkyl alcohol is produced by enzymatic conversion of FPP catalyzed by:
[0119] a) a polypeptide having a sesquiterpene synthase activity for forming the sesquiterpene alcohol (single-step biosynthesis); or
[0120] b) forming a combination of a polypeptide having thiamin phosphate synthase activity having at least one thiamin phosphate intermediate and a polypeptide having phosphatase activity converting the at least one thiamin phosphate (monophosphate and / or diphosphate) intermediate into at least one thiamin alcohol (two-step biosynthesis).
[0121] 12. The method according to embodiment 11, wherein
[0122] a) the polypeptide having tamipane sesquiterpene synthase activity is selected from polypeptides having tamipane synthase activity, tamipane synthase activity, bicyclofarnesol synthase activity or any combination of these activities, and the polypeptide particularly preferentially exhibits one of the activities, more particularly, specifically exhibits one of the activities; and
[0123] b) The combination of polypeptides comprises an alkyl diphosphate synthase activity, in particular a pyrrolidone diphosphate synthase activity, and a phosphatase, such as a bacterial alkaline phosphatase.
[0124] 13. The method according to embodiment 12, wherein
[0125] a) the polypeptide having bisulphane sesquiterpene synthase activity is selected from the group consisting of bisulphane synthase as described in PCT / EP2018 / 064344 (filed on May 31, 2018) and bisulphanol synthase as described in published WO 2015 / 169871 and WO 2015 / 176959;
[0126] b) The polypeptide having alkyl phosphate synthase activity is the phenylalanine diphosphate synthase described in PCT / CN2018 / 088902 filed on May 29, 2018, comprising the ability to produce phenylalanine phosphate derivatives such as monophosphates, more particularly phenylalanine diphosphate, from farnesyl diphosphate (FPP) as a substrate.
[0127] As described in PCT / CN2018 / 088902 (filed May 29, 2018), the pyrrolidone diphosphate synthase is:
[0128] DfHAD, DfHAD-9(V274A), DfHAD-His_GST, and DfHAD-8(K532R) from Dryopteris fragrans
[0129] and polypeptides derived therefrom having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
[0130] As described in PCT / EP2018 / 064344 (filed on May 31, 2018), the pyrrolidine synthase (i.e., pyrrolidine synthase or pyrrolidine synthase) is
[0131] Name or NCBI accession number source product CvTps1 Cryptoporus volvatus Fennel LoTps1 Laricifomes officinalis Fennel OCH93767.1 White rot fungus (Obba rivulosa) Fennel EMD37666.1 Gelatoporia subvermispora Fennel EMD37666-B Gelatoporia subvermispora Fennel XP_001217376.1 Aspergillus terreus Fennel OJJ98394.1 Aspergillus aculeatus Fennel GAO87501.1 Aspergillus udagawae Fennel XP_008034151.1 Trametes versicolor Fennel XP_007369631.1 Dichomitus squalens Fennel ACg006372 Antrodia cinnamomea Fennel KIA75676.1 Aspergillus ustus Bu Shen Chun XP_001820867.2 Aspergillus oryzae Bu Shen Chun CEN60542.1 Aspergillus calidoustus Bu Shen Chun XP_009547469.1 Heterobasidion irregulare Bu Shen Chun KLO09124.1 Schizopora paradoxa Bu Shen Chun OJI95797.1 Aspergillus versicolor Bu Shen Chun XP_006461126 Agaricus bisporus Bu Shen Chun
[0132] and polypeptides derived therefrom having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
[0133] As described in WO2015 / 169871, the acetaminophen synthase is
[0134] name source DlTps589 Pepperberry (Drimys lanceolota) SCH51_3228_11 Drimys winteri SCH51_3228_9 Drimys winteri SCH51_998_28 Drimys winteri SCH52_13163_6 Pepperberry (Drimys lanceolota)
[0135] and polypeptides derived therefrom having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
[0136] As described in WO 2015 / 176959, the acetaminophen synthase is
[0137] VaTPS3 from Blackwater Valerian (Valeriana amurensis)
[0138] and polypeptides derived therefrom having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
[0139] The SEQ ID NOs for the amino acid and nucleotide sequences of the above-mentioned synthases are listed at the end of this specification. These polypeptides and nucleic acids, as well as polypeptides and nucleic acids derived therefrom that have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to at least one of these sequences, are also part of the present disclosure.
[0140] 14. The method according to embodiment 13, wherein the sesquiterpene synthase is selected from the group consisting of:
[0141] a) a polypeptide having (bifunctional) zirconia synthase activity and comprising the amino acid sequence of SEQ ID NO: 5, or a mutant or variant polypeptide having zirconia synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 5 described in PCT / EP2018 / 064344;
[0142] b) a polypeptide having (bifunctional) bupropion synthase activity and comprising the amino acid sequence of SEQ ID NO: 7, or a mutant or variant polypeptide having bupropion synthase activity and comprising an amino acid sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 7 described in PCT / EP2018 / 064344.
[0143] 15. The method according to any one of the preceding embodiments, which is performed in vivo in a host cell culture or in vitro in a liquid reaction medium comprising a host cell lysate or enriched or isolated polypeptide desired for the production of at least one aminoalkyl acetate, each under conditions favorable for the production of at least one aminoalkyl acetate.
[0144] In particular, the reaction is carried out in the presence of endogenously formed or exogenously added acetyl-CoA as an acetyl donor. In particular, the reaction is carried out in the presence of endogenously formed or exogenously added FPP. Endogenously formed FPP is particularly the result of the metabolism of at least one carbon source, such as a sugar substrate, that is bioconverted to FPP. In vivo methods are particularly interesting in cells where FPP and acetyl-CoA are endogenously formed.
[0145] Some of these host cells or organisms do not naturally produce FPP. To be suitable for practicing the methods of the embodiments described herein, organisms or cells that do not naturally produce acyclic terpene pyrophosphate precursors, such as FPP, are genetically modified to produce the precursor. For example, they can be so transformed prior to or concurrently with modification with a nucleic acid according to any of the above embodiments. Methods for transforming organisms to produce acyclic terpene pyrophosphate precursors, such as FPP, are known in the art. For example, introducing enzyme activity from the mevalonate pathway is a suitable strategy for causing an organism to produce FPP.
[0146] 16. The method of embodiment 15, which is performed in a recombinant host cell or a recombinant non-human host organism capable of functionally expressing:
[0147] a) at least one acetyltransferase as defined in embodiment 5; optionally
[0148] b) at least one polypeptide having the ability to convert the acyclic sesquiterpene precursor FPP into at least one alkyl alcohol as defined in any one of embodiments 9 to 14; and optionally
[0149] c) at least one enzyme selected from the group consisting of enzymes of the mevalonate pathway as defined above.
[0150] In a particular embodiment, enzymes a) and b) or enzymes a), b) and c) are functionally expressed by the cell system used in the in vivo method of the invention.
[0151] 17. The method of embodiment 16, wherein the non-human host cell or host organism is selected from a prokaryotic or eukaryotic microorganism, or a cell derived therefrom.
[0152] 18. The method of embodiment 17, wherein the non-human host cell or host organism is selected from bacteria, fungi, and plant cells or plants.
[0153] 19. The method according to embodiment 18, wherein the fungal cell is a yeast cell, in particular selected from the genera Saccharomyces, Pichia or Yarrowia, in particular selected from the species Saccharomyces cerevisiae, Pichia pastoris or Yarrowia lipolytica.
[0154] 20. The method according to embodiment 18, wherein the bacterial cell is selected from the genera Rhodococcus, Pseudomonas, Bacillus or Escherichia, in particular E. coli species.
[0155] 21. The method according to any one of the preceding embodiments, further comprising, as step (3), treating the at least one alkyl acetate of step (1) or step (2) using chemical or biocatalytic synthesis or a combination of both to obtain a derivative.
[0156] 22. The method of embodiment 21, wherein the derivative is a hydrocarbon, alcohol, diol, triol, acetal, ketal, aldehyde, acid, ether, amide, ketone, lactone, epoxide, acetate, glycoside, ester and / or polycyclic compound.
[0157] 23. The process according to any one of the preceding embodiments, wherein the alkyl acetate comprises zephyryl acetate, zephyryl acetate or bicyclofarnesyl acetate, in particular zephyryl acetate or zephyryl acetate, as the main alkyl alcohol product or in particular as the sole alkyl alcohol product.
[0158] 24. The method according to any one of the preceding embodiments, comprising providing the non-human host organism or host cell with:
[0159] a) at least one nucleic acid, expression construct or vector comprising a nucleic acid sequence encoding at least one polypeptide having acetyltransferase activity, which polypeptide is capable of transferring an acetyl group from an acetyl donor to an alkyl alcohol, optionally stably integrated into the genome; optionally
[0160] b) at least one nucleic acid, expression construct or vector comprising a nucleic acid sequence encoding at least one polypeptide having salsaquinol synthase activity capable of producing salsaquinol from an acyclic sesquiterpene precursor, optionally stably integrated into the genome; and optionally
[0161] c) at least one nucleic acid, expression construct or vector comprising a nucleic acid sequence encoding at least one polypeptide involved in a biosynthetic pathway for the production of said acyclic sesquiterpene precursor, optionally stably integrated into the genome.
[0162] In a specific embodiment, the non-human host organism or host cell is transformed with a) and b) or a), b) and c), and more particularly comprises said nucleic acid stably integrated into the genome. The nucleic acids a), b) and / or c) may be located on the same or on two or more different vectors.
[0163] 25. A polypeptide having acetyltransferase activity capable of transferring an acetyl group from an acetyl donor to an alkyl alcohol to produce an alkyl acetate, comprising an amino acid sequence having 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to less than 100% sequence identity to at least one amino acid sequence selected from SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 118, 121, 124, 127, 130, 133, 136, 143 and 144.
[0164] 26. An isolated nucleic acid molecule,
[0165] a) comprising a nucleotide sequence encoding the polypeptide of embodiment 5; or
[0166] b) comprising a nucleotide sequence having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% and less than 100% sequence identity to a nucleotide sequence selected from SEQ ID NO: 8, 10, 12, 14, 16, 16, 18, 20, 22, 24, 116, 117, 119, 120, 122, 123, 125, 126, 128, 129, 131, 132, 134 and 135; or
[0167] c) comprises a nucleotide sequence comprising a sequence complementary to one of sequences a) or b); or
[0168] d) comprises a nucleotide sequence that hybridizes to the nucleotide sequence a), b) or c) under stringent conditions.
[0169] 27. An expression construct comprising at least one nucleic acid molecule according to embodiment 26.
[0170] 28. A vector comprising at least one nucleic acid molecule according to embodiment 25 or at least one expression construct according to embodiment 26.
[0171] 29. The vector according to embodiment 28, wherein the vector is a prokaryotic, viral or eukaryotic vector.
[0172] 30. The vector according to embodiment 28 or 29, wherein the vector is an expression vector.
[0173] 31. The vector of any one of embodiments 28 to 30, which is a plasmid vector.
[0174] 32. A recombinant host cell or recombinant non-human host organism comprising:
[0175] a) at least one isolated nucleic acid molecule according to embodiment 26, which is optionally stably integrated into the genome; or
[0176] b) at least one expression construct according to embodiment 27, which is optionally stably integrated into the genome; or
[0177] c) at least one vector according to any one of embodiments 28 to 31.
[0178] In a particular embodiment, the non-human host organism or host cell is transformed with a) and b) or a), b) and c), and more particularly comprises said nucleic acid stably integrated into the genome.
[0179] 33. The host cell or host organism of embodiment 32, which is selected from a prokaryotic or eukaryotic microorganism, or a cell derived therefrom.
[0180] 34. The host cell or host organism of embodiment 33, which is selected from bacteria, fungi, and plant cells or plants.
[0181] 35. The host cell or host organism of embodiment 34, wherein the fungal cell is a yeast cell.
[0182] 36. The host cell or host organism according to embodiment 35, wherein the bacterial cell is selected from the genus Escherichia, in particular the species E. coli, and the yeast cell is selected from the genera Saccharomyces, Pichia or Yarrowia, in particular from the species Saccharomyces cerevisiae, Pichia pastoris or Yarrowia lipolytica.
[0183] 37. A method for producing at least one catalytically active polypeptide according to embodiment 25, comprising:
[0184] a) cultivating the non-human host organism or host cell of one of embodiments 32 to 34 to express or overexpress at least one polypeptide according to embodiment 25; and
[0185] b) Optionally, isolating the polypeptide from the non-human host cell or organism cultured in step a).
[0186] 38. The method according to embodiment 37, further comprising, before step a), providing the non-human host organism or cell with, in particular transforming the non-human host organism or host cell with, at least one nucleic acid according to claim 26, or at least one construct according to claim 27, or at least one vector according to any one of claims 28 to 31, such that it expresses or overexpresses the polypeptide according to claim 25.
[0187] 39. A method for preparing a mutant polypeptide having acetyltransferase activity, wherein the mutant polypeptide is capable of transferring an acetyl group from an acetyl donor to at least one, particularly one, amyl alcohol to produce at least one, particularly one, amyl acetate, the method comprising the steps of:
[0188] a) selecting a nucleic acid molecule encoding a polypeptide selected from SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 118, 121, 124, 127, 130, 133, 136, 143 and 144,
[0189] b) modifying the selected nucleic acid molecule to obtain at least one mutant nucleic acid molecule;
[0190] c) transforming a host cell or a unicellular host organism with the mutant nucleic acid sequence to express the polypeptide encoded by the mutant nucleic acid sequence;
[0191] d) screening the expression products for at least one mutant having acetyltransferase activity; and,
[0192] e) optionally, if the polypeptide does not have the desired mutant activity, repeating steps a) to d) until a polypeptide having the desired mutant activity is obtained; and
[0193] f) Optionally, if a polypeptide having the desired mutant activity is identified in step d), isolating the corresponding mutant nucleic acid obtained in step c).
[0194] 40. Use of an acetyltransferase as defined in any one of the preceding embodiments for the preparation of a scent, flavor or fragrance ingredient or for insect / pest control, such as for the preparation of a composition selected from body care, home care or fragrance compositions.
[0195] b. Polypeptides suitable for use according to the present invention
[0196] In the context of this article, the following definitions apply:
[0197] The general terms "polypeptide" or "peptide", which are used interchangeably, refer to a linear chain or sequence of amino acid residues linked in a peptide-like manner, whether natural or synthetic, comprising from about 10 to more than 1000 residues. Short-chain polypeptides of up to 30 residues are also referred to as "oligopeptides".
[0198] The term "protein" refers to a macromolecular structure composed of one or more polypeptides. The amino acid sequence of its polypeptides represents the "primary structure" of the protein. The amino acid sequence also predetermines the "secondary structure" of the protein by forming special structural elements (such as the α-helix and β-pleated structures formed in the polypeptide chain). The arrangement of multiple such secondary structural elements defines the "tertiary structure" or spatial arrangement of the protein. If a protein contains more than one polypeptide chain, the chains are arranged in space to form the "quaternary structure" of the protein. The correct spatial arrangement or "folding" of the protein is a prerequisite for protein function. Denaturation or unfolding will destroy protein function. If this destruction is reversible, protein function can be restored by refolding.
[0199] The typical protein function referred to herein is "enzyme function", i.e. the protein acts as a biocatalyst on a substrate, such as a compound, and catalyzes the conversion of the substrate to a product. Enzymes can exhibit a high or low degree of substrate and / or product specificity.
[0200] Thus, a "polypeptide" referred to herein as having a particular "activity" implicitly refers to a correctly folded protein that exhibits the indicated activity, eg, a particular enzymatic activity.
[0201] Thus, unless otherwise indicated, the term "polypeptide" also encompasses the terms "protein" and "enzyme."
[0202] Similarly, the term "polypeptide fragment" encompasses the terms "protein fragment" and "enzyme fragment."
[0203] The term "isolated polypeptide" refers to an amino acid sequence that has been removed from its natural environment by any method known in the art, or a combination of methods, including recombinant, biochemical, and synthetic methods.
[0204] "Target peptide" refers to an amino acid sequence that targets a protein or polypeptide to an intracellular organelle (i.e., mitochondria or plastids) or the extracellular space (secretion signal peptide). The nucleic acid sequence encoding the target peptide can be fused to the nucleic acid sequence encoding the amino terminus (e.g., N-terminus) of the protein or polypeptide, or can be used to replace the native targeting polypeptide.
[0205] The present invention also relates to "functional equivalents" (also called "analogs" or "functional mutants") of the polypeptides specifically described herein.
[0206] For example, a "functional equivalent" refers to a polypeptide which, in a test for determining enzymatic activity, exhibits at least 1 to 10% higher or lower enzymatic activity than the polypeptide specifically described herein and serving as the basis for said comparison, or at least 20% higher, or at least 50% lower, or at least 75% lower.
[0207] According to the invention, "functional equivalents" also encompass specific mutants which have, in at least one sequence position of the amino acid sequences described herein, an amino acid which differs from the specifically stated amino acid, but which nevertheless possess one of the above-mentioned biological activities, e.g. enzymatic activity. Thus, "functional equivalents" include mutants which can be obtained by additions, substitutions, in particular conservative substitutions (i.e. as a result of which the amino acid in question is replaced by an amino acid of the same charge, size, polarity and / or solubility), deletions and / or inversions of one or more, e.g. 1 to 20, 1 to 15 or 5 to 10 amino acids, wherein said changes may occur at any sequence position, as long as they result in a mutant having the profile of the properties according to the invention. Functional equivalence is also provided in particular if the activity pattern qualitatively overlaps between the mutant and the unchanged polypeptide, i.e. if, for example, an interaction with the same agonist or antagonist or substrate is observed, but at a different rate (i.e. by EC 50 or IC 50 The following table shows examples of suitable (conservative) amino acid substitutions:
[0208]
[0209] "Functional equivalents" in the above sense are also "precursors" of the polypeptides described herein, as well as "functional derivatives" and "salts" of said polypeptides.
[0210] In this context, a "precursor" is a natural or synthetic precursor of a polypeptide that may or may not possess the desired biological activity.
[0211] The expression "salts" refers to salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the present invention. Salts of carboxyl groups can be produced in a known manner and include inorganic salts, such as sodium, calcium, ammonium, iron and zinc salts, and salts formed with organic bases, such as amines, for example triethanolamine, arginine, lysine, piperidine, etc. Acid addition salts, such as salts formed with inorganic acids, such as hydrochloric acid or sulfuric acid, and salts formed with organic acids, such as acetic acid and oxalic acid, are also encompassed by the present invention.
[0212] "Functional derivatives" of the polypeptides according to the present invention can also be produced at the functional amino acid side groups or at their N-termini or C-termini using known techniques. Such derivatives include, for example: aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, which can be obtained by reaction with ammonia or with primary or secondary amines; N-acyl derivatives of free amino groups, which are produced by reaction with acyl groups; or O-acyl derivatives of free hydroxyl groups, which are produced by reaction with acyl groups.
[0213] "Functional equivalents" naturally also include polypeptides obtainable from other organisms and naturally occurring variants. For example, the area of homologous sequence regions can be determined by sequence comparison, and equivalent polypeptides can be determined based on the specific parameters of the present invention.
[0214] "Functional equivalents" also include "fragments" of the polypeptides according to the invention, such as single domains or sequence motifs, or N-terminal and / or C-terminal truncated forms, which may or may not exhibit the desired biological function. Preferably, such "fragments" at least qualitatively retain the desired biological function.
[0215] Furthermore, a "functional equivalent" is a fusion protein comprising one of the polypeptide sequences described herein or a functional equivalent derived therefrom and at least one further functionally different heterologous sequence in functional N-terminal or C-terminal association (i.e., without substantial mutual functional impairment of the fusion protein parts). Non-limiting examples of such heterologous sequences are, for example, signal peptides, histidine anchors or enzymes.
[0216] Also included according to the present invention are "functional equivalents" which are homologs of the specifically disclosed polypeptides. They have at least 60%, preferably at least 75%, in particular at least 80 or 85%, for example 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% homology (or identity) with the specifically disclosed amino acid sequences, as calculated by the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448. The homology or identity expressed as a percentage of the homologous polypeptides according to the present invention refers in particular to the identity expressed as a percentage of amino acid residues over the total length of one of the amino acid sequences specifically described herein.
[0217] Identity data expressed as a percentage can also be determined with the aid of BLAST alignments, the algorithm blastp (protein-protein BLAST) or by applying the Clustal settings as detailed herein below.
[0218] In case of possible protein glycosylation, "functional equivalents" according to the invention include the polypeptides described herein in deglycosylated or glycosylated form, as well as modified forms which can be obtained by altering the glycosylation pattern.
[0219] Functional equivalents or homologues of the polypeptides according to the invention can be generated by mutagenesis, for example by point mutations, lengthening or shortening the protein or as described in more detail below.
[0220] The functional equivalent of polypeptide according to the present invention or homologue can be identified by screening mutants such as the combined database of shortened mutants.For example, the diversity database of protein variants can be produced by the combined mutagenesis on the nucleic acid level, for example, by the enzymatic connection of synthetic oligonucleotide mixtures.There are many methods that can be used for producing the database of potential homologues from degenerate oligonucleotide sequences.The chemical synthesis of degenerate gene sequences can be carried out in an automatic DNA synthesizer, and then the synthetic gene can be connected in a suitable expression vector.The use of degenerate genome makes it possible to provide all sequences in the mixture, the potential protein sequence set required for its encoding.The synthetic method of degenerate oligonucleotide is well known to those skilled in the art.
[0221] In the prior art, several techniques are known for screening gene products of combinatorial databases produced by point mutation or shortening, as well as cDNA libraries for screening gene products with selected properties. These techniques can be applied to rapidly screen gene libraries produced by combinatorial mutagenesis of homologues according to the present invention. The most commonly used techniques for screening large gene libraries based on high-throughput analysis include cloning the gene library in a reproducible expression vector, transforming suitable cells with the resulting vector database, and expressing the combinatorial genes under specific conditions, under which the detection of the desired activity promotes the isolation of the vector encoding the gene (whose product is detected). Recursive integration mutagenesis (REM) is a technique that increases the frequency of functional mutants in a database and can be used in conjunction with screening tests to identify homologues.
[0222] Embodiments provided herein provide orthologues and paralogues of the polypeptides disclosed herein, as well as methods for identifying and isolating such orthologues and paralogues. The definitions of terms "orthologues" and "paralogues" are given below and are applicable to amino acid and nucleic acid sequences.
[0223] c. Encoding nucleic acid sequences suitable for use according to the present invention
[0224] In the context of this article, the following definitions apply:
[0225] The terms "nucleic acid sequence," "nucleic acid," "nucleic acid molecule," and "polynucleotide" are used interchangeably to refer to a sequence of nucleotides. A nucleic acid sequence can be single-stranded or double-stranded deoxyribonucleotides or ribonucleotides of any length and includes coding and non-coding sequences of genes, exons, introns, sense and antisense complementary sequences, genomic DNA, cDNA, miRNA, siRNA, mRNA, rRNA, tRNA, recombinant nucleic acid sequences, isolated and purified naturally occurring DNA and / or RNA sequences, synthetic DNA and RNA sequences, fragments, primers, and nucleic acid probes. The skilled artisan understands that the nucleic acid sequence of RNA is identical to the sequence of DNA, except that thymine (T) is replaced by uracil (U). The term "nucleotide sequence" should also be understood to include polynucleotide molecules or oligonucleotide molecules, either in the form of individual fragments or as components of a larger nucleic acid.
[0226] "Isolated nucleic acid" or "isolated nucleic acid sequence" refers to a nucleic acid or nucleic acid sequence that is in an environment that is different from that in which it occurs in nature, and can include those that are substantially free of contaminating endogenous material.
[0227] As used herein, the term "naturally-occurring" as applied to nucleic acids refers to a nucleic acid that is found in the cells of an organism in nature and has not been intentionally modified by man in the laboratory.
[0228] A "fragment" of a polynucleotide or nucleic acid sequence refers to a continuous nucleotide sequence, which is particularly at least 15 bp, at least 30 bp, at least 40 bp, at least 50 bp and / or at least 60 bp of the length of a polynucleotide of one embodiment herein. In particular, a fragment of a polynucleotide comprises at least 25, more particularly at least 50, more particularly at least 75, more particularly at least 100, more particularly at least 150, more particularly at least 200, more particularly at least 300, more particularly at least 400, more particularly at least 500, more particularly at least 600, more particularly at least 700, more particularly at least 800, more particularly at least 900, more particularly at least 1000 continuous nucleotides of a polynucleotide of one embodiment herein. Without limitation, fragments of the polynucleotides herein can be used as PCR primers and / or probes, or for antisense gene silencing or RNAi.
[0229] As used herein, the term "hybridization" or hybridization under certain conditions is intended to describe the conditions of hybridization and washing, under which significantly identical or homologous nucleotide sequences remain bound to each other. The conditions can be such that sequences of at least about 70%, for example, at least about 80%, and for example, at least about 85%, 90% or 95% identity remain bound to each other. The definition of low stringency, medium and high stringency hybridization conditions is provided below. Those skilled in the art can select suitable hybridization conditions with minimal experiments as illustrated by, for example, Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6). In addition, stringent conditions are described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11).
[0230] A "recombinant nucleic acid sequence" is a nucleic acid sequence produced by combining genetic material from more than one source using laboratory methods (e.g., molecular cloning), thereby creating or modifying a nucleic acid sequence that does not occur in nature and is not otherwise found in a biological organism.
[0231] "Recombinant DNA technology" refers to molecular biology methods for preparing recombinant nucleic acid sequences as described, for example, in Laboratory Manuals, ed., Weigel and Glazebrook, 2002, Cold Spring Harbor Lab Press; and Sambrook et al., 1989 Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
[0232] The term "gene" refers to a DNA sequence comprising a region that is transcribed into an RNA molecule (e.g., an mRNA in a cell) operably linked to an appropriate regulatory region (e.g., a promoter). Thus, a gene may comprise several operably linked sequences, such as a promoter, a 5' leader sequence (comprising, for example, sequences involved in translation initiation), a coding region of a cDNA or genomic DNA, introns, exons, and / or a 3' untranslated sequence (comprising, for example, a transcription termination site).
[0233] "Polycistronic" refers to a nucleic acid molecule, particularly mRNA, that can encode more than one polypeptide within the same nucleic acid molecule.
[0234] "Chimeric gene" refers to any gene that can not usually be found in species in nature, particularly a gene in which one or more parts of the nucleic acid sequence are not associated with each other in nature. For example, a promoter is not associated with part or all of a transcription region or with another regulatory region in nature. The term "chimeric gene" should be understood to include expression constructs in which a promoter or transcriptional regulatory sequence is operably linked to one or more coding sequences or antisense (i.e., the reverse complementary strand of the sense strand) or inverted repeats (sense and antisense, whereby RNA transcripts form double-stranded RNA after transcription). The term "chimeric gene" also includes genes obtained by combining parts of one or more coding sequences to produce new genes.
[0235] "3' URT" or "3' untranslated sequence" (also called "3' untranslated region" or "3' end") refers to a nucleic acid sequence found downstream of the coding sequence of a gene that contains, for example, a transcription termination site and (in most but not all eukaryotic mRNAs) a polyadenylation signal, such as AAUAAA or a variant thereof. Following transcription termination, the mRNA transcript may be cleaved downstream of the polyadenylation signal and a poly(A) tail may be added, which participates in the transport of the mRNA to the site of translation, such as the cytoplasm.
[0236] The term "primer" refers to a short nucleic acid sequence that hybridizes to a template nucleic acid sequence and is used to polymerize a nucleic acid sequence complementary to the template.
[0237] The term "selectable marker" refers to any gene that, after expression, can be used to select for one or more cells containing the selectable marker. Examples of selectable markers are described below. Those skilled in the art will appreciate that different antibiotic, fungicide, auxotrophic or herbicide selectable markers may be suitable for use with different target species.
[0238] The present invention also relates to nucleic acid sequences encoding the polypeptides as defined herein.
[0239] In particular, the invention also relates to nucleic acid sequences (single-stranded and double-stranded DNA and RNA sequences, such as cDNA, genomic DNA and mRNA) encoding one of the above polypeptides and functional equivalents thereof, which can be obtained, for example, by using artificial nucleotide analogs.
[0240] The present invention relates both to isolated nucleic acid molecules encoding polypeptides according to the invention or biologically active segments thereof, and to nucleic acid fragments useful as hybridization probes or primers, for example, for identifying or amplifying encoding nucleic acids according to the invention.
[0241] The present invention also relates to nucleic acids having a certain degree of "identity" to the sequences specifically disclosed herein. "Identity" between two nucleic acids refers in each case to the identity of the nucleotides over the entire length of the nucleic acid.
[0242] " Identity " between two nucleotide sequences (applicable also to peptide or amino acid sequences) is the function of the number of nucleotide residues (or amino acid residues) when producing the comparison of these two sequences, or the number of identical residues in the two sequences. Identical residues are defined as the identical residues at a given position of the comparison in the two sequences. The percentage of sequence identity used herein is calculated from the best comparison by dividing the number of identical residues between the two sequences by the total number of residues in the shortest sequence and multiplying by 100. The best comparison is the comparison with the highest probability of identity percentage. Rooms can be introduced into one or more positions of the comparison in one or two sequences to obtain the best comparison. These rooms are then considered as non-identical residues for calculating sequence identity percentage. The comparison for determining amino acid or nucleic acid sequence identity percentage can be implemented in a variety of ways using computer programs and, for example, publicly available computer programs on the Internet.
[0243] In particular, the BLAST program (Tatiana et al., FEMS Microbiol Lett., 1999, 174: 247-250, 1999), available from the National Center for Biotechnology Information (NCBI) at http: / / www.ncbi.nlm.nih.gov / BLAST / bl2seq / wblast2.cgi, set to default parameters, can be used to obtain optimal alignment of protein or nucleic acid sequences and calculate percentages of sequence identity.
[0244] In another example, the identity can be calculated by the Vector NTI Suite 7.1 program of Informax Corporation (USA) using the Clustal method (Higgins DG, Sharp PM. ((1989))) with the following settings:
[0245] Multiple alignment parameters:
[0246]
[0247] Pairwise alignment parameters:
[0248]
[0249] Alternatively, identity can be determined according to the method of Chenna et al. (2003), webpage: http: / / www.ebi.ac.uk / Tools / clustalw / index.html# and the following settings:
[0250]
[0251] All nucleic acid sequences mentioned herein (single-stranded and double-stranded DNA and RNA sequences, such as cDNA and mRNA) can be produced from nucleotide building blocks by chemical synthesis in a known manner, for example, by condensation of the fragments of the complementary nucleic acid building blocks of each overlap of a double helix. The chemical synthesis of oligonucleotides can be carried out in a known manner, for example, by the phosphoamidite method (Voet, Voet, 2nd edition, Wiley Press, New York, pages 896-897). The accumulation of synthetic oligonucleotides, and the filling of the vacancies by means of the Klenow fragments of DNA polymerase and ligation, as well as general cloning techniques are described in Sambrook et al. (1989), see below.
[0252] Furthermore, the nucleic acid molecules according to the present invention may additionally comprise untranslated sequences from the 3' and / or 5' end of the coding genetic region.
[0253] The present invention further relates to nucleic acid molecules that are complementary to the specifically described nucleotide sequences or segments thereof.
[0254] The nucleotide sequences according to the invention allow the generation of probes and primers that can be used to identify and / or clone homologous sequences in other cell types and organisms. Such probes or primers typically comprise a region of nucleotide sequence that hybridizes under "stringent" conditions (as defined elsewhere herein) to at least about 12, preferably at least about 25, for example about 40, 50 or 75 consecutive nucleotides of the sense strand or the corresponding antisense strand of a nucleic acid sequence according to the invention.
[0255] "Homologous" sequences include orthologous or paralogous sequences. Methods for identifying orthologs or paralogs include phylogenetic methods, sequence similarity and hybridization methods known in the art and described herein.
[0256] "Paralogs" or paralogous sequences result from gene duplication, which results in two or more genes with similar sequences and similar functions. Paralogs are often clustered together and formed by duplication of genes within related plant species. Paralogs are found in groups of similar genes using Pairwise Blast analysis or using programs such as CLUSTAL during phylogenetic analysis of gene families. Among paralogs, consensus sequences can be identified as sequences that are characteristic of related genes and have similar functions to the genes.
[0257] "Orthologs" or orthologous sequences are sequences that are similar to each other because they are found in species descended from a common ancestor. For example, plant species with a common ancestor are known to contain many enzymes with similar sequences and functions. For example, by constructing a phylogenetic tree of a species' gene family using the CLUSTAL or BLAST programs, technicians can identify orthologous sequences and predict the functions of orthologs. A method for identifying or confirming similar functions between homologous sequences is by comparing transcript profiles in host cells or organisms (such as plants or microorganisms) that overexpress or lack (in gene knockout / knockdown) the relevant polypeptides. It will be understood by the technician that genes with similar transcript profiles (having a common transcript that is greater than 50% regulated, or having a common transcript that is greater than 70% regulated, or a common transcript that is greater than 90% regulated) will have similar functions. By causing a host cell, an organism such as a plant or microorganism to produce a terpene synthase protein, homologs, paralogs, orthologs, and any other variants of the sequences described herein are expected to function in a similar manner.
[0258] The term "selectable marker" refers to any gene that, after expression, can be used to select for one or more cells containing the selectable marker. Examples of selectable markers are described below. Those skilled in the art will appreciate that different antibiotic, fungicide, auxotrophic or herbicide selectable markers may be suitable for use with different target species.
[0259] An "isolated" nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and may be substantially free of other cellular material or culture medium if produced by recombinant techniques, or free of chemical precursors or other chemicals if chemically synthesized.
[0260] Can be separated according to nucleic acid molecules according to the present invention by means of molecular biological standard techniques and the sequence information provided according to the present invention.For example, can use one of concrete disclosed complete sequence or its fragment as hybridization probe and standard hybridization technique (for example, be described in Sambrook, (1989)) from suitable cDNA library, separate cDNA.
[0261] In addition, the nucleic acid molecules that comprises one of disclosed sequence or its segmental can use the oligonucleotide primers that make up based on this sequence, separates by polymerase chain reaction.The nucleic acid that increases in this way can be cloned in the suitable carrier, and can characterize by dna sequencing.Oligonucleotide according to the present invention also can be by the synthetic method of standard, for example use automatic DNA synthesizer to prepare.
[0262] According to nucleotide sequence of the present invention or its derivative, homologue or part of these sequences can for example be separated from other bacteria by conventional hybridization technique or PCR technology, for example by genome or cDNA library.These dna sequences are hybridized with sequence according to the present invention under standard conditions.
[0263] "Hybridization" refers to the ability of a polynucleotide or oligonucleotide to bind to nearly complementary sequences under standard conditions, without nonspecific binding occurring between non-complementary pairs under these conditions. For this purpose, sequences may be 90-100% complementary. The property of complementary sequences to be able to bind specifically to each other is exploited, for example, in Northern or Southern blotting or in primer binding in PCR or RT-PCR.
[0264] Short oligonucleotides of conserved regions are advantageously used for hybridization. However, longer nucleic acid fragments or complete sequences of the invention may also be used for hybridization. These "standard conditions" vary depending on the nucleic acid used (oligonucleotide, longer fragment or complete sequence) or the type of nucleic acid used for hybridization (DNA or RNA). For example, the melting temperature of a DNA:DNA hybrid is approximately 10°C lower than that of a DNA:RNA hybrid of the same length.
[0265] For example, depending on the specific nucleic acid, standard conditions refer to a temperature of 42 to 58°C in an aqueous buffer solution with a concentration of 0.1 to 5 x SSC (1 x SSC = 0.15 M NaCl, 15 mM sodium citrate, pH 7.2), or alternatively in the presence of 50% formamide (e.g., 42°C, 5 x SSC, 50% formamide). Advantageously, hybridization conditions for DNA:DNA hybrids are 0.1 x SSC at a temperature of about 20°C to 45°C, preferably about 30°C to 45°C. For DNA:RNA hybrids, hybridization conditions are advantageously 0.1 x SSC at a temperature of about 30°C to 55°C, preferably about 45°C to 55°C. These stated hybridization temperatures are examples of calculated melting temperature values for a nucleic acid of approximately 100 nucleotides in length and a G+C content of 50% in the absence of formamide. The experimental conditions for DNA hybridization are described in relevant genetics textbooks (e.g., Sambrook et al., 1989) and can be calculated using formulas known to those skilled in the art, for example depending on the length of the nucleic acids, the type of hybrid or the G+C content. Those skilled in the art can obtain more information on hybridization from the following textbooks: Ausubel et al. (eds), (1985), Brown (ed) (1991).
[0266] Hybridization can be performed under stringent conditions. Such hybridization conditions are described, for example, in Sambrook (1989) or Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6.
[0267] As used herein, the term "hybridizes or hybridizes under conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain bound to each other. The conditions can be such that sequences that are at least about 70%, such as at least about 80%, and for example at least about 85%, 90%, or 95% identical remain bound to each other. Definitions of low stringency, medium stringency, and high stringency hybridization conditions are provided herein.
[0268] Those skilled in the art can select appropriate hybridization conditions with minimal experimentation by, for example, the examples described by Ausubel et al. (1995, Current Protocols in Molecular Biology, John Wiley & Sons, sections 2, 4, and 6). Additionally, stringent conditions are described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, chapters 7, 9, and 11).
[0269] As used herein, the low stringency conditions are defined as follows. The filter containing DNA is pretreated at 40°C for 6 hours in a solution containing 35% formamide, 5xSSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500μg / ml denatured salmon sperm DNA. Hybridization is performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100μg / ml salmon sperm DNA, 10% (wt / vol) dextran sulfate, and using 5-20x10 6 32P-labeled probe. Incubate the filter in hybridization mixture at 40°C for 18-20 hours, then wash at 55°C for 1.5 hours. Replace the wash solution with fresh solution and incubate at 60°C for an additional 1.5 hours. Blot dry and perform autoradiography.
[0270] As used herein, the medium stringency conditions are defined as follows. The filter containing DNA is pretreated at 50°C for 7 hours in a solution containing 35% formamide, 5x SSC, 50mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500μg / ml denatured salmon sperm DNA. Hybridization is performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100μg / ml salmon sperm DNA, 10% (wt / vol) dextran sulfate, and using 5-20x10 6 32P-labeled probe. Incubate the filter in hybridization mixture at 50°C for 30 hours, then wash at 55°C for 1.5 hours. In a solution containing 2x SSC, 25mM Tris-HCl (pH 7.4), 5mM EDTA, and 0.1% SDS. Replace the wash solution with fresh solution and incubate at 60°C for an additional 1.5 hours. Blot dry and perform autoradiography.
[0271] As used herein, high stringency conditions are defined as follows. The DNA-containing filter is prehybridized at 65°C for 8 hours to overnight in a buffer consisting of 6x SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg / ml denatured salmon sperm DNA. 6 The filters were hybridized at 65°C for 48 hours in a prehybridization mixture containing a cpm 32P-labeled probe. The filters were washed in a solution containing 2x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA at 37°C for 1 hour, followed by a wash in 0.1x SSC at 50°C for 45 minutes.
[0272] If the above conditions are not suitable (eg, as for interspecies hybridization), other low, medium, and high stringency conditions well known in the art (eg, for interspecies hybridization) can be used.
[0273] A detection kit for a nucleic acid sequence encoding a polypeptide of the present invention can include primers and / or probes specific for the nucleic acid sequence encoding the polypeptide, as well as protocols for using the primers and / or probes to detect the nucleic acid sequence encoding the polypeptide in a sample. Such a detection kit can be used to determine whether a plant, organism, microorganism, or cell has been modified, i.e., transformed with a sequence encoding the polypeptide.
[0274] To test the functionality of a variant DNA sequence according to one embodiment herein, the sequence of interest is operably linked to a selectable or screenable marker gene and expression of the reporter gene is tested in transient expression assays using microorganisms or protoplasts or in stably transformed plants.
[0275] The present invention also relates to derivatives of the specifically disclosed or derivable nucleic acid sequences.
[0276] Thus, further nucleic acid sequences according to the invention may be derived from the sequences specifically disclosed herein and may differ therefrom by one or more, for example 1 to 20, in particular 1 to 15 or 5 to 10 additions, substitutions, insertions or deletions of one or several (for example 1 to 10) nucleotides and still encode a polypeptide having the desired properties.
[0277] The invention also encompasses nucleic acid sequences which contain so-called silent mutations or which have been altered compared to the specifically stated sequence according to the codon usage of the particular origin or host organism.
[0278] According to a specific embodiment of the present invention, variant nucleic acid can be prepared to adapt its nucleotide sequence to a specific expression system. For example, if amino acid is encoded by a specific codon, then known bacterial expression systems can more effectively express polypeptides. Due to the degeneracy of the genetic code, more than one codon can encode the same amino acid sequence, and a plurality of nucleic acid sequences can encode the same protein or polypeptide, and all of these DNA sequences are encompassed in one embodiment of this paper. Where appropriate, the nucleic acid sequence encoding polypeptides described herein can be optimized to increase expression in a host cell. For example, a nucleic acid of one embodiment of this paper can be synthesized using host-specific codons to improve expression.
[0279] The invention also encompasses naturally occurring variants of the sequences described herein, such as splice variants or allelic variants.
[0280] Allelic variants have at least 60% homology, preferably at least 80% homology, and very particularly preferably at least 90% homology over the entire amino acid range at the derived amino acid level (with regard to homology at the amino acid level, reference should be made to the detailed information given above for the polypeptides). Advantageously, the homology may be higher over partial regions of the sequence.
[0281] The invention also relates to sequences obtainable by conservative nucleotide substitutions, ie as a result of which the amino acid in question is replaced by an amino acid of the same charge, size, polarity and / or solubility.
[0282] The present invention also relates to molecules derived from the specifically disclosed nucleic acids through sequence polymorphisms. Due to natural allelic variation, such genetic polymorphisms may exist in cells from different populations or in cells within a population. Allelic variants may also include functional equivalents. These natural variations typically produce 1-5% variation in the nucleotide sequence of a gene. Such polymorphisms may result in alterations in the amino acid sequence of the polypeptides disclosed herein. Allelic variants may also include functional equivalents.
[0283] Furthermore, derivatives are also to be understood as meaning homologues of the nucleic acid sequences according to the invention, for example animal, plant, fungal or bacterial homologues, shortened sequences, single-stranded DNA or RNA of coding and non-coding DNA sequences. For example, at the DNA level, homologues have a homology of at least 40%, preferably at least 60%, particularly preferably at least 70%, and very particularly preferably at least 80% over a given DNA region in the sequences specifically disclosed herein.
[0284] Furthermore, derivatives are understood to include, for example, fusions with promoters. Promoters added to the nucleotide sequence may be modified by at least one nucleotide exchange, at least one insertion, inversion and / or deletion, without impairing the function or efficacy of the promoter. Furthermore, the efficacy of promoters may be increased by altering their sequence, or they may be completely exchanged for more effective promoters, or even promoters from organisms of different genera.
[0285] d. Generation of functional polypeptide mutants
[0286] In addition, those skilled in the art are familiar with methods for generating functional mutants, that is, a nucleotide sequence encoding a polypeptide having at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the SEQ ID NOs disclosed herein with respect to amino acids; and / or encoded by a nucleic acid molecule comprising a nucleotide sequence having at least 70% sequence identity to any of the SEQ ID NOs disclosed herein with respect to nucleotides.
[0287] Depending on the technology used, those skilled in the art can introduce completely random or more targeted mutations into genes or non-coding nucleic acid regions (e.g., important for regulating expression) and subsequently generate genetic libraries. The molecular biology methods required for this purpose are known to the skilled person and are described, for example, in Sambrook and Russell, Molecular Cloning. 3rd Edition, Cold Spring Harbor Laboratory Press 2001.
[0288] Methods for modifying genes and thereby modifying the polypeptides encoded thereby have long been known to those skilled in the art, for example:
[0289] - site-specific mutagenesis, in which single or multiple nucleotides of a gene are replaced in a targeted manner (Trower MK (Ed.) 1996; In vitro mutagenesis protocols. Humana Press, New Jersey),
[0290] - saturation mutagenesis, in which the codon for any amino acid can be exchanged or added at any site in the gene (Kegler-Ebo DM, Docktor CM, DiMaio D (1994) Nucleic Acids Res 22: 1593; Barettino D, Feigenbutz M, Valcarel R, Stunnenberg HG (1994) Nucleic Acids Res 22: 541; Barik S (1995) Mol Biotechnol 3: 1),
[0291] - Error-prone polymerase chain reaction, in which the nucleotide sequence is mutated by an error-prone DNA polymerase (Eckert KA, Kunkel TA (1990) Nucleic Acids Res 18: 3739);
[0292] - SeSaM method (sequence saturation method), in which preferred exchange is prevented by the polymerase. Schenk et al., Biospektrum, Vol. 3, 2006, 277-279,
[0293] - gene propagation in mutant strains in which the mutation rate of the nucleotide sequence is increased, for example due to defects in the DNA repair mechanisms (Greener A, Callahan M, Jerpseth B (1996) An efficient random mutagenesis technique using an E. coli mutator strain. In: Trower MK (Ed.) In vitro mutagenesis protocols. Humana Press, New Jersey), or
[0294] - DNA shuffling, in which a group of closely related genes is created and digested, and these fragments are used as templates for polymerase chain reactions, in which, through repeated chain separation and recombination, the full-length mosaic gene is ultimately generated (Stemmer WPC (1994) Nature 370:389; Stemmer WPC (1994) Proc Natl Acad Sci USA 91:10747).
[0295] Using so-called directed evolution (described, inter alia, in Reetz MT and Jaeger KE (1999), Topics Curr Chem 200: 31; Zhao H, Moore JC, Volkov AA, Arnold FH (1999), Methods for optimizing industrial polypeptides by directed evolution, In: Demain AL, Davies JE (Ed.) Manual of industrial microbiology and biotechnology. American Society for Microbiology), a skilled worker can produce functional mutants in a directed manner on a large scale. To this end, in a first step, a gene library for the respective polypeptide is first generated, for example using the methods given above. The gene library is expressed in a suitable manner, for example by bacterial or phage display systems.
[0296] The relevant gene (its function is corresponding to required characteristic to a great extent) of the host organism expressing functional mutant can be submitted to another mutation cycle.The step of sudden change and selection or screening can be repeated iteratively until functional mutant of the present invention has the required characteristic of enough degree.Use this iterative process, can carry out the sudden change of limited number, for example 1,2,3,4 or 5 sudden changes in stages, and assess and select their influence on the activity studied.Then can be carried out further sudden change step by the selected mutant in the same manner.Like this, can significantly reduce the quantity of single mutant to be studied.
[0297] The results according to the present invention also provide important information about the structure and sequence of related polypeptides, which is necessary for generating other polypeptides with desired modified properties in a targeted manner. In particular, so-called "hot spots" can be defined, i.e., sequence segments that are potentially suitable for modifying properties by introducing targeted mutations.
[0298] Information can also be deduced regarding positions in the amino acid sequence where mutations may occur that may have little effect on activity and can be designated as potential "silent mutations."
[0299] e. Constructs expressing the polypeptides of the present invention
[0300] In the context of this article, the following definitions apply:
[0301] "Gene expression" encompasses "heterologous expression" and "overexpression" and involves the transcription of a gene and the translation of mRNA into protein. Overexpression refers to the production of a gene product in a transgenic cell or organism, as measured by mRNA, polypeptide, and / or enzyme activity levels, that exceeds the level of production in a non-transformed cell or organism of a similar genetic background.
[0302] As used herein, "expression vector" refers to a nucleic acid molecule that is engineered using molecular biology methods and recombinant DNA technology to deliver foreign or exogenous DNA into a host cell. An expression vector typically includes sequences required for the correct transcription of the nucleotide sequence. The coding region usually encodes a protein of interest, but may also encode RNA, such as antisense RNA, siRNA, etc.
[0303] As used herein, "expression vector" includes any linear or circular recombinant vector, including but not limited to viral vectors, phages and plasmids. The skilled person can select a suitable vector according to the expression system. In one embodiment, the expression vector includes a nucleic acid of the embodiments herein, which is operably linked to at least one "regulatory sequence" that controls transcription, translation, initiation and termination, such as a transcriptional promoter, operator or enhancer, or an mRNA ribosome binding site, and optionally includes at least one selection marker. When a regulatory sequence is functionally related to a nucleic acid of the embodiments herein, the nucleotide sequence is "operably linked".
[0304] As used herein, "expression system" encompasses any combination of nucleic acid molecules required to co-express two or more polypeptides in a given expression host in vivo or in vitro. The respective coding sequences can be located on a single nucleic acid molecule or vector, such as a vector comprising multiple cloning sites, or on a polycistronic nucleic acid, or can be distributed on two or more physically distinct vectors.
[0305] As used herein, the terms "amplifying" and "amplification" refer to the use of any suitable amplification method for generating or detecting recombinants of naturally expressed nucleic acids, as described in detail below. For example, the present invention provides methods and reagents (e.g., specific degenerate oligonucleotide primer pairs, oligo dT primers) for amplifying (e.g., by polymerase chain reaction, PCR) naturally expressed (e.g., genomic DNA or mRNA) or recombinant nucleic acids (e.g., cDNA) of the present invention in vivo, ex vivo, or in vitro.
[0306] "Regulatory sequence" refers to a nucleic acid sequence that determines the expression level of the nucleic acid sequence of the embodiments herein and is capable of regulating the transcription rate of the nucleic acid sequence operably linked to the regulatory sequence. Regulatory sequences include promoters, enhancers, transcription factors, promoter elements, etc.
[0307] According to the present invention, "promoter", "nucleic acid with promoter activity" or "promoter sequence" are understood to refer to a nucleic acid that, when functionally linked to a nucleic acid to be transcribed, regulates the transcription of said nucleic acid. "Promoter" refers in particular to a nucleic acid sequence that controls the expression of a coding sequence by providing a binding site for RNA polymerase and other factors suitable for transcription, including but not limited to transcription factor binding sites, repressor and activator protein binding sites. The term promoter also includes the term "promoter regulatory sequence". Promoter regulatory sequences may include upstream and downstream elements that may affect transcription, RNA processing or the stability of the associated coding nucleic acid sequence. Promoters include sequences of natural origin and synthesis. The coding nucleic acid sequence is typically located downstream of the promoter relative to the direction of transcription starting at the transcription start site.
[0308] In this context, "functional" or "operably" connection is understood to refer to, for example, the sequential arrangement of one of the nucleic acids with regulatory sequences. For example, a sequence with promoter activity, and a nucleic acid sequence to be transcribed and optional other regulatory elements (for example, nucleic acid sequences that ensure nucleic acid transcription) and, for example, terminators, are arranged in such a way that each regulatory element can perform its function after the nucleic acid sequence is transcribed. This does not necessarily require a direct connection in a chemical sense. Genetic control sequences, such as enhancer sequences, can even play a role on the target sequence from a more distant position or even from other DNA molecules. A preferred arrangement is such that the nucleic acid sequence to be transcribed is located downstream (i.e., 3' end) of the promoter sequence, so that the two sequences are covalently linked together. The distance between the promoter sequence and the nucleic acid sequence to be recombinantly expressed can be less than 200 base pairs, or less than 100 base pairs or less than 50 base pairs.
[0309] Besides promoters and terminators, the following may be mentioned as examples of further regulatory elements: targeting sequences, enhancers, polyadenylation signals, selection markers, amplification signals, replication origins, etc. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
[0310] The term "constitutive promoter" refers to an unregulated promoter that allows for continuous transcription of a nucleic acid sequence to which it is operably linked.
[0311] As used herein, the term "operably connected" refers to the connection of a polynucleotide element in a functional relationship. When a nucleic acid is in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably connected". For example, if a promoter or transcriptional regulatory sequence can affect the transcription of a coding sequence, the promoter or transcriptional regulatory sequence is operably connected to the coding sequence. Operably connected means that the DNA sequence being connected is usually adjacent. The nucleotide sequence associated with the promoter sequence can be of homologous or heterologous origin relative to the plant to be transformed. The sequence can also be fully or partially synthesized. Regardless of the source, the nucleic acid sequence associated with the promoter sequence will be expressed or silenced according to the promoter properties connected after being attached to the polypeptide of this paper's embodiment. The relevant nucleic acid can encode a protein that needs to be expressed or suppressed at all times or alternatively at a specific time in the entire organism or in a specific tissue, cell or cell compartment. Such a nucleotide sequence particularly encodes a protein that gives a desired phenotypic trait to a host cell or organism that is changed or transformed by it. More particularly, the relevant nucleotide sequence causes one or more target products as defined herein to be produced in a cell or organism. In particular, the nucleotide sequence encodes a polypeptide having enzymatic activity as defined herein.
[0312] The nucleotide sequence described herein may be part of an "expression cassette". The terms "expression cassette" and "expression construct" are used synonymously. A (preferably recombinant) expression construct comprises a nucleotide sequence encoding a polypeptide according to the invention and under the genetic control of a regulatory nucleic acid sequence.
[0313] In the methods used according to the invention, the expression cassette may be part of an "expression vector", in particular a recombinant expression vector.
[0314] According to the present invention, an "expression unit" is understood to mean a nucleic acid with expression activity, which comprises a promoter as defined herein and which, after functional linkage to a nucleic acid or gene to be expressed, regulates expression, i.e., the transcription and translation of said nucleic acid or gene. Therefore, in this context, it is also referred to as a "regulatory nucleic acid sequence." In addition to the promoter, other regulatory elements, such as enhancers, may also be present.
[0315] According to the present invention, an "expression cassette" or "expression construct" is understood to be an expression unit that is functionally linked to a nucleic acid to be expressed or a gene to be expressed. Thus, in contrast to an expression unit, an expression cassette contains not only nucleic acid sequences that regulate transcription and translation, but also nucleic acid sequences that are expressed as a protein as a result of transcription and translation.
[0316] In the context of the present invention, the terms "expression" or "overexpression" describe the production or increase in the intracellular activity of one or more polypeptides encoded by the corresponding DNA in a microorganism. This can be achieved, for example, by introducing a gene into the organism, replacing an existing gene with another, increasing the copy number of a gene, using a strong promoter, or using a gene encoding a highly active corresponding polypeptide. Alternatively, these measures can be combined.
[0317] Preferably, such constructs according to the invention comprise a promoter 5' upstream and a terminator sequence 3' downstream of the respective coding sequence, and optionally further customary regulatory elements, in each case operably linked to the coding sequence.
[0318] The nucleic acid construct according to the present invention comprises in particular a sequence encoding a polypeptide, which is derived, for example, from an amino acid related SEQ ID NO as described herein or its reverse complement, or derivatives and homologues thereof, and which has been operably or functionally linked to one or more regulatory signals for advantageously controlling, for example increasing, gene expression.
[0319] In addition to these regulatory sequences, the natural regulation of these sequences may still be present before the actual structural gene, and optionally may have been genetically modified so that the natural regulation has been switched off and gene expression has been enhanced. However, the nucleic acid construct may also have a simpler construction, i.e., no additional regulatory signals are inserted before the coding sequence, and the natural promoter with regulatory effects has not been removed. Instead, the natural regulatory sequences are mutated so that regulation no longer occurs and gene expression is increased.
[0320] Preferred nucleic acid constructs advantageously also comprise one or more " enhancer " sequences already mentioned that are functionally connected with the promoter, and this sequence makes the expression of the enhanced nucleic acid sequence become possibility. Other advantageous sequences, for example other regulatory elements or terminators can also be inserted at the 3 ' end of the dna sequence. One or more copies of nucleic acid according to the present invention can be present in the construct. In this construct, other markers can also be present alternatively, for example with genes complementary to auxotrophy or antibiotic resistance, so that this construct can be selected.
[0321] Examples of suitable regulatory sequences are found in promoters such as cos, tac, trp, tet, trp-tet, lpp, lac, lpp-lac, lacI q , T7, T5, T3, gal, trc, ara, rhaP(rhaP BAD )SP6, lambda-P R , or in lambda-P LAmong the promoters, they are advantageously used in Gram-negative bacteria. Other advantageous regulatory sequences are found, for example, in the Gram-positive promoters amy and SPO2, and in the yeast or fungal promoters ADC1, MFalpha, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH. Artificial promoters can also be used for regulation.
[0322] In order to express in the host organism, the nucleic acid construct is advantageously inserted into a carrier, for example a plasmid or a phage, which makes the optimal expression of the gene in the host possible. Except plasmids and phages, carriers are also understood to be all other carriers well known to those skilled in the art, i.e., for example viruses, for example SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids and linear or circular DNA or artificial chromosomes. These carriers can replicate autonomously or by chromosome replication in the host organism. These carriers are a further development of the present invention. Binary or cpo integrating vectors are also applicable.
[0323] Suitable plasmids are, for example, pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1, pKK223-3, pDHE19.2, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III, 113 -B1, λgt11, or pBdCI, in Streptomyces pIJ101, pIJ364, pIJ702, or pIJ361, in Bacillus pUB110, pC194, or pBD214, in Corynebacterium pSA77 or pAJ667, in fungi pALS1, pIL2, or pBB116, in yeast 2alphaM, pAG-1, YEp6, YEp13, or pEMBLYe23, or in plants pLGV23, pGHlac + , pBIN19, pAK2004 or pDH51. The above plasmids are a small selection of possible plasmids. Other plasmids are well known to the skilled person and can be found, for example, in the book Cloning Vectors (Eds. Pouwels PH et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018).
[0324] In the further development of vectors, vectors comprising the nucleic acid construct of the present invention or the nucleic acid of the present invention can also advantageously be introduced into microorganisms in the form of linear DNA and integrated into the genome of the host organism by heterologous or homologous recombination. This linear DNA can consist of a linearized vector, for example a plasmid, or can consist solely of the nucleic acid construct of the present invention or the nucleic acid.
[0325] For optimal expression of heterologous genes in an organism, it is advantageous to modify the nucleic acid sequence to match the specific "codon usage" used in the organism."Codon usage" can be readily determined by computer evaluation of other known genes of the organism in question.
[0326] The expression cassette according to the present invention is produced by fusing a suitable promoter to a suitable coding nucleotide sequence and terminator or polyadenylation signal. Conventional recombination and cloning techniques are used for this purpose, as for example described in T. Maniatis, E. F. Ritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) and T. J. Silhavy, M. L. Berman and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience (1987).
[0327] For expression in a suitable host organism, the recombinant nucleic acid construct or gene construct is advantageously inserted into a host-specific vector, which enables optimal expression of the gene in the host. Vectors are well known to the skilled person and can be found, for example, in "cloning vectors" (Pouwels PH et al., Ed., Elsevier, Amsterdam-New York-Oxford, 1985).
[0328] An alternative embodiment of the present invention provides a method of "altering gene expression in a host cell." For example, under certain circumstances (e.g., exposure to certain temperature or culture conditions), the polynucleotides of the present invention can be enhanced or overexpressed or induced in a host cell or host organism.
[0329] Alteration of expression of the polynucleotides provided herein can also result in ectopic expression, which is a different expression pattern in the altered and control or wild-type organisms. Alteration of expression occurs by contact of a polypeptide of an embodiment herein with an exogenous or endogenous modulator or by chemical modification of the polypeptide. The term also refers to an altered expression pattern of a polynucleotide of an embodiment herein, which is altered to below the level of detection or completely inhibited in activity.
[0330] Also provided herein as an embodiment are isolated, recombinant or synthetic polynucleotides encoding the polypeptides or variant polypeptides provided herein.
[0331] In one embodiment, multiple polypeptide encoding nucleic acid sequences are co-expressed in a single host, particularly under the control of different promoters. In another embodiment, multiple polypeptide encoding nucleic acid sequences can be present on a single transformation vector, or separate vectors can be used and transformants containing two chimeric genes can be selected for simultaneous co-transformation. Similarly, one or more polypeptide encoding genes can be expressed in a single plant, cell, microorganism or organism along with other chimeric genes.
[0332] f. Hosts suitable for the present invention
[0333] Depending on the context, the term "host" may refer to a wild-type host or a genetically altered recombinant host or both.
[0334] In principle, all prokaryotic or eukaryotic organisms can be regarded as hosts or recombinant host organisms for the nucleic acids or nucleic acid constructs according to the invention.
[0335] Using the vector according to the present invention, a recombinant host can be produced, which, for example, can be transformed with at least one vector according to the present invention and can be used to produce a polypeptide according to the present invention. Advantageously, the recombinant construct according to the present invention as described above is introduced into a suitable host system and expressed. Preferably, common cloning and transfection methods known to those skilled in the art, such as coprecipitation, protoplast fusion, electroporation, retroviral transfection, etc., are used to express the nucleic acid in their respective expression systems. Suitable systems are described in Current Protocols in Molecular Biology, F. Ausubel et al., Ed., Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
[0336] Advantageously, microorganisms such as bacteria, fungi or yeast are used as host organisms. Advantageously, Gram-positive or Gram-negative bacteria are used, preferably bacteria of the families Enterobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Streptomycetaceae, Streptococcaceae or Nocardiaceae, particularly preferably bacteria of the genus Escherichia, Pseudomonas, Streptomyces, Lactococcus, Nocardia, Burkholderia, Salmonella, Agrobacterium, Clostridium or Rhodococcus. The genus and species of Escherichia coli are very particularly preferred. In addition, other advantageous bacteria are found in the alpha-Proteobacteria, beta-Proteobacteria or gamma-Proteobacteria groups. Advantageously, yeasts such as the Saccharomyces or Pichia families are also suitable hosts.
[0337] Alternatively, whole plants or plant cells can be used as natural or recombinant hosts. As non-limiting examples, the following plants or cells derived therefrom may be mentioned: Nicotiana, in particular Nicotiana benthamiana and Nicotiana tabacum (tobacco); and Arabidopsis, in particular Arabidopsis thaliana.
[0338] Depending on the host organism, the organisms used in the method according to the invention are grown or cultured in a manner known to those skilled in the art. Cultivation can be carried out in batches, semi-batch or continuously. Nutrients can be given at the beginning of fermentation or can be provided later, semi-continuously or continuously. This is also described in more detail below.
[0339] g. Recombinant production of the polypeptide according to the present invention
[0340] The present invention further relates to a method for the recombinant production of a polypeptide according to the invention or a functional, biologically active fragment thereof, wherein a microorganism producing the polypeptide is cultured, expression of the polypeptide is optionally induced by administering at least one inducer of gene expression, and the polypeptide is isolated from the culture. If desired, the polypeptide can also be produced on an industrial scale in this manner.
[0341] The microorganism that produces according to the present invention can be cultivated continuously or discontinuously by batch process or fed-batch process or repeated fed-batch process.The general introduction of known culture method can be in the textbook (Bioprozesstechnik 1.Einführungin die Bioverfahrenstechnik [Bioprocess technology 1.Introduction tobioprocess technology] (Gustav Fischer Verlag, Stuttgart, 1991)) of Chmiel or in the textbook (Bioreaktoren und periphere Einrichtungen [Bioreactors and peripheralequipment] (Vieweg Verlag, Braunschweig / Wiesbaden, 1994)) of Storhas.
[0342] The culture medium used must be appropriately adapted to the requirements of the respective strain. Descriptions of culture media for various microorganisms are given in the manual "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington DC, USA, 1981).
[0343] The culture media which can be used according to the invention generally comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.
[0344] The preferred carbon source is sugar, for example monosaccharide, disaccharide or polysaccharide. Good carbon source is for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose. Sugar also can be added in the substratum by other by-products of complex compound (for example molasses) or sugar refining. It is also favourable to add the mixture of different carbon sources. Other possible carbon sources are oil and fat, for example soybean oil, sunflower seed oil, peanut oil and coconut oil, fatty acid for example palmitic acid, stearic acid or linoleic acid, alcohol for example glycerol, methanol or ethanol, and organic acid, for example acetic acid or lactic acid.
[0345] The nitrogen source is generally an organic or inorganic nitrogen compound or a material containing such a compound. Examples of nitrogen sources include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources, such as corn steep liquor, soy flour, soy protein, yeast extract, meat extract, etc. The nitrogen sources can be used alone or in combination.
[0346] Inorganic salt compounds that may be present in the culture medium include chloride, phosphorus or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
[0347] Inorganic sulfur-containing compounds, such as sulfates, sulfites, dithionites, tetrasulfates, thiosulfates, sulfides, and organic sulfur compounds, such as mercaptans and thiols, can be used as sulfur sources.
[0348] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as phosphorus sources.
[0349] Chelating agents may be added to the culture medium to keep the metal ions in solution. Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
[0350] The fermentation medium used according to the present invention generally also includes other growth factors, such as vitamins or growth promoters, which include, for example, biotin, riboflavin, thiamine, folic acid, nicotinic acid, pantothenic acid and pyridoxine. Growth factors and salts are generally derived from the components of complex culture media, such as yeast extract, molasses, corn steep liquor, etc. In addition, suitable precursors can be added to the culture medium. The exact composition of the compound in the culture medium depends to a large extent on the corresponding experiment and is determined respectively for each specific case. Information about culture medium optimization can be found in the textbook " Applied Microbiol. Physiology, A Practical Approach " (Ed. PM Rhodes, PF Stanbury, IRL Press (1997) p.53-73, ISBN 0 19 963577 3). Growth medium can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (brain heart infusion, DIFCO) etc.
[0351] All components of the culture medium are sterilized by heating (1.5 bar and 121°C for 20 minutes) or by sterile filtration. These components can be sterilized together or separately as needed. All components of the culture medium can be given at the beginning of the culture or added continuously or in batches.
[0352] The temperature of the culture is generally between 15°C and 45°C, preferably 25°C to 40°C, and can be changed or kept constant during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0. The pH value during growth can be controlled by adding alkaline compounds (such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water) or acidic compounds (such as phosphoric acid or sulfuric acid). Defoaming agents such as fatty acid polyethylene glycol esters can be used to control foaming. In order to maintain the stability of the plasmid, suitable selective substances such as antibiotics can be added to the culture medium. In order to maintain aerobic conditions, oxygen or an oxygen-containing gas mixture (such as ambient air) is supplied to the culture. The temperature of the culture is generally in the range of 20°C to 45°C. Continue to cultivate until the maximum amount of the desired product is formed. This goal is usually achieved within 10 to 160 hours.
[0353] The fermentation broth is then processed further. Depending on requirements, the biomass can be completely or partially removed from the fermentation broth by separation techniques such as centrifugation, filtration, decantation or a combination of these methods, or can remain completely therein.
[0354] If the polypeptide is not secreted in the culture medium, the cells can also be lysed and the product can be obtained from the lysate by known methods for isolating proteins. The cells can alternatively be disrupted by high-frequency ultrasound, high pressure, for example in a high-pressure cell lyser (French press), by osmosis, by the action of detergents, lytic enzymes or organic solvents, by homogenizers or by a combination of the above methods.
[0355] The polypeptide can be purified by known chromatographic techniques, such as molecular sieve chromatography (gel filtration), e.g., Q-agarose chromatography, ion exchange chromatography and hydrophobic chromatography, and other conventional techniques, such as ultrafiltration, crystallization, salting out, dialysis and native gel electrophoresis. Suitable methods are described, for example, in Cooper, TG, Biochemische Arbeitsmethoden [Biochemical processes], Verlag Walter de Gruyter, Berlin, New York, or Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin.
[0356] In order to separate the recombinant protein, it may be advantageous to use a carrier system or oligonucleotide that extends the cDNA by the nucleotide sequence of limitation, and therefore encodes a changed polypeptide or fusion protein, which is for example used for easier purification. Suitable modifications of this type are, for example, so-called "tags" that serve as anchors, such as modifications of hexa-histidine anchors or epi-positions that can be identified as antibody antigens (e.g., described in Harlow, E. and Lane, D., 1988, Antibodies:A Laboratory Manual. Cold Spring Harbor (NY) Press). These anchors can be used to connect the protein to a solid support, such as a polymer matrix, which can, for example, be used as the filler in a chromatographic column, or can be used in microtiter plates or other carriers.
[0357] At the same time, these anchors can also be used to identify proteins. In order to identify proteins, conventional labels such as fluorescent dyes, enzyme labels (which react with substrates to form detectable reaction products), or radioactive labels can also be used, alone or in combination with anchors to derivatize proteins.
[0358] h. Immobilization of polypeptides
[0359] Enzyme or polypeptide according to the present invention can be used in free form or immobilized in the method described herein.Immobilized enzyme is an enzyme fixed on an inert carrier. Suitable carrier materials and enzymes fixed thereon are known from EP-A-1149849, EP-A-1069183 and DE-OS100193773 and from the references cited therein. In this respect, the full disclosures of these documents are referred to. Suitable carrier materials include, for example, clay, clay minerals, such as kaolinite, diatomaceous earth, perlite, silicon dioxide, aluminum oxide, sodium carbonate, calcium carbonate, cellulose powder, anion exchanger materials, synthetic polymers, such as polystyrene, acrylic resins, phenolic resins, polyurethanes and polyolefins, such as polyethylene and polypropylene. In order to prepare the enzyme of load, carrier materials are usually used in a finely divided granular form, preferably in a porous form. The particle diameter of the carrier material is usually not more than 5 mm, particularly not more than 2 mm (particle size distribution curve). Similarly, when using dehydrogenase as a whole cell catalyst, free form or immobilized form can be selected. Carrier materials are, for example, calcium alginate and carrageenan. Enzymes and cells can also be directly cross-linked with glutaraldehyde (cross-linking with CLEAs). Corresponding and other immobilization techniques are described, for example, in J. Lalonde and A. Margolin "Immobilization of Enzymes" in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2002, Vol. III, 991-1032, Wiley-VCH, Weinheim. Further information on biotransformations and bioreactors for carrying out the method according to the invention is given in Rehm et al. (Ed.) Biotechnology, 2nd Edn, Vol. 3, Chapter 17, VCH, Weinheim.
[0360] i. Reaction conditions of the biocatalytic production method of the present invention
[0361] The reaction of the present invention can be carried out under in vivo or in vitro conditions.
[0362] The at least one polypeptide / enzyme present in the method of the present invention or in a single step of the multi-step method defined above may be naturally present in living cells, or one or more enzymes may be recombinantly produced in harvested cells (i.e., under in vivo conditions), dead cells, permeabilized cells, crude cell extracts, purified extracts, or in substantially pure or completely pure form (i.e., under in vitro conditions). The at least one enzyme may be present in solution or as an enzyme immobilized on a support. One or more enzymes may be present in both soluble and / or immobilized form.
[0363] The method according to the present invention can be carried out in common reactors known to those skilled in the art, and can be carried out in different scale ranges, for example, from laboratory scale (a few milliliters to tens of liters of reaction volume) to industrial scale (a few liters to thousands of cubic meters of reaction volume). If the polypeptide is used in the form of encapsulation by inanimate, optionally permeabilized cells, in the form of more or less purified cell extracts or in purified form, a chemical reactor can be used. Chemical reactors generally allow the control of the amount of at least one enzyme, the amount of at least one substrate, pH, temperature and the circulation of the reaction medium. When at least one polypeptide / enzyme is present in living cells, the process will be fermentation. In this case, biocatalytic production will be carried out in a bioreactor (fermenter), where the parameters necessary for the suitable living conditions of the living cells (e.g., culture medium with nutrients, temperature, ventilation, aerobic or anaerobic or other gases, antibiotics, etc.) can be controlled. The person skilled in the art is familiar with chemical reactors or bioreactors, for example using procedures for scaling up chemical or biotechnological processes from the laboratory scale to the industrial scale or for optimizing process parameters, which are also widely described in the literature (for biotechnological processes, see, for example, Crueger und Crueger, Biotechnologie—Lehrbuch der angewandten Mikrobiologie, 2. Ed., R. Oldenbourg Verlag, München, Wien, 1984).
[0364] The cells containing at least one enzyme can be permeabilized by physical or mechanical means such as ultrasound or radiofrequency pulses, high pressure cell lysers (French press) or chemical means such as the presence of a hypotonic medium, a lytic enzyme and a detergent in the culture medium or a combination of these methods. Examples of detergents are digitoxin, n-dodecyl maltoside, octyl glucoside, X-100, 20, deoxycholate, CHAPS (3-[(3-chloroamidopropyl)dimethylammonium]-1-propanesulfonate), P40 (ethylphenol poly (ethylene glycol ether)), etc.
[0365] Instead of living cells, non-living cell biomass containing the desired biocatalyst can also be used in the bioconversion reaction of the present invention.
[0366] If at least one enzyme is immobilized, it is attached to an inert support as described above.
[0367] The conversion reaction can be carried out batchwise, semi-batchwise or continuously. The reactants (and optionally nutrients) can be provided at the start of the reaction, or can be provided subsequently semi-continuously or continuously.
[0368] Depending on the particular reaction type, the reactions of the present invention can be carried out in aqueous, aqueous-organic or non-aqueous reaction media.
[0369] The aqueous or aqueous-organic medium may contain a suitable buffer to adjust the pH to 5 to 11, for example 6 to 10.
[0370] In aqueous-organic media, organic solvents that are miscible, partially miscible or immiscible with water can be used. Non-limiting examples of suitable organic solvents are listed below. Further examples are monobasic or polybasic, aromatic or aliphatic alcohols, particularly polybasic aliphatic alcohols, such as glycerol.
[0371] The non-aqueous medium may comprise substantially no water, ie, will comprise less than about 1% or 0.5% by weight water.
[0372] The biocatalytic process can also be carried out in an organic non-aqueous medium. Suitable organic solvents include, for example, aliphatic hydrocarbons having 5 to 8 carbon atoms, such as pentane, cyclopentane, hexane, cyclohexane, heptane, octane or cyclooctane; aromatic hydrocarbons, such as benzene, toluene, xylene, chlorobenzene or dichlorobenzene; aliphatic acyclic hydrocarbons and ethers, such as diethyl ether, methyl tert-butyl ether, ethyl tert-butyl ether, dipropyl ether, diisopropyl ether, dibutyl ether; or mixtures thereof.
[0373] The concentrations of reactants / substrates may be adapted to the optimal reaction conditions, which may depend on the specific enzyme being applied. For example, the initial substrate concentration may be from 0.1 to 0.5 M, such as from 10 to 100 mM.
[0374] The reaction temperature can be adapted to the optimal reaction conditions, which may depend on the specific enzyme being used. For example, the reaction can be carried out at a temperature of 0 to 70° C., such as 20 to 50 or 25 to 40° C. Examples of reaction temperatures are about 30° C., about 35° C., about 37° C., about 40° C., about 45° C., about 50° C., about 55° C., and about 60° C.
[0375] The process can be continued until equilibrium is reached between the substrate and the subsequent product, but can be stopped earlier. Common process times are 1 minute to 25 hours, particularly 10 minutes to 6 hours, for example 1 hour to 4 hours, particularly 1.5 hours to 3.5 hours. These parameters are non-limiting examples of suitable process conditions.
[0376] If the host is a transgenic plant, optimal growing conditions can be provided, such as optimal light, water, and nutrient conditions.
[0377] The specific reaction conditions for preparing the alkyl acetate compounds are as follows. The acetyltransferase can be present as a purified polypeptide or a whole cell system in an aqueous environment incubated at 20 to 35°C and a pH of 4 to 7. The substrate concentration can vary between 10 and 100 mM.
[0378] k. Product separation
[0379] The method of the present invention may further include the step of recovering the final product or intermediate product, which is optionally in the substantially pure form of a stereoisomer or enantiomer. The term "recovery" includes extracting, harvesting, separating or purifying the compound from a culture medium or reaction medium. The recovery of the compound can be carried out according to any conventional separation or purification method known in the art, including but not limited to treatment with conventional resins (e.g., anion or cation exchange resins, nonionic adsorption resins, etc.), treatment with conventional adsorbents (e.g., activated carbon, silicic acid, silica gel, cellulose, aluminum oxide, etc.), changes in pH, solvent extraction (e.g., using conventional solvents such as alcohol, ethyl acetate, hexane, etc.), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, freeze-drying, etc.
[0380] The identity and purity of the isolated product can be determined by known techniques, such as high performance liquid chromatography (HPLC), gas chromatography (GC), spectroscopy (e.g. IR, UV, NMR), staining methods, TLC, NIRS, enzyme or microbiological assays (see, for example: Patek et al. (1994) Appl. Environ. Microbiol. 60: 133-140; Malakhova et al. (1996) Biotekhnologiya 1127-32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70. Ullmann's Encyclopedia of Industrial Chemistry (1996) Bd. A27, VCH: Weinheim, S. 89-90, S. 521-540, S. 540-547, S. 559-566, 575-581 and S.581-587; Michal, G (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. et al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, Bd. 17.).
[0381] The cyclic terpene compounds produced by any of the methods described herein can be converted into derivatives such as, but not limited to, hydrocarbons, esters, amides, glycosides, ethers, epoxides, aldehydes, ketones, alcohols, diols, acetals, or ketals. Terpene compound derivatives can be obtained by chemical methods such as, but not limited to, oxidation, reduction, alkylation, acylation, and / or rearrangement. Alternatively, terpene compound derivatives can be obtained by biochemical methods by contacting the terpene compound with an enzyme such as, but not limited to, an oxidoreductase, a monooxygenase, a dioxygenase, or a transferase. Biochemical conversions can be performed in vitro using isolated enzymes, enzymes from lysed cells, or in vivo using whole cells.
[0382] 1. Fermentation of acetic acid and alkyl alcohols
[0383] The present invention also relates to a method for the fermentative production of alkyl acetate.
[0384] The fermentation used according to the invention can be carried out, for example, in stirred fermentor tanks, bubble columns and loop reactors. For a comprehensive overview of possible method types, including agitator types and geometric designs, see "Chmiel: Bioprozesstechnik: Einfuhrung in die Bioverfahrenstechnik, Band 1". In the method of the present invention, available typical variations are those known to those skilled in the art or, for example, explained in "Chmiel, Hammes and Bailey: Biochemical Engineering", such as batch, fed-batch, repeated fed-batch or continuous fermentation with or without biomass recovery. Depending on the production strain, injection of air, oxygen, carbon dioxide, hydrogen, nitrogen or a suitable gas mixture can be used to achieve a good yield (YP / S).
[0385] The culture medium to be used must meet the requirements of the specific strain in an appropriate manner. Descriptions of culture media for various microorganisms are given in the manual "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington DC, USA, 1981).
[0386] The culture media which can be used according to the invention generally comprise one or more carbon sources, nitrogen sources, inorganic salts, vitamins and / or trace elements.
[0387] The preferred carbon source is sugar, for example monose, disaccharide or polysaccharide. Very good carbon source is for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose. Sugar also can be added in the substratum by other by-products of complex compound (for example molasses) or sugar refining. It is also favourable to add the mixture of various carbon sources. Other possible sources of carbon are oil and fat, for example soybean oil, sunflower seed oil, peanut oil and coconut oil, fatty acid for example palmitic acid, stearic acid or linoleic acid, alcohol for example glycerol, methanol or ethanol, and organic acid, for example acetic acid or lactic acid.
[0388] The nitrogen source is generally an organic or inorganic nitrogen compound or a material containing such a compound. Examples of nitrogen sources include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex nitrogen sources, such as corn steep liquor, soy flour, soy protein, yeast extract, meat extract, etc. The nitrogen sources can be used alone or in combination.
[0389] Inorganic salt compounds that may be present in the culture medium include chlorides, phosphates or sulfates of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
[0390] Inorganic sulfur-containing compounds, such as sulfates, sulfites, dithionites, tetrasulfates, thiosulfates, sulfides, and organic sulfur compounds, such as mercaptans and thiols, can be used as sulfur sources.
[0391] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as phosphorus sources.
[0392] Chelating agents may be added to the culture medium to keep the metal ions in solution. Particularly suitable chelating agents include dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
[0393] The fermentation medium used according to the present invention may also contain other growth factors, such as vitamins or growth promoters, including, for example, biotin, riboflavin, thiamine, folic acid, niacin, pantothenic acid, and pyridoxine. Growth factors and salts are typically derived from complex components of the culture medium, such as yeast extract, molasses, corn steep liquor, etc. In addition, suitable precursors may be added to the culture medium. The precise composition of the compounds in the culture medium depends largely on the specific experiment and must be determined for each specific case. Information on culture medium optimization can be found in the textbook "Applied Microbiol. Physiology, A Practical Approach" (1997). Growth media can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (brain heart infusion, DIFCO).
[0394] All components of the culture medium are sterilized by heating (1.5 bar and 121°C for 20 minutes) or by sterile filtration. These components can be sterilized together or separately as needed. All components of the culture medium can be given at the beginning of growth, or you can choose to add them continuously or in batches.
[0395] The temperature of the culture is generally between 15°C and 45°C, preferably 25°C to 40°C, and can be kept constant or can be varied during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0. The pH during growth can be controlled by adding alkaline compounds (such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water) or acidic compounds (such as phosphoric acid or sulfuric acid). Defoaming agents such as fatty acid polyethylene glycol esters can be used to control foaming. In order to maintain the stability of the plasmid, suitable substances with selective effects such as antibiotics can be added to the culture medium. In order to maintain aerobic conditions, oxygen or an oxygen-containing gas mixture (such as ambient air) is supplied to the culture. The temperature of the culture is generally between 20°C and 45°C. Cultivation is continued until the maximum amount of the desired product is formed. This goal is usually achieved within 1 to 160 hours.
[0396] The method of the present invention may further comprise the step of recovering the ammonium alkyl acetate.
[0397] The term "recovery" includes extracting, harvesting, isolating or purifying the compound from the culture medium. The recovery of the compound can be carried out according to any conventional separation or purification method known in the art, including but not limited to treatment with conventional resins (e.g., anion or cation exchange resins, nonionic adsorption resins, etc.), treatment with conventional adsorbents (e.g., activated carbon, silicic acid, silica gel, cellulose, alumina, etc.), pH modification, solvent extraction (e.g., using conventional solvents such as alcohols, ethyl acetate, hexane, etc.), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization, etc.
[0398] Before the separation of expectation, the biomass of fermented liquid can be removed.The method of removing biomass is well known to those skilled in the art, for example, filtration, sedimentation and flotation.Therefore, can for example, remove biomass by centrifuge, separator, decanter, filter or in flotation equipment.In order to reclaim valuable product to the greatest extent, it is usually recommended to wash biomass, for example, in the form of diafiltration.The selection of method depends on the content of biomass and the character of biomass in the fermented liquid, and the interaction of biomass and valuable product.
[0399] In one embodiment, the fermentation broth can be sterilized or pasteurized. In another embodiment, the fermentation broth is concentrated. This concentration can be performed in batches or continuously, as desired. The pressure and temperature ranges should be selected to prevent product damage and minimize equipment and energy use. Skilled selection of pressure and temperature levels for multi-stage evaporation can be particularly energy-efficient.
[0400] The following examples are illustrative only and are not meant to limit the scope of the claims and embodiments described herein.
[0401] Numerous possible variations that will become immediately apparent to those skilled in the art after considering the disclosure provided herein also fall within the scope of the invention.
[0402] Experimental part
[0403] Material:
[0404] Unless otherwise stated, all chemical and biochemical materials, and microorganisms or cells used herein are commercially available products.
[0405] Unless otherwise indicated, recombinant proteins were cloned and expressed by standard methods, such as those described in Sambrook, J., Fritsch, EF and Maniatis, T., Molecular cloning: A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
[0406] Gas chromatography-mass spectrometry (GC-MS)
[0407] An Agilent Intuvo 9000 series gas chromatography system was equipped with a DB-5MS UI column (10 m × 0.25 mm × 0.25 μm film thickness (custom column, manufactured by Agilent Technologies Inc, Santa Clara, CA). The gas chromatograph was connected to two detectors via a 1:1 detector splitter chip (G4588-60502, Agilent Technologies Inc, Santa Clara, CA). The first detector was an Agilent 5977B series mass spectrometer, and the second detector was a standard Intuvo 9000 flame ionization detector (FID). The carrier gas was helium at a flow rate of 2.5 ml / min. The injector was operated in split (1:100) mode, and the injector temperature was set to 240°C. The oven temperature was programmed to increase from 150°C (hold for 0.1 min) to 240°C at a rate of 40°C / min, then to 325°C at a rate of 180°C / min and held for 0.5 min).
[0408] Example 1
[0409] Acetyltransferase candidates are selected to convert salbutane sesquiterpenes to salbutane acetylated sesquiterpenes.
[0410] Acetyltransferases constitute a genetically diverse class of enzymes, with over 8,000 known representatives (PFAM database: PF02458 transferase family). Despite the vast repertoire of molecules accepted as substrates by acetyltransferases, none have been reported to accept sesquiterpene alcohols as substrates. To identify acetyltransferases capable of acetylation of bisulfanane-type sesquiterpene alcohols, 54 (Table 1) were selected from the thousands of known acetyltransferases from plants, fungi, and bacteria based on the following rationale:
[0411] Members of two of the five known clades of the plant acetyltransferase family, clades 3 and 5, have been identified that use acetyl-CoA as the acyl donor for acetylation of alkaloids and terpenoids (Curr Opin Plant Biol. 2006, 9(3):331-40). In addition, some substrates used by acetyltransferases from clades 3 and 5 are bulky, polycyclic, and carry sterically hindered alcohol groups as acyl acceptors (BMC Genomics 2011, 12:236; Curr Opin Plant Biol. 2006, 9:331-40; Elife. 2017 Mar 14; 6:e23001; Planta. 2015, 242:709-19). Based on this, 21 candidates were selected from plant BAHD family evolutionary branches 3 and 5, including the identified acetyltransferase involved in the biosynthesis of the polycyclic diterpene taxol (Proc Natl Acad Sci US A. 2000, 18; 97(2): 583–587) and two acetyltransferases from Plectranthus barbatus involved in the biosynthesis of the bicyclic lysane diterpene forskolin (Elife 2017, 14; 6: e23001).
[0412] Similar to the candidate plants, seven fungal acetyltransferases were selected based on their recognized or experimentally determined ability to accept acetyl-CoA as an acyl donor and the structural characteristics of their substrates: bulky polycyclic compounds with sterically hindered alcohol groups (FEMS Microbiol Lett. 2005, 251: 193-201; Chembiochem. 2009, 10: 2325-8; Biotechnol Biotechnol Equip. 2014, 28(5): 818-826; Nat Chem. 2010, 2: 858-64). Among them, the protein AstG (from Aspergillus oryzae, NCBI accession number XP_023091083.1), which is involved in the biosynthesis of the acetyl-acid esterification of the telolide-type sesquiterpene lactone astellolide (Sci Rep. 2016, 6: 32865), was selected.
[0413] In addition, 21 putative fungal acetyltransferases were retrieved from the NCBI protein database based on their sequence similarity to AstG using a PSI Blast search (Trends Biochem Sci. 2002, 27:161-4.) (standard parameters and two iterations). The results were visualized on a phylogenetic tree using the NCBI Blast Tree View function to display the homology between AstG and 500 PSI-Blast derived sequences. Candidates were selected based on their homology to the query sequence, which was from a single branch of the phylogenetic tree.
[0414] Finally, chloramphenicol acetyltransferase is a promiscuous enzyme that can accommodate substrates larger than chloramphenicol (Protein Sci. 2012, 21(4): 520–530). Therefore, five bacterial chloramphenicol acetyltransferases of classes 1 to 3 were selected as putative chloramphenicol acetyltransferases from the NCBI protein database or from the literature (Biochem J. 1990, 272: 505–10).
[0415] Table 1: Acetyltransferases selected for the conversion of bisulphane sesquiterpenes to bisulphane acetylated sesquiterpenes
[0416]
[0417]
[0418]
[0419] Example 2
[0420] In vivo acetate conversion in Saccharomyces cerevisiae co-expressing pyrifos synthase and different acetyltransferase candidates Production of phytosteryl esters.
[0421] Each enzyme candidate was screened for in vivo bioconversion of zizolin to zizolin acetate. To perform the screening, the acetyltransferase candidate was co-expressed with the gene encoding zizolin synthase XP_007369631.1, NCBI Accession No. XP_007369631.1, from Dichomitus squalens in an engineered Saccharomyces cerevisiae strain that has elevated levels of endogenous farnesyl diphosphate (FPP).
[0422] To increase the level of endogenous FPP pools in Saccharomyces cerevisiae cells, additional copies of all yeast endogenous genes involved in the mevalonate pathway, from ERG10 encoding acetyl-CoA C-acetyltransferase to ERG20 encoding FPP synthase, were integrated into the genome of Saccharomyces cerevisiae strain CEN.PK2-1C (Euroscarf, Frankfurt, Germany) under the control of a galactose-inducible promoter, similar to that described in Paddon et al., Nature, 2013, 496: 528-532. Briefly, three cassettes were integrated into the LEU2, TRP1, and URA3 loci, respectively. The first cassette contains the ERG20 gene and a truncated HMG1 (tHMG1, as described in Proc Natl Acad Sci USA, 1997, 109: E111-8) under the control of the GAL10 / GAL1 bidirectional promoter, and the ERG19 and ERG13 genes also under the control of the GAL10 / GAL1 promoter, and is flanked by two 100 nucleotide regions corresponding to the upstream and downstream portions of LEU2, respectively. In the second cassette, the genes IDI1 and tHMG1 are under the control of the GAL10 / GAL1 promoter, while the gene ERG13 is under the control of the GAL7 promoter region, and is flanked by two 100 nucleotide regions corresponding to the upstream and downstream portions of TRP1, respectively. The third cassette contains the ERG10, ERG12, tHMG1, and ERG8 genes, all under the control of the GAL10 / GAL1 promoter, flanked by two 100-nucleotide regions corresponding to the upstream and downstream portions of URA3. All genes in the three cassettes contain 200 nucleotides of their own terminator regions. Furthermore, upstream of the ERG9 promoter region, an additional copy of GAL4 under the control of a mutant form of its own promoter, as described in Proc Natl Acad Sci USA, 1991, 88:8597-8601, was integrated. In addition, ERG9 expression was modified by promoter swapping. A cassette containing the HIS3 gene with its own promoter and terminator was used to delete the GAL7, GAL10, and GAL1 genes. The resulting strain was mated with strain CEN.PK2-1D (Euroscarf, Frankfurt, Germany) to obtain a diploid strain designated YST045, which was induced to form spores according to Solis-Escalante et al., FEMS Yeast Res, 2015, 15: 2. Spores were isolated by resuspending the asci in 200 μL of 0.5 M sorbitol and 2 μL of zymolyase (1000 U mL -1, Zymo research, Irvine, CA) and incubated for 20 minutes at 37° C. The mixture was then plated on a medium containing 20 g / L protein, 10 g / L yeast extract, and 20 g / L agar, and one germinated spore was isolated and designated YST069.
[0423] To express XP_007369631.1 and the acetyltransferases evaluated in YST069, plasmids were constructed in vivo using yeast endogenous homologous recombination as previously described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. The plasmid consisted of four DNA fragments for co-transformation of Saccharomyces cerevisiae. These fragments were:
[0424] a) Plasmid pF167 (SEQ ID NO: 1) linearized by enzymatic restriction with BsmBI. pF167 was previously constructed by in vivo assembly in yeast and contains the yeast marker LEU2 with its own promoter and terminator, the E. coli marker AmpR, a 2μ yeast origin of replication, the E. coli pUC origin of replication, and the sequences 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 2) and 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 3) for homologous recombination;
[0425] b) a fragment consisting of the sequence 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 2), the terminator region of the yeast gene PGK1, and the DNA codons of sesquiterpene synthase XP_007369631.1 (optimized for expression in Saccharomyces cerevisiae) (SEQ ID NO: 4), obtained by DNA synthesis (ATUM, Menlo Park, CA 94025). The bidirectional GAL1 / GAL10 promoter region from yeast was added to this fragment by PCR overlap extension (Yolov and Shabarova., Nucleic Acids Res. 1990, 18(13): 3983-6);
[0426] c) a fragment consisting of 60 bp corresponding to the first nucleotides of the yeast GAL10 promoter region, one of the acetyltransferase DNA coding sequences to be evaluated (codon-optimized for expression in Saccharomyces cerevisiae), and 60 bp of the yeast CYC1 terminator region, obtained by DNA synthesis (ATUM, Menlo Park, CA 94025); and
[0427] d) A fragment consisting of the terminator region of the yeast gene CYC1 and the sequence 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 3), which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025).
[0428] YST069 was transformed with the fragments required for in vivo plasmid assembly. Yeast transformation was performed using a lithium acetate protocol as described in Gietz and Woods, Methods Enzymol., 2002, 350:87-96. The transformation mixture was plated onto SmLeu medium containing 6.7 g / L yeast nitrogen base without amino acids (BD Difco, New Jersey, USA), 1.6 g / L leucine-free drip supplement (Sigma Aldrich, Missouri, USA), 20 g / L glucose, and 20 g / L agar. The plates were incubated at 30°C for 3 to 4 days. Using a single colony, calendulin and calendulin acetate were produced in deep-well plates containing 250 μL of culture medium as described in Westfall et al., Proc Natl Acad Sci USA, 2012, 109: E111-118 and 50 μL of diisodecyl adipate (abcr GmbH, Germany) as an organic overlay. The deep-well plates were incubated at 30°C for 3 days in a plate incubator. To extract calendulin and calendulin acetate produced by the yeast cells, each well of the deep-well plate was extracted with 700 μL of ethyl acetate containing an internal standard. The production of calendulin and calendulin acetate was identified using GC-MS analysis and quantified by GC-FID using the above-mentioned internal standard.
[0429] Under these experimental conditions, zygomycin acetate was detected for all nine combinations of zygomycin synthases and acetyltransferases (Table 2). It is noteworthy that under non-optimized screening conditions, the two most active acetyltransferases (CrDAT and FgaAT) produced zygomycin acetate at titers exceeding 150 mg / L. The GC-FID chromatograms are shown in Table 2. Figure 2 In addition, Figure 2It was shown that the MS spectrum of yeast-derived hydoxyl acetate was identical to that of the reference hydoxyl acetate.
[0430] Interestingly, the most active acetyltransferase in our screen, CrDAT, is a member of the plant BAHD family, clade 3, which is involved in plant alkaloid biosynthesis. However, other tested acetyltransferases from the same family and clade, PsSalAT and RsVISY, which are also involved in plant alkaloid biosynthesis (thebaine and vinorine, respectively), were inactive when using zizol as a substrate. Furthermore, FgaAT from Aspergillus fumigatus, also involved in alkaloid biosynthesis (active against Fumigaclavine B), produced significant amounts of zizolyl acetate in our screen. In contrast, surprisingly, the putative Fumigaclavine B O-acetyltransferase, GAO81666.1, produced an order of magnitude less zizolyl acetate than FgaAT.
[0431] Notably, although AstG is involved in the biosynthesis of the modified bisulfan-type sesquiterpenoid astellolide, neither the acetyltransferase AstG nor any of the proteins selected based on their similarity to AstG (excluding GAO81666.1, see above) produces the bisulfan-acetylated sesquiterpenoid fennel acetate.
[0432] The only acetyltransferases identified in diterpene biosynthesis are those involved in the production of taxol and forskolin. Of the eight acetyltransferases tested from C. forskohlii, only CfACT1-6 and CfACT1-8 were able to acetylate taurocholine. Although the genes TcTAT and TcDBAT are able to acetylate structurally similar intermediates in the biosynthesis of taxol (4(20),11(12)-dien-5a-yl acetate and baccatin III, respectively), only TcTAT produces taurocholine acetate.
[0433] To add to the complexity demonstrated in identifying an acetyltransferase capable of using zizol as an acyl acceptor, only one of the five substrate-universal chloramphenicol acetyltransferases tested was able to convert zizol to zizyl acetate.
[0434] Table 2: Acetyltransferases found to convert zirconia to zirconia acetate in Saccharomyces cerevisiae
[0435]
[0436] Example 3
[0437] In vivo acetate uptake in Saccharomyces cerevisiae co-expressing acetyltransferase and selected acetyltransferase candidates Production of alkenyl esters.
[0438] In order to produce fenvalerate acetate in Saccharomyces cerevisiae, nine acetyltransferases (CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6, CfACT1-8) capable of converting fenvalerate acetate as shown in Example 2 can be used to evaluate the conversion of fenvalerate to fenvalerate acetate.
[0439] By co-expressing each selected acetyltransferase candidate with the gene encoding the acetyltransferase XP_006461126 from Agaricus bisporus (NCBI Accession No. XP_006461126), acetyl acetate was produced in vivo in the engineered Saccharomyces cerevisiae strain YST069, which has increased levels of endogenous FPP (see Example 2).
[0440] To express XP_006461126 and selected acetyltransferases (CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6, and CfACT1-8) in YST069, plasmids were constructed in vivo using yeast endogenous homologous recombination as previously described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. The plasmid consisted of four DNA fragments for co-transformation of Saccharomyces cerevisiae. These fragments were:
[0441] a) Plasmid pF167 (SEQ ID NO: 1) linearized by enzymatic restriction with BsmBI. pF167 was previously constructed by in vivo assembly in yeast and contains the yeast marker LEU2 with its own promoter and terminator, the E. coli marker AmpR, a 2μ yeast origin of replication, the E. coli pUC origin of replication, and the sequences 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 2) and 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 3) for homologous recombination;
[0442] b) a fragment consisting of the sequence 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 2), the terminator region of the yeast gene PGK1, and the DNA codons for sesquiterpene synthase XP_006461126 (optimized for expression in Saccharomyces cerevisiae) (SEQ ID NO: 6), obtained by DNA synthesis (ATUM, Menlo Park, CA 94025). The bidirectional GAL1 / GAL10 promoter region from yeast was added to this fragment by PCR overlap extension (Yolov and Shabarova., Nucleic Acids Res. 1990, 18(13): 3983-6);
[0443] c) a fragment consisting of 60 bp corresponding to the first nucleotides of the yeast GAL10 promoter region, one of the acetyltransferase DNA coding sequences to be evaluated (codon-optimized for expression in Saccharomyces cerevisiae), and 60 bp of the yeast CYC1 terminator region, obtained by DNA synthesis (ATUM, Menlo Park, CA 94025); and
[0444] d) A fragment consisting of the terminator region of the yeast gene CYC1 and the sequence 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 3), which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025).
[0445] Yeast transformation, screening conditions, and quantification of zebuconazole and zebuconazole acetate were performed as described in Example 2 for the production of zebuconazole and zebuconazole acetate.
[0446] The relative amounts of zeyl acetate (from Example 2) and fenvalerate acetate are shown in Table 1. Figure 3 and Figure 4 Of the nine candidate enzymes tested, seven (CrDAT, FgaAT, OAH94415.1, TcTAT, GAO81666.1, CfACT1-6, and CfACT1-8) produced buprenoyl acetate. Given the high structural similarity between buprenoyl acetate and buprenoyl acetate, similar relative conversion rates were expected.
[0447] Surprisingly, significant variations were found in the conversion of cinnamyl acetate to its corresponding acetate. Specifically, CrDAT, which produced the highest relative amounts of cinnamyl acetate, was found to be among the lowest producers of cinnamyl acetate. In contrast, FgaAT and CfACT1-8 produced the highest relative amounts of acetate, while their activity toward cinnamyl acetate was relatively weak. These surprising findings suggest the difficulty in identifying suitable acetyltransferase candidates that accept nonphysiological substrates.
[0448] Example 4
[0449] Based on the acetyltransferase activity towards bumitol and fennel, the enzyme was selected for converting bumitane sesquiterpenes to fennel. Acetyltransferase candidates for acetylated alkyl sesquiterpenes.
[0450] a) Experiment 1
[0451] To identify other acetyltransferases capable of acetylation of bumane-type sesquiterpenoids, the amino acid sequences of the acetyltransferases CrDAT and FgaAT (shown in Examples 2 and 3, respectively), which are active on bumaneol and bumaneol, were used in an NCBI Protein Blast search to search for close protein sequence homologs. Protein Blast searches were performed using default parameters (Tatiana et al, FEMS Microbiol Lett., 1999, 174: 247-250, 1999).
[0452] The plant acetyltransferase XP_008340165.2 homologous to CrDAT and four fungal acetyltransferases corresponding to FgaAT (KEY80391, PYI04555.1, XP_001276734.1, XP_024709055.1) were retrieved from the Blast search and are listed in Table 3.
[0453] Table 3: Acetyltransferases selected based on amino acid sequence homology to CrDAT or FgaAT for the conversion of succinanyl sesquiterpenes to succinanyl acetylated sesquiterpenes
[0454]
[0455] b) Experiment 2
[0456] In addition, additional acetyltransferase candidates were retrieved from the transcriptomes of the liverwort Bazzania trilobata and the fern Dryopteris fragrans. Liverworts are a rich source of terpenoids, including sesquiterpenes. In addition, hydoxyl acetate and hydoxyl caffeate are reported to be natural products from the liverwort liverwort (Asakawa et al, Phytochemistry, Volume 30, Issue 9, 1991, Pages 3037-3040). Similarly, several different natural products, including hydoxyl acetate, have been reported in Dryopteris. (Hideyuki Ito et al. Chem. Pharm. Bull. 48(8)1190-1195(2000); Froissard Det al. Nat Prod Commun. 2014 Jan;9(1):137-40.)
[0457] The Bazzania trilobata (NCBI accession number ER364415) transcriptome was assembled using the CLC genomic workbench (Qiagen), resulting in a total of 22,083 contigs with an average length of 1,225 base pairs. The CrDAT amino acid sequence was used to search for homologous sequences in the Bazzania trilobata transcriptome. For this search, the tBlastn algorithm (Altschul et al. 1990, J. Mol. Biol. 215, 403-410) was used with default parameters. Transcripts with an E value exceeding 0.001 were considered. Ten transcripts belonging to the plant acetyltransferase BAHD family were selected, with amino acid sequence homology as low as 20% to CrDAT.
[0458] Plant material of D. fragrans was collected from northern China. Fresh leaves of D. fragrans (sample ID PNLI20141074) were used for transcriptome analysis. Total RNA of D. fragrans was extracted using the RNeasy Plant Mini Kit (Cat. No. 74904) from QIAGEN. The RNA was analyzed using the RNeasy Plant Mini Kit for Illumina. Total RNA sample PNLI20141074 was processed using the Ultra™ RNA Library Preparation Kit (NEB, USA) and the TruSeq PE Cluster Kit (Illumina, USA), and then sequenced on an Illumina Miseq sequencer. 20.88 million 2x 350bp paired-end reads were generated. Reads were assembled using Trinity (http: / / trinityrnaseq.sf.net / ) software, and 85,753 contigs with an N50 of 1373bp were obtained. Contigs were analyzed using EMBOSS software (http: / / emboss.sourceforge.net / ) to obtain protein sequences. The amino acid sequence of acetyltransferase ERR364415-1_contig_8546 (as described above, obtained from the Bazzania trilobata (NCBI accession number ERR364415) transcriptome) (SEQ ID NO: 144) was used to search for homologous sequences in the Dryopteris trilobata transcriptome. For this search the tBlastn algorithm (Altschul et al 1990, J. Mol. Biol. 215, 403-410) was used with standard parameters. This method provided 20 transcripts belonging to the BAHD family of plant acetyltransferases.
[0459] Example 5
[0460] By co-expressing the enzymes for producing zizol, buminol or bicyclic farnesol and selected acetyltransferase candidates, Selected enzymes produce alkyl acetate in vivo in Saccharomyces cerevisiae.
[0461] An expanded screen for acetyltransferases was performed to convert zizol, buxinol, and bicyclic farnesol to their corresponding acetate derivatives. A total of 89 acetyltransferases described in Table 1 of Example 1 and Example 4 were screened in vivo in engineered Saccharomyces cerevisiae cells. The screening data generated on the initial number of acetyltransferases described in Examples 2 and 3 were not repeated. Therefore, only new combinations of acetyltransferases and Saccharomyces cerevisiae cells that produced zizol, buxinol, or bicyclic farnesol that were not tested in Examples 2 and 3 were screened.
[0462] As described above in Examples 2 and 3, the engineered Saccharomyces cerevisiae strain YST069 was used to screen for the production of zeyl acetate and fenvalerate acetate.
[0463] Bicyclic farnesyl acetate was produced in vivo in an engineered Saccharomyces cerevisiae YST069 strain by co-expressing each selected acetyltransferase candidate with the enzymes AstC (SEQ ID NO: 138), AstI (SEQ ID NO: 140), and AstK (SEQ ID NO: 142), which are responsible for producing bicyclic farnesol from astellolide biosynthesis (Yasutomo Shinohara et al. Sci Rep. 2016, 6: 32865).
[0464] To express AstC and AstI simultaneously, an expression cassette containing codons and bidirectional GAL1 / GAL10 promoters optimized for the Saccharomyces cerevisiae version of the gene encoding AstC (SEQ ID NO: 138) and AstI (SEQ ID NO: 140) was constructed and integrated into the genome of YST069 to generate a new strain called YST216. Codon-optimized DNA sequences for AstC and AstI were obtained by DNA synthesis (ATUM, Menlo Park, CA 94025). The bidirectional GAL1 / GAL10 promoter region from yeast was added to these genes by PCR overlap extension (Yolov and Shabarova., Nucleic Acids Res. 1990, 18(13): 3983-6).
[0465] To express AstK and the acetyltransferases evaluated in YST216, plasmids were constructed in vivo using yeast endogenous homologous recombination as previously described in Kuijpers et al., Microb Cell Fact., 2013, 12:47. The plasmid consisted of four DNA fragments for co-transformation of Saccharomyces cerevisiae. These fragments were:
[0466] a) Plasmid pF167 (SEQ ID NO: 1) linearized by enzymatic restriction with BsmBI.
[0467] b) a fragment consisting of the sequence 5'-GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG-3' (SEQ ID NO: 2), the terminator region of the yeast gene PGK1, and the codons of the AstK DNA sequence optimized for expression in Saccharomyces cerevisiae (SEQ ID NO: 141), obtained by DNA synthesis (ATUM, Menlo Park, CA 94025). The bidirectional GAL1 / GAL10 promoter region from yeast was added to this fragment by PCR overlap extension (Yolov and Shabarova., Nucleic Acids Res. 1990, 18(13): 3983-6);
[0468] c) a fragment consisting of 60 bp corresponding to the first nucleotides of the yeast GAL10 promoter region, one of the acetyltransferase DNA coding sequences to be evaluated (codon-optimized for expression in Saccharomyces cerevisiae), and 60 bp of the yeast CYC1 terminator region, obtained by DNA synthesis (ATUM, Menlo Park, CA 94025); and
[0469] d) A fragment consisting of the terminator region sequence 5'-AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT-3' (SEQ ID NO: 3) of the yeast gene CYC1, which was obtained by DNA synthesis (ATUM, Menlo Park, CA 94025).
[0470] YST216 was transformed with the fragments required for in vivo plasmid assembly. Yeast transformation was performed as described in Example 2. The screening conditions and quantification of bicyclic farnesol and bicyclic farnesyl acetate were the same as described in Example 2, except that 25 μL of mineral oil (2705-01, VWR International, LLC.) was used as an organic overlay during the screening process.
[0471] result:
[0472] In addition to the nine enzymes previously described as active on zizylosan (CrDAT, FgaAT, OAH94415.1, TcTAT, CrMAT, LiAAT-4, GAO81666.1, CfACT1-6, CfACT1-8) (see Example 2), under these experimental conditions, zizylosan acetate was also detected when the acetyltransferase ERR364415-1_contig_8546 from Bazzania trilobata (SEQ ID NO: 124 or 144) and DfATC13 from Dryopteris fragrans (SEQ ID NO: 118) were used. However, their activities were lower than those of CrDAT and FgaAT. The relative amounts of zizylosan acetate are shown in Figure 5 .
[0473] In addition to the seven candidate enzymes that can convert buminol to buminyl acetate (CrDAT, FgaAT, OAH94415.1, TcTAT, GAO81666.1, CfACT1-6, and CfACT1-8), three additional acetyltransferases, XP_001258079.1 from Aspergillus fischeri (SEQ ID NO: 127), ERR364415-1_contig_8546 from Bazzania trilobata (SEQ ID NO: 124 or 144), and DfATC13 from Dryopteris fragrans (SEQ ID NO: 118), were found to produce buminyl acetate from buminol in the extended screen. The relative amounts of buminyl acetate obtained are shown in Table 1. Figure 6 . Figure 7 The MS spectra of yeast-derived fenvalerate acetate were identical to those of the reference fenvalerate acetate. Interestingly, under these experimental conditions, ERR364415-1_contig_8546 and DfATC13 showed the highest activity among all acetyltransferases tested.
[0474] AstC, AstI, and AstK detected bicyclic farnesyl acetate in combination with 13 of the 89 acetyltransferases tested. Figure 8 The MS spectrum of yeast-derived bicyclic farnesyl acetate is shown to be identical to that of reference bicyclic farnesyl acetate. The relative amounts of bicyclic farnesyl acetate are shown in Figure 9The acetyltransferases FgaAT from Aspergillus fumigatus and ERR364415-1_contig_8546 from Bazzania trilobata showed the highest acetylation activity towards bicyclic farnesol. Among the 13 acetyltransferases discovered, namely, CrDAT, FgaAT, TcTAT, CrMAT, GAO81666.1, CfACT1-6, CfACT1-8, and BAU61551.1 (SEQ ID NO: 133), PsSalAT (SEQ ID NO: 136), XP_001217250.1 (SEQ ID NO: 130), ERR364415-1_contig_8546 (SEQ ID NO: 124 or 144), PYI04555.1 (SEQ ID NO: 121 or 143), DfACT13 (SEQ ID NO: 134), and PsSalAT (SEQ ID NO: 137) were also found. IDNO: 118) (they are active on bicyclic farnesol), and 9 compounds, namely CrDAT, FgaAT, TcTAT, CrMAT, GAO81666.1, CfACT1-6, CfACT1-8, ERR364415-1_contig_8546, and DfACT13, were also found to be active on zizyphus ol and astellolide. It is worth noting that the acetyltransferase AstG involved in the biosynthesis of the aromatic esterified astellolide (SciRep. 2016, 6: 32865) is inactive on any of the astellolide-type sesquiterpenoids tested. This once again demonstrates the uncertainty and complexity of identifying acetyltransferases that can use zizyphus ol, astellolide, or bicyclic farnesol as acyl acceptors.
[0475] The contents of the cross-referenced documents are incorporated herein by reference.
[0476] The sequences referred to in this article are:
[0477]
[0478]
[0479]
[0480] NA = Nucleic Acid AA = amino acid.
[0481] Sequence Listing
[0482] SEQ ID NO: 1
[0483] Plasmid pF167
[0484]
[0485] SEQ ID NO:2
[0486] Sequences for homologous recombination
[0487] GCACTTGCTACACTGTCAGGATAGCTTCCGTCACATGGTGGCGATCACCGTACATCTGAG
[0488] SEQ ID NO:3
[0489] Sequences for homologous recombination
[0490] AGGTGCAGTTCGCGTGCAATTATAACGTCGTGGCAACTGTTATCAGTCGTACCGCGCCAT
[0491] SEQ ID NO:4
[0492] XP_007369631.1 DNA sequence of Dichomitus squalens pyrenoidose synthase, codon-optimized for expression in Saccharomyces cerevisiae
[0493]
[0494] SEQ ID NO:5
[0495] XP_007369631.1 Amino acid sequence of Dichomitus squalens pyrol synthase
[0496] MASIHRRYTTLILDLGDVLFRWSPKTETAIPPQQLKDILSSVTWFEYERGRLSQEACYERCAEEFKIEASVIAEAFKQARGSLRPNEEFIALIRDLRREMHGDLTVLALSNISLPDYEYEYIMSLSSDWTTVF DRVFPSALVGERKPHLGCYRKVISEMNLEPQTTVFVDDKLDNVASARSLGMHGIVFDNQANVFRQLRNIFGDPIRRGQEYLRGHAGKLESSTDNGLIFEENFTQLIIYELTQDRTLISLSECPRTWNFFRGE PLFSETFPDDVDTTSVALTVLQPDRALVNSVLDEMLEYVDADGIMQTYFDRSRPRMDPFVCVNVLSLFYENGRGHELPRTLDWVYEVLLHRAYHGGSRYYLSPDCFLFFMSRLLKRADDPAVQARLRPLFVE RVNERVGAAGDSMDLAFRILAAASVGVQCPRDLERLTAGQCDDGGWDLCWFYVFGSTGVKAGNRGLTTALAVVGSTGVTAIGRPPSPSSAASSSFRPSSPYKFLGISRPASPIRFGDLLRPWRKMSRSNLKSQ
[0497] SEQ ID NO:6
[0498] XP_006461126 Agaricus bisporus buprenorphine synthase DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0499]
[0500] SEQ ID NO:7
[0501] XP_006461126 Protein sequence of Agaricus bisporus buprenorphine synthase
[0502] MAPPQRPFTAIVFDIGDVLFQWSATTKTSISPKTLRSILNCPTWFDYERGRLAENACYAAISQEFNVNPDEVRDAFSQARDSLQANHDFISLIRELKAQANGRLRVYAMSNISLPDWEVLRMKPADWDIFDHVFT SGAVGERKPNLAFYRHVIAATDLQPHQTIFVDDKLENVLSARSLGFTGIVFDEPSEVKRALRNLIGDPVQRGGEFLVRNAGKLGSITRTTAKHESIPLDENFAQLLILEITGNRALVNLVEHPQTWNFFQGKGQL TTEEFPFDLDTTSLGLTILKRSREIADSVMDEMLEYVDPDGIIQTYFDHRRPRFDPVVCVNALSLFYAYGRGEQLRSTLTWVHEVLLNRAYLDGTRYYETAECFLYFMSRLLATSGDPDLHSLLKPLLKERVQER IGADGDSLALAMRILACDFVGIRDEVDLRTLLTLQCEDGGWEVGWMYKYGSSGISIGNRGLATALAIKAVDTMFQPQIRFSESPTDTLVENAIHKRRPSFSEKFLGKRPRSGSFRKPLQWILQGSKLRKSVEIGS
[0503] SEQ ID NO:8
[0504] CrDAT DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0505]
[0506] SEQ ID NO:9
[0507] CrDAT protein sequence
[0508] MESGKISVETETLSKTLIKPSSPTPQSLSRYNLSYNDQNIYQTCVSVGFFYENPDGIEISTIREQLQNSLSKTLVSYYPFAGKVVKNDYIHCNDDGIEFVEVRIRCRMN DILKYELRSYARDLVLPKRVTVGSEDTTAIVQLSHFDCGGLAVAFGISHKVADGGTIASFMKDWAASACYLSSSHHVPTPLLVSDSIFPRQDNIICEQFPTSKNCVEKTF IFPPEAIEKLKSKAVEFGIEKPTRVLTAFLSRCATVAGKSAAKNNNCGQSLPFPVLQAINLRPILELPQNSVGNLVSIYFSRTIKENDYLNEKEYTKLVINELRKEKQ KIKNLSREKLTYVAQMEEFVKSLKEFDISNFLDIDAYLSDSWCRFPFYDVDFGWGKPIWVCLFQPYIKNCVVMMDYPFGDDYGIEAIVSFEQEKMSAFEKNEQLLQFVSN
[0509] SEQ ID NO: 10
[0510] TcTAT DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0511]
[0512] SEQ ID NO:11
[0513] TcTAT protein sequence
[0514] MEKTDLHVNLIEKVMVGPSPPLPKTTLQLSSIDNLPGVRGSIFNALLIYNASPSPTMISADPAKPIREALAKILVYYPPFAGRLRETENGDLEVECTGEGAMFLEAMAD NELSVLGDFDDSNPSFQQLLFSLPLDTNFKDLSLLVVQVTRFTCGGFVVGVSFHHGVCDGRGAAQFLKGLAEMARGEVKLSLEPIWNRELVKLDDPKYLQFFHFEFLRAP SIVEKIVQTYFIIDFETINYIKQSVMEECKEFCSSFEVASAMTWIARTRAFQIPESEYVKILFGMDMRNSFNPPLPSGYYGNSIGTACAVDNVQDLLSGSLLRAIMIIKK SKVSLNDNFKSRAVVKPSELDVNMNHENVVAFADWSRLGFDEVDFGWGNAVSVSPVQQQSALAMQNYFLFLKPSKNKPDGIKILMFLPLSKMKSFKIEMEAMMKKYVAKV
[0515] SEQ ID NO:12
[0516] CrMAT DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0517]
[0518] SEQ ID NO:13
[0519] CrMAT protein sequence
[0520] MDSITMVETETLSKTLIKPSSPTPQSLSHYNLSYNDQNIYPEYIFAGFFYSNPDGHEISTIREQLQNSLSKTLVSYYPFAGKVVKNDYIHCNDDGIEFVDVRIHCRMNDI LKPELRSYASELIRPNRSTVGSEDSTALVQLSHFDCGGVAVAFGISHKVADAATILSFIKDWAASTCDLSSSHDVSTPVLVSDSIFPRQDNIICGQFPASPNCVRKRFLFS PEAIERLKSKAIEFGIEKPTRVEVLTAFLCRCATVAGKSAAKNNNCGQSLPFAVIQAVNLRPLLELPKNSVGNLISIYFSTIKENDTVNIEQEFTKLVIGELRKAKDKLKN LSQEKLNYVARMQDFANCLKELDISSFFDMENVDIDAYLFSSWCRFPFYDIDFGLGKPIWVCMFQPHFKNCIILMDYPFGDDYGIEALITLEQEKMPAFENNELLLSFASN
[0521] SEQ ID NO:14
[0522] LiAAT-4 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0523]
[0524] SEQ ID NO:15
[0525] LiAAT-4 protein sequence
[0526] MAMIITKQILRPSSPTPQAFKNHKLSYLDQIQAPIYIPLLFFYKNEESKYPDQISQRFKQSLSEILTIFYPLAGTMRHNSFVDCNDRGVEFVEVRVHARLAQFI QDPKMEELKQLIPVDCISHTDDDFLLLVKISYFDCGEVVVGVCMSHKIGDGISLAAFMNAWAATCRGESSSEIIHPSFDLALHFPPKDHLSSASSFRVAIAQEN IMTKRLVFDREKLEKLRKRIAASSDGVRDPSRVEAVSVFIWKSLIEAHKAESHMTETPAVSIASHAVNLRPRTVPQMDQTFGNCYAPASAVVSWDEDYVHHSRL RAALREIDDDYINKVLKADNNYLTQDQIGDLFKPENSVLSSWWRFPVYKVDFGWGKPVWVSTTTIQYMNLIIFTSTPSEDGIEAWVTTTHNFFQVLQANYNKLDT
[0527] SEQ ID NO:16
[0528] FgaAT DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0529]
[0530] SEQ ID NO: 17
[0531] FgaAT protein sequence
[0532] MKKQVTFKPFRLSPVDHSLPKVYIFKSLYFRGVDDTGSLSRLQDGIDRLISCLPFLSGEVVPCADIPDKVGVLQVQMPCPSLQEIPMLLVKSYPNHTWPAASTSERWRNTALLDQSYRPLPDF IPPSKPRPVLRFQANFLADGLMLCMGYNHSVFDGTGAGNILEMLADCCRANPNSILALPTNGDIESELRGLLSSPGVAVANASQEAYAINCAHTEVEPEPSSAMLYCWPFLLSSEKIECLQEAC NSLLPHIVRLYSGTQSSLINQDTNWPHILSSNDVLTALLAVSIEKAREATGALGHMSRSLAMAVNLRERLKPMPRHYLGNLVTTVWVSHHRPAVKDLETMVLPVPACNRHEIDRDDLLWITHV AFRIRLGLNAINEEHIRGLIHYLHSQDDWEQIGIHFTDPIFISSWRHLKVYELDFGPTIGHAEHFEMDVGTTDDGVCVVMPANTRAVGKTKKAPWDIRIVLNPEVLQALIASAIFGWAMVKDAST
[0533] SEQ ID NO: 18
[0534] GAO81666.1 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0535]
[0536] SEQ ID NO: 19
[0537] GAO81666.1 protein sequence
[0538] MEEHTRSFEPFDLACLDHTVGPVFMNFFLSFKPAKIEESLISIEEGVTRLVNRLPFLAGDVVNSENVDGRVNVMRIQPSSTLIREIPMLHTKHHPHHILPNTPRQINPGSDQDQRFAPLDDSYVPPVS LLPLAPGPRPVVRFQTNVVIDGIVLALGFHHSVFDATGVGLLIEMLATCCSSDCPALSSHIELEEEIRLRRSVDKIGNGATDLASQRDEVQDPNGSITESPAHVPMGDSSWVPPKLSVYSFNLSAAGLA HLKTACNKLLPAIHASQNGSPQSAESEGEKLQQEFVSTNDVLTALLATSIHQARSRVTETELVPTKAKLAMAVNLRERASSLPKTYLGNSLTVTEAFVYSLAATDGFDGVPERHYHPDLRNALLLEIAR VALQLRKGLAAIDDAYFRQFVSRLRANLDWSQLGANLPDTMVSSWRHLKVYRLDFGARLGRVVEFHPQTALVDGICIIQPERIAHEDDSADMAPESGWEVCVTLQSDAMECFLRGGLFTSLSQGAIRRV
[0539] SEQ ID NO:20
[0540] CfACT1-6 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0541]
[0542] SEQ ID NO:21
[0543] CfACT1-6 protein sequences
[0544] MKVERFSRKLIKPHTPTPENLKKYKLSLLDKCLGHDNFAIVLFYESKPRNKSELEESLEKVLVDFYPLAGRHTMNDHIVDCSDVGAVFVEAEALDVELTMDELVKN MEAQTIHHLLPNQYFSADAPNPLLSIQVTHFPSGGLAIGIAVSHAVFDGFSLGVFVAAWSKATMNPDRKIKITPSFDLPSLLPYKDDNFGLTAAEIVSQSEDIVVKR FIFGKEAITRLRSKLSPNRNGKKISRVRVVCAVIVKALMGLERAKHGKTRDFLITQSINMRERTKAPLQKHACGNLAVLSCTRRVEAEEMMELQNLVNLIGDSTEKD IADFAELLSPDQVGRDIIIKMMKSFMQFLDNDIYSVCFTDWSKFEFYEADFGFGKPVWMAAGPQRPIISTAILMSDREGDGIEAWLHLNKNDMLIFEQDEEIKLFTT
[0545] SEQ ID NO:22
[0546] CfACT1-8 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0547]
[0548] SEQ ID NO:23
[0549] CfACT1-8 protein sequences
[0550] MKVERISRKFIKPYTPTPQNLKKYKLSLLDKCMGHMDFAVVLFYESKPRNKNELEESLEKVLVDFYPLAGRYTMNDHIVDCSDEGAVFVEAEAPNVELTVDQLVKN MEAQTIHDFLPDQYFPADAPNPLLSIQVTHFPCGGLAIGIVVSHAVFDGFSLGVFLAAWSKATMNPERKIEITPSFDLPSLLPYKDESFGLNFSEIVKAENIVVKR LNFGKEAITRLRSKLSPNQNGKTISRVRVVCAVIVKALMGLERAKTRDFMICQGINMRERTKAPLQKHACGNLAVSSYTRRVAAAEAEELQSLVNLIGDSIEKSIA DYADILSSDQDGRHIISTMMKSFMQFAAPDIKAISFTDWSKFGFYQVDFGFGKPVWTGVRPERPIFSAAILMSNREGDGIEAWLHLDKNDMLIFEQDEEIKLLITT
[0551] Alternatively, the C-terminal "T" may be deleted
[0552] SEQ ID NO:24
[0553] OAH94415.1 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae
[0554] ATGGATACCAAGAGGGTCGGTTATACAGTCGTTGATTTGAGTCAGTGGGGCAGAAAAGAACACTTCGAAGCATTCCAGAGCTTCGCCCAGTGCACCTTTTCCCAGACTGTTCAATTAGACATAACTTCCCTGCTGAAGACTGTCAAGCAGAACGGATATAAATTCTACCCGACCTTTATCTACATAATAAGCCGTTTAGTGAACAAGCATGCCGAATTCCGTATGGCCATGAAGGATGGTGAACTGGTAATTTGGGACTCCGTAAACCCTGGTTACACAATCTTTCACGAACAGACCGAAACATTTTCATCTCTGTGGAGCTATTACCACAAGGACATCAATCAGTTTCTTAAAACGTATTCTGAAGACATCGCTCAGTACGGGGACGATCTGGCGTACTTCCCCAAGGAGTTTATTGAAAATATGTTCTTCGTGTCAGCGAACCCATGGGTGAGCTTCACAAGTTTCAACTTAAACGTGGCCAATATTAATAACTTCTTCGCACCGGTCTTTACAATCGGTAAATACTACACGCAGGGCGACAAGGTGTTGATGCCGTTAGCTATTCAGGTCCATCATGCAGTCTGCGACGGGTTTCATGTCGGCAGGTTATTGAACGAAATTCAGCAGTACTGCGATGAGGGATGCAAGTAA
[0555] SEQ ID NO:25
[0556] OAH94415.1 protein sequence
[0557] MDTKRVGYTVVDLSQWGRKEHFEAFQSFAQCTFSQTVQLDITSLLKTVKQNGYKFYPTFIYIISRLVNKHAEFRMAMKDGELVIWDSVNPGYTIFHEQTETFSSLWSYYHKDINQFLKTYSEDIAQYGDDLAYFPKEFIENMFFVSANPWVSFTSFNLNVANINNFFAPVFTIGKYYTQGDKVLMPLAIQVHHAVCDGFHVGRLLNEIQQYCDEGCK
[0558] SEQ ID NO:116
[0559] DfACT13 native nucleotide sequence
[0560]
[0561] SEQ ID NO:117
[0562] DfACT13 nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0563]
[0564] SEQ ID NO:118
[0565] DfACT13 protein sequence
[0566] MACGGGVRNIEVKAQEPVLVQPLSTAQSSAYNLLTKLDQTLAQLVVQIVFVFDVKNPVTRRPHDGADPAKLLKEALRKVLVPFYPLAGRLCLSPDDGSLFIDCNAQGVSFVEANADADISELGDFSQPDFATLGSLVFPLPPIASDDGPLLSAQVTRFKCGGFVLGFVFHHCLFDGFALSEFLNAWAETACGVPLSTPPVLDRTFPRARSPLQIKYPHTEFLEVEDVSLTQNISNDAINRSFCFTSASLEILKKKALEDGVLSKCTTFEALSGLIWRARTRALWSDYPEHKLKVLIVVDPRARFEPRVVPKGYVGNAVLFTCAFASARELEENPLSHAVKHVQHAIGRMTEEYMLSQIDYMEHQKVWCPPLGASTSFMTKWSRLAFNILDFGWGRPKYVGPATSLSMETTTFVSYGKGMSVVLALPPEAMRKFEKIVHPYLNP
[0567] SEQ ID NO:119
[0568] PYI04555.1 natural nucleotide sequence
[0569]
[0570] SEQ ID NO:120
[0571] The nucleotide sequence of PYI04555.1, codon-optimized for expression in Saccharomyces cerevisiae, encodes a C-terminal expansion protein variant of SEQ ID NO: 143.
[0572]
[0573] SEQ ID NO:121
[0574] The PYI04555.1 protein sequence, a C-terminal extended protein variant of SEQ ID NO:143.
[0575] MGASVSFQPFVPTPLDHAMPPIYVSQFLCFPTTTPQSAIQSLQVGIERLFERLPFLAGEILINEHTGAIKVQAPSALIREIPYMALRAHPDLYLPAKQCATTPIERQLKTNSLDESYHPLPAALPLSQPQPVIRFQANTLADGILFAVSYHHCIFDGTGCGQILEMLAQCCSASDDKISLPTDCHTDVLLREYISNLSPTTNIPHDYTQAYSTTVQPDPDASDPDTSPAIPSSLYTEAFTFPSQQITTLRDACNHLLPKLPSTSNAHPHKPTPNPLSSNDVLTALIALCITRATNTTTPPLQPNNHSLSMAVNLRTRIQPQVPDHFLGNFATLLPIHFTSPVHTQQSDLLLTTEPPDPALIHLTTLASQIRSSLSTVNTDYICGLMTDLRTRRNAGENSSLLIEGIKISSWRHLSVYKPDFGPGLGKIAGFEFQAGLMDNLVVILPWRNGDWDVRVTLLERDMRGFREDRLVRWALGSGTGPFSFVDIM
[0576] SEQ ID NO:122 <
[0579] SEQ ID NO:123
[0580] The nucleotide sequence of ERR364415-1_contig_8546, codon-optimized for expression in Saccharomyces cerevisiae, encodes a C-terminal expanded protein variant of SEQ ID NO: 144.
[0581]
[0582] SEQ ID NO:124
[0583] ERR364415-1_contig_8546 protein sequence, a C-terminal expansion protein variant of SEQ ID NO: 144.
[0584] MARAPPPPPPGLRMRDTVLSIVKPIRKTQHLETIDATFVDLMRMDSFIPVIFAYRPADKSEAAYSRLVNRIKESLQKVLVPFFGFAGRWVPSSGGSRRLLCNDEGVPFIEAFVDEELDSVV KASAAFQPVTELNGLGVLGMDMTSYDQRMPPEGGQPCVVAQVTRFKCGGVVLGVAFNHTHTDGQGFYTFMRAWSDFSRTNGTAIKVDHNRALPELASLSQFFIKQHDRIGGKTSTDRVNDH CSKVPERLALKAFEVRASKIKAAKLAAEDGGVGYVSTVDCIVAHLWKTLARLPPVVLDGREITVFSPVEGRNRFLDPPRPNMCGNCFAAMVTPKIPTQELLEMPLAAAIAGKQREKLSTTRR EEWFGQQSFRELASAMNTSKSALLIVTSWFNFPMYEIDFGAGKPFFASTTNMISPINGVCCGVIAPPTPGSCSSIATLYILCLPAVLEALENVPDFLSFFVPHPNHKDNSQTGPFSFVDIM
[0585] SEQ ID NO:125
[0586] XP_001258079.1 native nucleotide sequence
[0587]
[0588] SEQ ID NO:126
[0589] The nucleotide sequence of XP_001258079.1 was codon-optimized for expression in Saccharomyces cerevisiae.
[0590]
[0591] SEQ ID NO:127
[0592] XP_001258079.1 protein sequence
[0593] MTVTISFEPYVGSSVDALSIPLYLRCQLVFKLSKPLAAVPLLESGVNRLVQALPFLSGEFTAVPASDGGKEILLVRPVLNFELSRILKIKYHETSLRHVCKQMNRPSSQGGDLPHEPYMPYPRLPDPSRPQPIVGFQVNVHTDGIILSVATHHCSFDATGMGSIVQNLAACCRSPPSDEPDLTTSPAQEAEARKVLSQVRETPFDPKMFPEYRPLDSMLSYYKGVQSALQGRQTTIVNRCFTIAADKINALKRRCNQLIPEMVKKYGLSTEDAIGSAWVSSNDVVAALLWTCINRARYPEIRERSVHQLPPDLLHATSSLGVPVNVRSRLSPPLPKSTLGNAVCLLREKVPLQFFALPSHANMEATSSVCADHSGDDEWALSFCRVAYGLRAKLNAIDDDYIRDYISYVQKSPCHLSVTLDTENLYLSNWREIGVYDADFGGMLGKPLRMRAPDGYTDGLIFVMAQRSEDKSAPWEFNISLEASTMKRIVHDPLWCKYVELDAFWHGEE
[0594] SEQ ID NO:128
[0595] XP_001217250.1 natural nucleotide sequence
[0596]
[0597] SEQ ID NO:129
[0598] The nucleotide sequence of XP_001217250.1 was codon-optimized for expression in Saccharomyces cerevisiae.
[0599]
[0600] SEQ ID NO:130
[0601] XP_001217250.1 Protein sequence
[0602] MATFDHIEDVIGQLPMLKSYTHILLCFPLAESQLNEAIESLESAVRQVIKTFSFLAGKVVNEGKGPNSSGTFRVAPCETWESPDHQFVRVVDRSFMLASYDEIRGAQAPASMLPGSQLGYRVAFPAHYHETEDDPAPVLDIQCNLIRGGLLLDIAAQHNIIDASGIFQIASLIALSMRGESIPEDVIKEGNRDRRNIIPLLEADEPLLDHSELKASSAVQNPPPVNFLQGYKWQIFKLSAEVLTRITAEGRRQPQEFVPSVTFVSANDCLTAFLWQRVIAMRLKRLHTPEAVSKLSRAVDLRRAMGITPAYMGHMIRVANTSLTFQEIVACSLSRLASLLRKSIIDVSQPYAIRSYVTFIANETDKSKIAYAGAFNPCTDMSCSSIAHITAPEFGRLGAPDFIRRPTYGPLPCCTYVAPDKNDGALDQNQAWSDVVKRIG
[0603] SEQ ID NO:131
[0604] BAU61551.1 Natural nucleotide sequence
[0605]
[0606] SEQ ID NO:132
[0607] BAU61551.1 nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0608]
[0609] SEQ ID NO:133
[0610] BAU61551.1 protein sequence
[0611] MSKPLFEAYPLTGLDHTIPPCYVRFLLTFPVPDVALAVNQLQKGAENLIEKLPFLAGYLASCETPGVRPGQLEIRPPAGERRPVCLVAHHSNSYLADSSATSTTEQLGTANENYLPVPFFPELDKPVPIFRVKVNAMTDGIILGFAFHHSVIDATGMGTIVRDFARCCRGPDGGPLEISLESQQDSREKLRHSGGPPDPRFDHNGEYPLVASLPADLEAMKQVLIQTARLMSTQYFRIPASLVNTLKESCNRMLRESPALRDEGENPWISSNDLVVSLLWLCLNRVRYPEDNTNVIPPSDSSVCMAVNIRGRLQSPIDPGYVGNAIVLLRESVGMNAFLHKPGDDDPLGAQCYETAKRLGREAWEAALVRIALAIRRKLNTINASYVRSVISYLEDVPDLSTVAFGQTDYHISSWRDIGVYEADFGGHMGHPSEMRVPDGMVDGMFYILPRRQGTHPCWEIHVTIHQDTMKRLIADPVWARYTVRKPSSLCRDE
[0612] SEQ ID NO:134
[0613] PsSalAT natural nucleotide sequence
[0614]
[0615] SEQ ID NO:135
[0616] PsSalAT nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0617]
[0618] SEQ ID NO:136
[0619] PsSalAT protein sequence
[0620] MATMYSAAVEVISKETIKPTTPTPSQLKNFNLSLLDQCFPLYYYVPIILFYPATAANSTGSSNHHDDLDLLKSSLSKTLVHFYPMAGRMIDNILVDCHDQGINFYKVKIRGKMCEFMS QPDVPLSQLLPSEVVSASVPKEALVIVQVNMFDCGGTAICSSVSHKIADAATMSTFIRSWASTTKTSRSGGSTAAVTDQKLIPSFDSASLFPPSERLTSPSGMSEIPFSSTPEDDK TVSKRFVFDFAKITSVREKLQVLMHDNYKSRRQTRVEVVTSLIWKSVMKSTPAGFLPVVHHAVNLRKKMDPPLQDVSFGNLSVTVSAFLPATTTTTTNAVNKTINSTSSSESQVVLHEL HDFIAQMRSEIDKVKGDKGSLEKVIQNFASGHDASIKKINDVEVINFWISSWCRMGLYEIDFGWGKPIWVTVDPNIKPNKNCFFMNDTKCGEGIEVWASFLEDDMAKFELHLSEILELI
[0621] SEQ ID NO:137
[0622] AstC nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0623]
[0624] SEQ ID NO:138
[0625] AstC protein sequence
[0626] MTKINPYKGILVELKDIVFTSSSDQIKLPINTFKSILCCGATAQYQCGKINRAQYYSRLARDFALSLADVTALFDTVQATIRPEESFLAFLAELKSRFGEQLKLYAVANMSREDYAMLKS LPIDWSLFDGVFLSADLGMRKPELRFFRHVLESISMKPEDTILVDNDTDNILCALSMGLKGILFGSTSVPQALTNLLEYDHISRAEQFLRSHAKSLHSVTHTGVTIRENFAQLLILEATG DIDLVELEYHPTTWNYFIGTPVLTQTEFPHDLDTTSLATTVLDRPKDIANEIMDEMLKYRSDDDLMLTFFTDFKNRVDPVVCCNVLSLFYKYGRGHELHHTLAWVRQVLIRRAYINGTAF YPMPEAFLYFFFRFLQHITHLPQLYDGLKVLLKERLQERVGVPVDPISLSMRLIACNGVGIHDRMGLNALLSMQNPDGSWDLGTMYHYASKRLPIGNQGVSTAMAIKAIKQCQANQCAGI
[0627] SEQ ID NO:139
[0628] AstI nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0629] ATGACTAGACAATCTCACTACCAAGCTATCATCTTGGACTTGGGTAACGTTGTTTTCGAATGGGACACTTCTCAAAACCCACCAACTGCTGCTCCAAACCAAATCTCTTTGTTGAGAACTTCTATGAAGTCTCCAGTTTACCACTCTTACGAAAGAGGTCAATTGTCTACTGAAGAATGTCACAGATTGTTGGGTGAATCTTTGCACGTTGACCCAGGTCAAATCAAGGAAGCTTTCGACTTGGCTAGACAATCTTTGAGATCTAACCCAGCTTTGTTGGACTTCATCAGACAATTGAAGCAAACTAGAGGTGTTGCTGTTTACGCTATGTCTAACATCCCACAAGCTGAAATCGAATACTTGAAGGAATCTAGAGCTGGTGACATGGAAGTTTTCGACGAAGTTTTCGCTTCTGGTTACGTTGGTTCTAGAAAGCCAGAAACTGAATTCTACAGAAGAGTTATGGGTGAAATCGGTTTGAAGGCTGAAAGAGTTGTTTTCGTTGACGACAAGGAAGAAAACGTTGACGTTGCTAGAGGTTTGGGTTTGTACGGTGTTTGTTTCGGTGGTGTTGAAGAATTGAGAGGTCACTTGTTGGGTATCTAA
[0630] SEQ ID NO:140
[0631] AstI protein sequence
[0632] MTRQSHYQAIILDLGNVVFEWDTSQNPPTAAPNQISLLRTSMKSPVYHSYERGQLSTEECHRLLGESLHVDPGQIKEAFDLARQSLRSNPALLDFIRQLKQTRGVAVYAMSNIPQAEIEYLKESRAGDMEVFDEVFASGYVGSRKPETEFYRRVMGEIGLKAERVVFVDDKEENVDVARGLGLYGVCFGGVEELRGHLLGI
[0633] SEQ ID NO:141
[0634] AstK nucleotide sequence, codon-optimized for expression in Saccharomyces cerevisiae.
[0635] ATGTGTACTACTTTCAAGGCTGCTATCTTCGACATGGGTGGTGTTTTGTTCACTTGGAACCCAATCGTTGACACTCAAGTTTCTTTGAAGGACTTGGGTACTATCATCAACTCTGAAACTTGGGAACAATTCGAAAGAGGTAAGATCGAACCAGACGACTGTTACCACCAATTGGGTTCTCAAATCGGTTTGCCAGGTTCTGAAATCGCTGCTACTTTCAGACAAACTACTGGTTGTTTGAGACCAGACGCTAGAATGACTTCTTTGTTGAGAGAATTGAAGGGTCAAGGTGTTGCTGTTTACATGATGACTAACATCCCAGCTCCAGACTTCCACCAATTGAGAGAAATGCACTACGAATGGGACTTGTTCGACGGTATCTTCGCTTCTGCTTTGGAAGGTATGAGAAAGCCAGACTTGGAATTCTACGAACACGTTTTGAAGCAAATCGACACTTCTGCTGCTGAAACTATCTTCGTTGACGACAAGTTGGAAAACGTTATCGCTGCTCAAGCTGTTGGTATGGTTGGTTTGCACTTGACTGACTCTTTGGCTACTTGTATGGAATTGAGACAATTGGTTGGTTGTTAA
[0636] SEQ ID NO:142
[0637] AstK protein sequence
[0638] MCTTFKAAIFDMGGVLFTWNPIVDTQVSLKDLGTIINSETWEQFERGKIEPDDCYHQLGSQIGLPGSEIAATFRQTTGCLRPDARMTSLLRELKGQGVAVYMMTNIPAPDFHQLREMHYEWDLFDGIFASALEGMRKPDLEFYEHVLKQIDTSAAETIFVDDKLENVIAAQAVGMVGLHLTDSLATCMELRQLVGC
[0639] SEQ ID NO:143
[0640] PYI04555.1 protein sequence, without C-terminal extension.
[0641] MGASVSFQPFVPTPLDHAMPPIYVSQFLCFPTTTPQSAIQSLQVGIERLFERLPFLAGEILINEHTGAIKVQAPSALIREIPYMALRAHPDLYLPAKQCATTPIERQLKTNSLDESYHPLPAALPLSQPQPVIRFQANTLADGILFAVSYHHCIFDGTGCGQILEMLAQCCSASDDKISLPTDCHTDVLLREYISNLSPTTNIPHDYTQAYSTTVQPDPDASDPDTSPAIPSSLYTEAFTFPSQQITTLRDACNHLLPKLPSTSNAHPHKPTPNPLSSNDVLTALIALCITRATNTTTPPLQPNNHSLSMAVNLRTRIQPQVPDHFLGNFATLLPIHFTSPVHTQQSDLLLTTEPPDPALIHLTTLASQIRSSLSTVNTDYICGLMTDLRTRRNAGENSSLLIEGIKISSWRHLSVYKPDFGPGLGKIAGFEFQAGLMDNLVVILPWRNGDWDVRVTLLERDMRGFREDRLVRWALGSG
[0642] SEQ ID NO:144
[0643] Protein sequence of ERR364415-1_contig_8546, without C-terminal extension.
[0644] MARAPPPPPPGLRMRDTVLSIVKPIRKTQHLETIDATFVDLMRMDSFIPVIFAYRPADKSEAAYSRLVNRIKESLQKVLVPFFGFAGRWVPSSGGSRRLLCNDEGVPFIEAFVDEELD SVVKASAAFQPVTELNGLGVLGMDMTSYDQRMPPEGGQPCVVAQVTRFKCGGVVLGVAFNHTHTDGQGFYTFMRAWSDFSRTNGTAIKVDHNRALPELASLSQFFIKQHDRIGGKTSTD RVNDHCSKVPERLALKAFEVRASKIKAAKLAAEDGGVGYVSTVDCIVAHLWKTLARLPPVVLDGREITVFSPVEGRNRFLDPPRPNMCGNCFAAMVTPKIPTQELLEMPLAAAIAGKQR EKLSTTRREEWFGQQSFRELASAMNTSKSALLIVTSWFNFPMYEIDFGAGKPFFASTTNMISPINGVCCGVIAPPTPGSCSSIATLYILCLPAVLEALENVPDFLSFFVPHPNHKDNSQ
[0645] Other sequences suitable for use in the present invention are listed below. "Previous" SEQ ID NOs refer to those used in the corresponding patent documents.
[0646] 1. The pyrocatechol diphosphate synthase described in PCT / CN2018 / 088902 (filed on May 29, 2018) is:
[0647] DfHAD, DfHAD-9(V274A), and DfHAD-8(K532R) from Dryopteris fragrans
[0648]
[0649] NA = Nucleic Acid
[0650] AA = amino acid
[0651] 2. PCT / EP2018 / 064344 (filed on May 31, 2018) describes a pyrrolidine synthase (i.e., pyrrolidine synthase or pyrrolidine synthase)
[0652]
[0653] AA = amino acid
[0654] 3. The buminol synthase described in WO2015 / 169871 is
[0655]
[0656] 4. The buminol synthase described in WO 2015 / 176959 is
[0657] VaTPS3 of Valeriana amurensis (SEQ ID NO: 6)
[0658] Sequence Listing <110> Vermenischer GmbH <120> Method for producing alkyl acetate compounds <130> 11110 / WO <160> 144 <170> PatentIn version 3.5 <210> 1 <211> 5689 <212> DNA <213> Plasmid pF167 <400> 1 tggtcagcaa caacgccgaa gaatcactct cgtgttgaga attgcacgcc ttgaccacga 60 cacgttaagg gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa 120 attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt 180 accaatgctt aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag 240 ttgcctgact ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca 300 gtgctgcaat gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc 360 agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt 420 ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca 540 gctccggttc ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca 660 tggttatggc agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg 780. tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg 960 tttctgggtg agcaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa aaataaaacaa ataggggttc 1140 cgcgcacatt tttggcattg gcaaagtgcg gactgcatag tcactgtggt gccgtactta 1200 gggtacgcgt tcctgaacga agcatctgtg cttcattttg tagaacaaaa atgcaacgcg 1260 agagcgctaa tttttcaaac aaagaatctg agctgcattt ttacagaaca gaaatgcaac 1320 gcgaaagcgc tattttacca acgaagaatc tgtgcttcat ttttgtaaaa caaaaatgca 1380 acgcgagagc gctaattttt caaacaaaga atctgagctg catttttaca gaacagaaat 1440 gcaacgcgag agcgctattt taccaacaaa gaatctatac ttcttttttg ttctacaaaa 1500 atgcatcccg agagcgctat ttttctaaca aagcatctta gattactttt tttctccttt 1560 gtgcgctcta taatgcagtc tcttgataac tttttgcact gtaggtccgt taaggttaga 1620 agaaggctac tttggtgtct attttctctt ccataaaaaa agcctgactc cacttcccgc 1680 gtttactgat tactagcgaa gctgcgggtg cattttttca agataaaggc atccccgatt 1740 atattctata ccgatgtgga ttgcgcatac tttgtgaaca gaaagtgata gcgttgatga 1800 ttctcattg gtcagaaaat tatgaacggt ttctctatt ttgtctat attackacgta 1860 taggaaatgt tacattttc gtattgtttt cgattcactc taggaatagt tcttactaca 1920 atttttttgt c'aagagta attackagaga taaactaaaaatgtagag gtcgagttta 1980 gatgcagtt agggagcga aaggtgaatg ggtaggttat agggaat agcacagaga 2040 tatatagcaa agagatactt ttgagcaatg ttgtggaag cggtattcgc atattttag 2100 tagctcgtta cagtccggtg cgtttttggt ttttgaaag tgcgtcttca gagcgctttt 2160 ggttttcaa agcgctctga agttcctata ctttcag ataggact tcggaatagg 2220 aacttcaaag cgtttccgaa aacgagcgct tccgaaatg caacgcgagc tgcgcacata 2280 cagctcactg ttcacgtcgc acctatatct gcgtgttgcc tgtatatata tatacatgag 2340 aagaacggca tagtgcgtgt ttatgcttaa atgcgtactt attgcgtct atttatgtag 2400 gatgaaaggt agtctagtac ctcctgtgat attatcccat tccatgcggg gtatcgtatg 2460 cttccttcag cactaccctt tagctgttct atatgctgcc actcctcaat tggattagtc 2520 tcatccttca atgctatcat tatgtcaccc gcagttctgt gtcgtagtca tcaacatagc 2580 acctatcctt tggcatctcg gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag 2640 gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca caaaaatcga 2700 cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 2760 ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc 2820 tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg 2880 gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca gcccgaccgc 2940 tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca 3000 ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag 3060 ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg tatctgcgct 3120 ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaaacc 3180 accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga 3240 tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagcactt gctacactgt 3300 caggatagct tccgtcacat ggtggcgatc accgtacatc tgagtgagac gttaattaaa 3360 gtagaccgct cacacatggg cggccgccgt ctcaaggtgc agttcgcgtg caattataac 3420 gtcgtggcaa ctgttatcag tcgtaccgcg ccattcgact acgtcgtaag gccgtttctg 3480 acagagtaaa attcttgagg gaactttcac cattatggga aatgcttcaa gaaggtattg 3540 acttaaactc catcaaatgg tcaggtcatt gagtgttttt tatttgttgt attttttttt 3600 ttttagagaa aatcctccaa tatcaaatta ggaatcgtag tttcatgatt ttctgttaca 3660 cctaactttt tgtgtggtgc cctcctcctt gtcaatatta atgttaaagt gcaattcttt 3720 ttccttatca cgttgagcca ttagtatcaa tttgcttacc tgtattcctt tactatcctc 3780 cttttctcc ttcttgataa atgtatgtag attgcgtata tagttcgtc taccctatga 3840 acatattcca ttttgtaatt tcgtgtcgtt tctattatga atttcattta taaagtttat 3900 gtacaaatat cataaaaaaa gagaatcttt ttaagcaagg atttctttaa cttcttcggc 3960 gacagcatca ccgacttcgg tggtactgtt ggaaccacct aaatcaccag ttctgatacc 4020 tgcatccaaa accttttaa ctgcatcttc aatggcctta ccttcttcag gcaagttcaa 4080 tgacaatttc aacatcattg cagcagacaa gatagtggcg atagggtcaa ccttatctt 4140 tggcaaatct ggagcagaac cgtggcatgg ttcgtacaaa ccaaatgcgg tgttcttgtc 4200 tggcaaagag gccaaggacg cagatggcaa caaacccaag gaacctggga taacggaggc 4260 ttcatcggag atgatatcac caaacatgtt gctggtgatt ttaggtggt 4320 tgggttctta actaggatca tggcggcaga atcaatcaat tgatgttgaa ccttcaatgt 4380 agggaattcg ttcttgatgg tttcctccac agtttttctc cataatcttg aagaggccaa 4440 aagattagct ttatccaagg accaaatagg caatggtggc tcatgttgta gggccatgaa 4500 agcggccatt cttgtgattc tttgcacttc tggaacggtg tattgttcac tatcccaagc 4560 gacaccatca ccatcgtctt cctttctctt accaaagtaa atacctccca ctaattctct 4620 gaacaacg aagtcagtac ctttagcaaa ttgtggcttg attggagata agtctaaaag 4680 agagtcggat gcaaagttac atggtcttaa gttggcgtac aattgaagtt ctttacggat 4740 ttttagtaaa ccttgttcag gtctaacact accggtaccc catttaggac cagccacagc 4800 acctaacaaa acggcatcaa ccttcttgga ggcttccagc gcctcatctg gaagtgggac 4860 acctgtagca tcgatagcag caccaccaat taaatgattt tcgaaatcga acttgacatt 4920 ggaacgaaca tcagaatag cttaagaac cttaatggct tcggctgtga tttcttgacc 4980 aacgtggtca cctggcaaaa cgacgatctt cttaggggca gacatagggg cagacattag 5040 aatggtatat ccttgaaata tatatatata ttgctgaaat gtaaaaggta agaaaagtta 5100 gaaagtaaga cgattgctaa ccacctattg gaaaaaacaa taggtcctta aataatattg 5160 tcaacttcaa gtattgtgat gcaagcattt agtcatgaac gcttctctat tctatatgaa 5220 aagccggttc cggcctctca cctttcctt ttctcccaat ttttcagttg aaaaaggtat 5280 atgcgtcagg cgacctctga aattaacaaa aaatttccag tcatcgaatt tgattctgtg 5340 cgatagcgcc cctgtgtgtt ctcgttatgt tgaggaaaaa aataatggtt gctaagagat 5400 tcgaactctt gcatcttacg atacctgagt attcccacag ttaactgcgg tcaagatatt 5460 tcttgaatca ggcgccttag accgctcggc caaacaacca attacttgtt gagaaataga 5520 gtataattat cctataaata taacgttttt gaacacacat gaacaaggaa gtacaggaca 5580 attgattttg aagagaatgt ggattttgat gtaattgttg ggattccatt tttaataagg 5640 caataatatt aggtatgtgg atatactaga agttctcctc gaccgtcga 5689 <210> 2 <211> 60 <212> DNA <213> Sequences for homologous recombination <400> 2 gcacttgcta cactgtcagg atagcttccg tcacatggtg gcgatcaccg tacatctgag 60 <210> 3 <211> 60 <212> DNA <213> Sequences for homologous recombination <400> 3 aggtgcagtt cgcgtgcaat tataacgtcg tggcaactgt tatcagtcgt accgcgccat 60 <210> 4 <211> 1584 <212> DNA <213> XP_007369631.1 Dichomitus squalens pyrenoid synthase, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1584) <400> 4 atg gct tct atc cac aga aga tac act act ttg atc ttg gac ttg ggt 48 Met Ala Ser Ile His Arg Arg Tyr Thr Thr Leu Ile Leu Asp Leu Gly 1 5 10 15 gac gtt ttg ttc aga tgg tct cca aag act gaa act gct atc cca cca 96 Asp Val Leu Phe Arg Trp Ser Pro Lys Thr Glu Thr Ala Ile Pro Pro 20 25 30 caa caa ttg aag gac atc ttg tct tct gtt act tgg ttc gaa tac gaa 144 Gln Gln Leu Lys Asp Ile Leu Ser Ser Val Thr Trp Phe Glu Tyr Glu 35 40 45 aga ggt aga ttg tct caa gaa gct tgt tac gaa aga tgt gct gaa gaa 192 Arg Gly Arg Leu Ser Gln Glu Ala Cys Tyr Glu Arg Cys Ala Glu Glu 50 55 60 ttc aag atc gaa gct tct gtt atc gct gaa gct ttc aag caa gct aga 240 Phe Lys Ile Glu Ala Ser Val Ile Ala Glu Ala Phe Lys Gln Ala Arg 65 70 75 80 ggt tct ttg aga cca aac gaa gaa ttc atc gct ttg atc aga gac ttg 288 Gly Ser Leu Arg Pro Asn Glu Glu Phe Ile Ala Leu Ile Arg Asp Leu 85 90 95 aga aga gaa atg cac ggt gac ttg act gtt ttg gct ttg tct aac atc 336 Arg Arg Glu Met His Gly Asp Leu Thr Val Leu Ala Leu Ser Asn Ile 100 105 110 tct ttg cca gac tac gaa tac atc atg tct ttg tct tct gac tgg act 384 Ser Leu Pro Asp Tyr Glu Tyr Ile Met Ser Leu Ser Ser Asp Trp Thr 115 120 125 act gtt ttc gac aga gtt ttc cca tct gct ttg gtt ggt gaa aga aag 432 Thr Val Phe Asp Arg Val Phe Pro Ser Ala Leu Val Gly Glu Arg Lys 130 135 140 cca cac ttg ggt tgt tac aga aag gtt atc tct gaa atg aac ttg gaa 480 Pro His Leu Gly Cys Tyr Arg Lys Val Ile Ser Glu Met Asn Leu Glu 145 150 155 160 cca caa act act gtt ttc gtt gac gac aag ttg gac aac gtt gct tct 528 Pro Gln Thr Thr Val Phe Val Asp Asp Lys Leu Asp Asn Val Ala Ser 165 170 175 gct aga tct ttg ggt atg cac ggt atc gtt ttc gac aac caa gct aac 576 Ala Arg Ser Leu Gly Met His Gly Ile Val Phe Asp Asn Gln Ala Asn 180 185 190 gtt ttc aga caa ttg aga aac atc ttc ggt gac cca atc aga aga ggt 624 Val Phe Arg Gln Leu Arg Asn Ile Phe Gly Asp Pro Ile Arg Arg Gly 195 200 205 caa gaa tac ttg aga ggt cac gct ggt aag ttg gaa tct tct act gac 672 Gln Glu Tyr Leu Arg Gly His Ala Gly Lys Leu Glu Ser Ser Thr Asp 210 215 220 aac ggt ttg atc ttc gaa gaa aac ttc act caa ttg atc atc tac gaa 720 Asn Gly Leu Ile Phe Glu Glu Asn Phe Thr Gln Leu Ile Ile Tyr Glu 225 230 235 240 ttg act caa gac aga act ttg atc tct ttg tct gaa tgt cca aga act 768 Leu Thr Gln Asp Arg Thr Leu Ile Ser Leu Ser Glu Cys Pro Arg Thr 245 250 255 tgg aac ttc ttc aga ggt gaa cca ttg ttc tct gaa act ttc cca gac 816 Trp Asn Phe Phe Arg Gly Glu Pro Leu Phe Ser Glu Thr Phe Pro Asp 260 265 270 gac gtt gac act act tct gtt gct ttg act gtt ttg caa cca gac aga 864 Asp Val Asp Thr Thr Ser Val Ala Leu Thr Val Leu Gln Pro Asp Arg 275 280 285 gct ttg gtt aac tct gtt ttg gac gaa atg ttg gaa tac gtt gac gct 912 Ala Leu Val Asn Ser Val Leu Asp Glu Met Leu Glu Tyr Val Asp Ala 290 295 300 gac ggt atc atg caa act tac ttc gac aga tct aga cca aga atg gac 960 Asp Gly Ile Met Gln Thr Tyr Phe Asp Arg Ser Arg Pro Arg Met Asp 305 310 315 320 cca ttc gtt tgt gtt aac gtt ttg tct ttg ttc tac gaa aac ggt aga 1008 Pro Phe Val Cys Val Asn Val Leu Ser Leu Phe Tyr Glu Asn Gly Arg 325 330 335 ggt cac gaa ttg cca aga act ttg gac tgg gtt tac gaa gtt ttg ttg 1056 Gly His Glu Leu Pro Arg Thr Leu Asp Trp Val Tyr Glu Val Leu Leu 340 345 350 cac aga gct tac cac ggt ggt tct aga tac ttg tct cca gac tgt 1104 His Arg Ala Tyr His Gly Gly Ser Arg Tyr Tyr Leu Ser Pro Asp Cys 355 360 365 ttc ttg ttc ttc atg tct aga ttg ttg aag aga gct gac gac cca gct 1152 Phe Leu Phe Phe Met Ser Arg Leu Leu Lys Arg Ala Asp Asp Pro Ala 370 375 380 gtt caa gct aga ttg aga cca ttg ttc gtt gaa aga gtt aac gaa aga 1200 Val Gln Ala Arg Leu Arg Pro Leu Phe Val Glu Arg Val Asn Glu Arg 385 390 395 400 gtt ggt gct gct ggt gac tct atg gac ttg gct ttc aga atc ttg gct 1248 Val Gly Ala Ala Gly Asp Ser Met Asp Leu Ala Phe Arg Ile Leu Ala 405 410 415 gct gct tct gtt gtt gtt caa tgt cca aga gac ttg gaa aga ttg act 1296 Ala Ala Ser Val Gly Val Gln Cys Pro Arg Asp Leu Glu Arg Leu Thr 420 425 430 gct ggt caa tgt gac gac ggt ggt tgg gac ttg tgt tgg ttc tac gtt 1344 Ala Gly Gln Cys Asp Asp Gly Gly Trp Asp Leu Cys Trp Phe Tyr Val 435 440 445 ttc ggt tct act ggt gtt aag gct ggt aac aga ggt ttg act act gct 1392 Phe Gly Ser Thr Gly Val Lys Ala Gly Asn Arg Gly Leu Thr Thr Ala 450 455 460 ttg gct gtt act gct atc caa act gct atc ggt aga cca cca tct cca 1440 Leu Ala Val Thr Ala Ile Gln Thr Ala Ile Gly Arg Pro Pro Ser Pro 465 470 475 480 tct cca tct gct gct tct tct tct ttc aga cca tct tct cca tac aag 1488 Ser Pro Ser Ala Ala Ser Ser Ser Phe Arg Pro Ser Ser Pro Tyr Lys 485 490 495 ttc ttg ggt atc tct aga cca gct tct cca atc aga ttc ggt gac ttg 1536 Phe Leu Gly Ile Ser Arg Pro Ala Ser Pro Ile Arg Phe Gly Asp Leu 500 505 510 ttg aga cca tgg aga aag atg tct aga tct aac ttg aag tct caa taa 1584 Leu Arg Pro Trp Arg Lys Met Ser Arg Ser Asn Leu Lys Ser Gln 515 520 525 <210> 5 <211> 527 <212> PRT <213> XP_007369631.1 Dichomitus squalens pyrenoid synthase, codon-optimized for expression in Saccharomyces cerevisiae <400> 5 Met Ala Ser Ile His Arg Arg Tyr Thr Thr Leu Ile Leu Asp Leu Gly 1 5 10 15 Asp Val Leu Phe Arg Trp Ser Pro Lys Thr Glu Thr Ala Ile Pro Pro 20 25 30 Gln Gln Leu Lys Asp Ile Leu Ser Ser Val Thr Trp Phe Glu Tyr Glu 35 40 45 Arg Gly Arg Leu Ser Gln Glu Ala Cys Tyr Glu Arg Cys Ala Glu Glu 50 55 60 Phe Lys Ile Glu Ala Ser Val Ile Ala Glu Ala Phe Lys Gln Ala Arg 65 70 75 80 Gly Ser Leu Arg Pro Asn Glu Glu Phe Ile Ala Leu Ile Arg Asp Leu 85 90 95 Arg Arg Glu Met His Gly Asp Leu Thr Val Leu Ala Leu Ser Asn Ile 100 105 110 Ser Leu Pro Asp Tyr Glu Tyr Ile Met Ser Leu Ser Ser Asp Trp Thr 115 120 125 Thr Val Phe Asp Arg Val Phe Pro Ser Ala Leu Val Gly Glu Arg Lys 130 135 140 Pro His Leu Gly Cys Tyr Arg Lys Val Ile Ser Glu Met Asn Leu Glu 145 150 155 160 Pro Gln Thr Thr Val Phe Val Asp Asp Lys Leu Asp Asn Val Ala Ser 165 170 175 Ala Arg Ser Leu Gly Met His Gly Ile Val Phe Asp Asn Gln Ala Asn 180 185 190 Val Phe Arg Gln Leu Arg Asn Ile Phe Gly Asp Pro Ile Arg Arg Gly 195 200 205 Gln Glu Tyr Leu Arg Gly His Ala Gly Lys Leu Glu Ser Ser Thr Asp 210 215 220 Asn Gly Leu Ile Phe Glu Glu Asn Phe Thr Gln Leu Ile Ile Tyr Glu 225 230 235 240 Leu Thr Gln Asp Arg Thr Leu Ile Ser Leu Ser Glu Cys Pro Arg Thr 245 250 255 Trp Asn Phe Phe Arg Gly Glu Pro Leu Phe Ser Glu Thr Phe Pro Asp 260 265 270 Asp Val Asp Thr Thr Ser Val Ala Leu Thr Val Leu Gln Pro Asp Arg 275 280 285 Ala Leu Val Asn Ser Val Leu Asp Glu Met Leu Glu Tyr Val Asp Ala 290 295 300 Asp Gly Ile Met Gln Thr Tyr Phe Asp Arg Ser Arg Pro Arg Met Asp 305 310 315 320 Pro Phe Val Cys Val Asn Val Leu Ser Leu Phe Tyr Glu Asn Gly Arg 325 330 335 Gly His Glu Leu Pro Arg Thr Leu Asp Trp Val Tyr Glu Val Leu Leu 340 345 350 His Arg Ala Tyr His Gly Gly Ser Arg Tyr Tyr Leu Ser Pro Asp Cys 355 360 365 Phe Leu Phe Phe Met Ser Arg Leu Leu Lys Arg Ala Asp Asp Pro Ala 370 375 380 Val Gln Ala Arg Leu Arg Pro Leu Phe Val Glu Arg Val Asn Glu Arg 385 390 395 400 Val Gly Ala Ala Gly Asp Ser Met Asp Leu Ala Phe Arg Ile Leu Ala 405 410 415 Ala Ala Ser Val Gly Val Gln Cys Pro Arg Asp Leu Glu Arg Leu Thr 420 425 430 Ala Gly Gln Cys Asp Asp Gly Gly Trp Asp Leu Cys Trp Phe Tyr Val 435 440 445 Phe Gly Ser Thr Gly Val Lys Ala Gly Asn Arg Gly Leu Thr Thr Ala 450 455 460 Leu Ala Val Thr Ala Ile Gln Thr Ala Ile Gly Arg Pro Pro Ser Pro 465 470 475 480 Ser Pro Ser Ala Ala Ser Ser Ser Ser Phe Arg Pro Ser Ser Pro Tyr Lys 485 490 495 Phe Leu Gly Ile Ser Arg Pro Ala Ser Pro Ile Arg Phe Gly Asp Leu 500 505 510 Leu Arg Pro Trp Arg Lys Met Ser Arg Ser Asn Leu Lys Ser Gln 515 520 525 <210> 6 <211> 1623 <212> DNA <213> XP_006461126 Agaricus bisporus buprenorphine synthase sequence, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1623) <400> 6 atg gct cca cca caa aga cca ttc act gct atc gtt ttc gac atc ggt 48 Met Ala Pro Pro Gln Arg Pro Phe Thr Ala Ile Val Phe Asp Ile Gly 1 5 10 15 gac gtt ttg ttc caa tgg tct gct act act aag act tct atc tct cca 96 Asp Val Leu Phe Gln Trp Ser Ala Thr Thr Lys Thr Ser Ile Ser Pro 20 25 30 aag act ttg aga tct atc ttg aac tgt cca act tgg ttc gac tac gaa 144 Lys Thr Leu Arg Ser Ile Leu Asn Cys Pro Thr Trp Phe Asp Tyr Glu 35 40 45 aga ggt aga ttg gct gaa aac gct tgt tac gct gct atc tct caa gaa 192 Arg Gly Arg Leu Ala Glu Asn Ala Cys Tyr Ala Ala Ile Ser Gln Glu 50 55 60 ttc aac gtt aac cca gac gaa gtt aga gac gct ttc tct caa gct aga 240 Phe Asn Val Asn Pro Asp Glu Val Arg Asp Ala Phe Ser Gln Ala Arg 65 70 75 80 gac tct ttg caa gct aac cac gac ttc atc tct ttg atc aga gaa ttg 288 Asp Ser Leu Gln Ala Asn His Asp Phe Ile Ser Leu Ile Arg Glu Leu 85 90 95 aag gct caa gct aac ggt aga ttg aga gtt tac gct atg tct aac atc 336 Lys Ala Gln Ala Asn Gly Arg Leu Arg Val Tyr Ala Met Ser Asn Ile 100 105 110 tct ttg cca gac tgg gaa gtt ttg aga atg aag cca gct gac tgg gac 384 Ser Leu Pro Asp Trp Glu Val Leu Arg Met Lys Pro Ala Asp Trp Asp 115 120 125 atc ttc gac cac gtt ttc act tct ggt gct gtt ggt gaa aga aag cca 432 Ile Phe Asp His Val Phe Thr Ser Gly Ala Val Gly Glu Arg Lys Pro 130 135 140 aac ttg gct ttc tac aga cac gtt atc gct gct act gac ttg caa cca 480 Asn Leu Ala Phe Tyr Arg His Val Ile Ala Ala Thr Asp Leu Gln Pro 145 150 155 160 cac caa act atc ttc gtt gac gac aag ttg gaa aac gtt ttg tct gct 528 His Gln Thr Ile Phe Val Asp Asp Lys Leu Glu Asn Val Leu Ser Ala 165 170 175 aga tct ttg ggt ttc act ggt atc gtt ttc gac gaa cca tct gaa gtt 576 Arg Ser Leu Gly Phe Thr Gly Ile Val Phe Asp Glu Pro Ser Glu Val 180 185 190 aag aga gct ttg aga aac ttg atc ggt gac cca gtt caa aga ggt ggt 624 Lys Arg Ala Leu Arg Asn Leu Ile Gly Asp Pro Val Gln Arg Gly Gly 195 200 205 gaa ttc ttg gtt aga aac gct ggt aag ttg ggt tct atc act aga act 672 Glu Phe Leu Val Arg Asn Ala Gly Lys Leu Gly Ser Ile Thr Arg Thr 210 215 220 act gct aag cac gaa tct atc cca ttg gac gaa aac ttc gct caa ttg 720 Thr Ala Lys His Glu Ser Ile Pro Leu Asp Glu Asn Phe Ala Gln Leu 225 230 235 240 ttg atc ttg gaa atc act ggt aac aga gct ttg gtt aac ttg gtt gaa 768 Leu Ile Leu Glu Ile Thr Gly Asn Arg Ala Leu Val Asn Leu Val Glu 245 250 255 cac cca caa act tgg aac ttc ttc caa ggt aag ggt caa ttg act act 816 His Pro Gln Thr Trp Asn Phe Phe Gln Gly Lys Gly Gln Leu Thr Thr 260 265 270 gaa gaa ttc cca ttc gac ttg gac act act tct ttg ggt ttg act atc 864 Glu Glu Phe Pro Phe Asp Leu Asp Thr Thr Ser Leu Gly Leu Thr Ile 275 280 285 ttg aag aga tct aga gaa atc gct gac tct gtt atg gac gaa atg ttg 912 Leu Lys Arg Ser Arg Glu Ile Ala Asp Ser Val Met Asp Glu Met Leu 290 295 300 gaa tac gtt gac cca gac ggt atc atc caa act tac ttc gac cac aga 960 Glu Tyr Val Asp Pro Asp Gly Ile Ile Gln Thr Tyr Phe Asp His Arg 305 310 315 320 aga cca aga ttc gac cca gtt gtt tgt gtt aac gct ttg tct ttg ttc 1008 Arg Pro Arg Phe Asp Pro Val Val Cys Val Asn Ala Leu Ser Leu Phe 325 330 335 tac gct tac ggt aga ggt gaa caa ttg aga tct act ttg act tgg gtt 1056 Tyr Ala Tyr Gly Arg Gly Glu Gln Leu Arg Ser Thr Leu Thr Trp Val 340 345 350 cac gaa gtt ttg ttg aac aga gct tac ttg gac ggt act aga tac tac 1104 His Glu Val Leu Leu Asn Arg Ala Tyr Leu Asp Gly Thr Arg Tyr Tyr 355 360 365 gaa act gct gaa tgt ttc ttg tac ttc atg tct aga ttg ttg gct act 1152 Glu Thr Ala Glu Cys Phe Leu Tyr Phe Met Ser Arg Leu Leu Ala Thr 370 375 380 tct ggt gac cca gac ttg cac tct ttg ttg aag cca ttg ttg aag gaa 1200 Ser Gly Asp Pro Asp Leu His Ser Leu Leu Lys Pro Leu Leu Lys Glu 385 390 395 400 aga gtt caa gaa aga atc ggt gct gac ggt gac tct ttg gct ttg gct 1248 Arg Val Gln Glu Arg Ile Gly Ala Asp Gly Asp Ser Leu Ala Leu Ala 405 410 415 atg aga atc ttg gct tgt gac ttc gtt ggt atc aga gac gaa gtt gac 1296 Met Arg Ile Leu Ala Cys Asp Phe Val Gly Ile Arg Asp Glu Val Asp 420 425 430 ttg aga act ttg ttg act ttg caa tgt gaa gac ggt ggt tgg gaa gtt 1344 Leu Arg Thr Leu Leu Thr Leu Gln Cys Glu Asp Gly Gly Trp Glu Val 435 440 445 ggt tgg atg tac aag tac ggt tct tct ggt atc tct atc ggt aac aga 1392 Gly Trp Met Tyr Lys Tyr Gly Ser Ser Gly Ile Ser Ile Gly Asn Arg 450 455 460 gct ttg gct act gct tg gct atc aag gct gtt gac act atg ttc caa 1440 Gly Leu Ala Thr Ala Leu Ala Ile Lys Ala Val Asp Thr Met Phe Gln 465 470 475 480 cca caa atc aga ttc tct gaa tct cca act gac act ttg gtt gaa aac 1488 Pro Gln Ile Arg Phe Ser Glu Ser Pro Thr Asp Thr Leu Val Glu Asn 485,490,495 gct atc cac aag aga cca tct ttc tct gaa aag ttc ttg ggt aag Ala Ile His Lys Arg Arg Pro Ser Phe Ser Glu Lys Phe Leu Gly Lys 500 505 510 aga cca aga tct ggt tct ttc aga aag cca ttg caa tg atc ttg caa Arg Pro Arg Ser Gly Ser Phe Arg Lys Pro Leu Gln Trp Ile Leu Gln 515,520,525 ggt tct aag ttg aga aag tct gtt gaa atc ggt tct taa 1623 Gly Ser Lys Leu Arg Lys Ser Val Glu Ile Gly Ser 530 535 540 <210> 7 <211> 540 <212> PRT <213> XP_006461126 Agaricus bisporus buprenorphine synthase sequence, codon-optimized for expression in Saccharomyces cerevisiae <400> 7 Met Ala Pro Pro Gln Arg Pro Phe Thr Ala Ile Val Phe Asp Ile Gly 1 5 10 15 Asp Val Leu Phe Gln Trp Ser Ala Thr Thr Lys Thr Ser Ile Ser Pro 20 25 30 Lys Thr Leu Arg Ser Ile Leu Asn Cys Pro Thr Trp Phe Asp Tyr Glu 35 40 45 Arg Gly Arg Leu Ala Glu Asn Ala Cys Tyr Ala Ala Ile Ser Gln Glu 50 55 60 Phe Asn Val Asn Pro Asp Glu Val Arg Asp Ala Phe Ser Gln Ala Arg 65 70 75 80 Asp Ser Leu Gln Ala Asn His Asp Phe Ile Ser Leu Ile Arg Glu Leu 85 90 95 Lys Ala Gln Ala Asn Gly Arg Leu Arg Val Tyr Ala Met Ser Asn Ile 100 105 110 Ser Leu Pro Asp Trp Glu Val Leu Arg Met Lys Pro Ala Asp Trp Asp 115 120 125 Ile Phe Asp His Val Phe Thr Ser Gly Ala Val Gly Glu Arg Lys Pro 130 135 140 Asn Leu Ala Phe Tyr Arg His Val Ile Ala Ala Thr Asp Leu Gln Pro 145 150 155 160 His Gln Thr Ile Phe Val Asp Asp Lys Leu Glu Asn Val Leu Ser Ala 165 170 175 Arg Ser Leu Gly Phe Thr Gly Ile Val Phe Asp Glu Pro Ser Glu Val 180 185 190 Lys Arg Ala Leu Arg Asn Leu Ile Gly Asp Pro Val Gln Arg Gly Gly 195 200 205 Glu Phe Leu Val Arg Asn Ala Gly Lys Leu Gly Ser Ile Thr Arg Thr 210 215 220 Thr Ala Lys His Glu Ser Ile Pro Leu Asp Glu Asn Phe Ala Gln Leu 225 230 235 240 Leu Ile Leu Glu Ile Thr Gly Asn Arg Ala Leu Val Asn Leu Val Glu 245 250 255 His Pro Gln Thr Trp Asn Phe Phe Gln Gly Lys Gly Gln Leu Thr Thr 260 265 270 Glu Glu Phe Pro Phe Asp Leu Asp Thr Thr Ser Leu Gly Leu Thr Ile 275 280 285 Leu Lys Arg Ser Arg Glu Ile Ala Asp Ser Val Met Asp Glu Met Leu 290 295 300 Glu Tyr Val Asp Pro Asp Gly Ile Ile Gln Thr Tyr Phe Asp His Arg 305 310 315 320 Arg Pro Arg Phe Asp Pro Val Val Cys Val Asn Ala Leu Ser Leu Phe 325 330 335 Tyr Ala Tyr Gly Arg Gly Glu Gln Leu Arg Ser Thr Leu Thr Trp Val 340 345 350 His Glu Val Leu Leu Asn Arg Ala Tyr Leu Asp Gly Thr Arg Tyr Tyr 355 360 365 Glu Thr Ala Glu Cys Phe Leu Tyr Phe Met Ser Arg Leu Leu Ala Thr 370 375 380 Ser Gly Asp Pro Asp Leu His Ser Leu Leu Lys Pro Leu Leu Lys Glu 385 390 395 400 Arg Val Gln Glu Arg Ile Gly Ala Asp Gly Asp Ser Leu Ala Leu Ala 405 410 415 Met Arg Ile Leu Ala Cys Asp Phe Val Gly Ile Arg Asp Glu Val Asp 420 425 430 Leu Arg Thr Leu Leu Thr Leu Gln Cys Glu Asp Gly Gly Trp Glu Val 435 440 445 Gly Trp Met Tyr Lys Tyr Gly Ser Ser Gly Ile Ser Ile Gly Asn Arg 450 455 460 Gly Leu Ala Thr Ala Leu Ala Ile Lys Ala Val Asp Thr Met Phe Gln 465 470 475 480 Pro Gln Ile Arg Phe Ser Glu Ser Pro Thr Asp Thr Leu Val Glu Asn 485 490 495 Ala Ile His Lys Arg Arg Pro Ser Phe Ser Glu Lys Phe Leu Gly Lys 500 505 510 Arg Pro Arg Ser Gly Ser Phe Arg Lys Pro Leu Gln Trp Ile Leu Gln 515 520 525 Gly Ser Lys Leu Arg Lys Ser Val Glu Ile Gly Ser 530 535 540 <210> 8 <211> 1320 <212> DNA <213> CrDAT, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1320) <400> 8 atg gaa agt ggt aaa ata tct gta gaa acg gaa acc cta tcg aaa acc 48 Met Glu Ser Gly Lys Ile Ser Val Glu Thr Glu Thr Leu Ser Lys Thr 1 5 10 15 ctt atc aag ccg tcc tcg ccc acg cca cag tct ctt tcc cgt tac aac 96 Leu Ile Lys Pro Ser Ser Pro Thr Pro Gln Ser Leu Ser Arg Tyr Asn 20 25 30 tta tct tac aat gat cag aac att tat cag acc tgc gta tct gta ggg 144 Leu Ser Tyr Asn Asp Gln Asn Ile Tyr Gln Thr Cys Val Ser Val Gly 35 40 45 ttc ttt tac gaa aat cct gat ggc atc gag ata tcc acg atc cgt gag 192 Phe Phe Tyr Glu Asn Pro Asp Gly Ile Glu Ile Ser Thr Ile Arg Glu 50 55 60 cag ctg cag aac agc ctg tcc aaa act ctg gtc tca tac tat ccc ttc 240 Gln Leu Gln Asn Ser Leu Ser Lys Thr Leu Val Ser Tyr Tyr Pro Phe 65 70 75 80 gca ggc aaa gta gtg aag aac gac tac ata cat tgt aac gac gat ggc 288 Ala Gly Lys Val Val Lys Asn Asp Tyr Ile His Cys Asn Asp Asp Gly 85 90 95 to gag ttc gtc gaa gtc aga to aga tgc agg atg aat gat ata ctt 336 Ile Glu Phe Val Glu Val Arg Ile Arg Cys Arg Met Asn Asp Ile Leu 100 105 110 aaa tac gaa cta cgt tct tac gct cgt gat tta gtc ctg cca aag agg 384 Lys Tyr Glu Leu Arg Ser Tyr Ala Arg Asp Leu Val Leu Pro Lys Arg 115 120 125 gtt acc gtg ggc tct gaa gat acc acc gct atc gtg cag ctg tcc cat 432 Val Thr Val Gly Ser Glu Asp Thr Thr Ala Ile Val Gln Leu Ser His 130 135 140 ttc gac tgt ggc ggt ttg gcc gtg gct ttt ggt atc tcc cac aag gtg 480 Phe Asp Cys Gly Gly Leu Ala Val Ala Phe Gly Ile Ser His Lys Val 145 150 155 160 gcc gat ggt ggt act ata gcc tct ttc atg aag gac tgg gcg gcc tct 528 Ala Asp Gly Gly Thr Ile Ala Ser Phe Met Lys Asp Trp Ala Ala Ser 165 170 175 gct tgc tac ttg tcc tca agt cac cac gtt cca acg cct cta ttg gtc 576 Ala Cys Tyr Leu Ser Ser Ser His His Val Pro Thr Pro Leu Leu Val 180 185 190 tca gac agt at ttc cca aga cag gac aac ata tgc gaa caa ttt 624 Ser Asp Ser Ile Phe Pro Arg Gln Asp Asp Ile Ile Cys Glu Gln Phe 195 200 205 ccc acc tca aag aat tgc gtg gag aag aca ttc att ttc cca cca gaa 672 Pro Thr Ser Lys Asn Cys Val Glu Lys Thr Phe Ile Phe Pro Pro Glu 210 215 220 gca atc gaa aag tta aag agt aag gcc gtt gaa ttc ggc att gag aaa 720 Ala Ile Glu Lys Leu Lys Ser Lys Ala Val Glu Phe Gly Ile Glu Lys 225 230 235 240 ccg acc aga gta gag gtc ctg act gca ttc tta tct aga tgc gcc acc 768 Pro Thr Arg Val Glu Val Leu Thr Ala Phe Leu Ser Arg Cys Ala Thr 245 250 255 gta gca gt aag tcg gca gct aag aac aac aat tgt ggt caa agc ctg 816 Val Ala Gly Lys Ser Ala Ala Lys Asn Asn Asn Cys Gly Gln Ser Leu 260 265 270 ccc ttt ccg gtt cta cag gcc att aat ttg agg ccg att cta gaa ttg 864 Pro Phe Pro Val Leu Gln Wing Ile Asn Leu Arg Pro Ile Leu Glu Leu 275 280 285 cca cag aac tct gtg ggt aat cta gtt tcg atc tac ttc agc agc agg aca 912 Pro Gln Asn Ser Val Gly Asn Leu Val Ser Ile Tyr Phe Ser Arg Thr 290,295,300 att aag gaa aac gac tac cta aat gaa aag gag tac act aaa ttg gtg 960 Ile Lys Glu Asn Asp Tyr Leu Asn Glu Lys Glu Tyr Thr Lys Leu Val 305 310 315 320 ata aac gag ttg cgt aaa gaa aag caa aag atc aag aat ttg agc aga With Arg Glu Lys Glu Lys Gln Lys With Lys Asn With Ser Arg 325 330 335 gag aag ttg acc tac gtc gcc cag atg gaa gag ttc gtt aag tca ctt 1056 Glu Lys Thr Tyr Val Ala Gln Met Glu Glu Phe Val Lys Ser Leu 340 345 350 aaa gag ttc gat atc tcc aac ttc cta gat atc gat gcc tac tta agc 1104 Lys Glu Phe Asp Ile Ser Asn Phe Leu Asp Ile Asp Ala Tyr Leu Ser 355 360 365 gat agt tgg tgc agg ttt cct ttc tac gac gtc gac ttc gga tgg gga 1152 Asp Ser Trp Cys Arg Phe Pro Phe Tyr Asp Val Asp Phe Gly Trp Gly 370 375 380 aag cct atc tgg gtc tgc cta ttc cag cct tac atc aag aac tgc gtt 1200 Lys Pro Ile Trp Val Cys Leu Phe Gln Pro Tyr Ile Lys Asn Cys Val 385 390 395 400 gtt atg atg gac tat cct ttc ggt gac gat tat ggt atc gag gct att 1248 Val Met Met Asp Tyr Pro Phe Gly Asp Asp Tyr Gly Ile Glu Ala Ile 405 410 415 gtt tct ttc gag caa gag aaa atg tcc gcg ttc gag aag aac gaa cag 1296 Val Ser Phe Glu Gln Glu Lys Met Ser Ala Phe Glu Lys Asn Glu Gln 420 425 430 tta ctg cag ttt gtg tct aac taa 1320 Leu Leu Gln Phe Val Ser Asn 435 <210> 9 <211> 439 <212> PRT <213> CrDAT, codon-optimized for expression in Saccharomyces cerevisiae <400> 9 Met Glu Ser Gly Lys Ile Ser Val Glu Thr Glu Thr Leu Ser Lys Thr 1 5 10 15 Leu Ile Lys Pro Ser Ser Pro Thr Pro Gln Ser Leu Ser Arg Tyr Asn 20 25 30 Leu Ser Tyr Asn Asp Gln Asn Ile Tyr Gln Thr Cys Val Ser Val Gly 35 40 45 Phe Phe Tyr Glu Asn Pro Asp Gly Ile Glu Ile Ser Thr Ile Arg Glu 50 55 60 Gln Leu Gln Asn Ser Leu Ser Lys Thr Leu Val Ser Tyr Tyr Pro Phe 65 70 75 80 Ala Gly Lys Val Val Lys Asn Asp Tyr Ile His Cys Asn Asp Asp Gly 85 90 95 Ile Glu Phe Val Glu Val Arg Ile Arg Cys Arg Met Asn Asp Ile Leu 100 105 110 Lys Tyr Glu Leu Arg Ser Tyr Ala Arg Asp Leu Val Leu Pro Lys Arg 115 120 125 Val Thr Val Gly Ser Glu Asp Thr Thr Ala Ile Val Gln Leu Ser His 130 135 140 Phe Asp Cys Gly Gly Leu Ala Val Ala Phe Gly Ile Ser His Lys Val 145 150 155 160 Ala Asp Gly Gly Thr Ile Ala Ser Phe Met Lys Asp Trp Ala Ala Ser 165 170 175 Ala Cys Tyr Leu Ser Ser Ser His His Val Pro Thr Pro Leu Leu Val 180 185 190 Ser Asp Ser Ile Phe Pro Arg Gln Asp Asn Ile Ile Cys Glu Gln Phe 195 200 205 Pro Thr Ser Lys Asn Cys Val Glu Lys Thr Phe Ile Phe Pro Pro Glu 210 215 220 Ala Ile Glu Lys Leu Lys Ser Lys Ala Val Glu Phe Gly Ile Glu Lys 225 230 235 240 Pro Thr Arg Val Glu Val Leu Thr Ala Phe Leu Ser Arg Cys Ala Thr 245 250 255 Val Ala Gly Lys Ser Ala Ala Lys Asn Asn Asn Cys Gly Gln Ser Leu 260 265 270 Pro Phe Pro Val Leu Gln Ala Ile Asn Leu Arg Pro Ile Leu Glu Leu 275 280 285 Pro Gln Asn Ser Val Gly Asn Leu Val Ser Ile Tyr Phe Ser Arg Thr 290 295 300 Ile Lys Glu Asn Asp Tyr Leu Asn Glu Lys Glu Tyr Thr Lys Leu Val 305 310 315 320 Ile Asn Glu Leu Arg Lys Glu Lys Gln Lys Ile Lys Asn Leu Ser Arg 325 330 335 Glu Lys Leu Thr Tyr Val Ala Gln Met Glu Glu Phe Val Lys Ser Leu 340 345 350 Lys Glu Phe Asp Ile Ser Asn Phe Leu Asp Ile Asp Ala Tyr Leu Ser 355 360 365 Asp Ser Trp Cys Arg Phe Pro Phe Tyr Asp Val Asp Phe Gly Trp Gly 370 375 380 Lys Pro Ile Trp Val Cys Leu Phe Gln Pro Tyr Ile Lys Asn Cys Val 385 390 395 400 Val Met Met Asp Tyr Pro Phe Gly Asp Asp Tyr Gly Ile Glu Ala Ile 405 410 415 Val Ser Phe Glu Gln Glu Lys Met Ser Ala Phe Glu Lys Asn Glu Gln 420 425 430 Leu Leu Gln Phe Val Ser Asn 435 <210> 10 <211> 1320 <212> DNA <213> TcTAT, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1320) <400> 10 atg gag aag acg gat tta cac gtg aac ctt atc gaa aag gtt atg gtc 48 Met Glu Lys Thr Asp Leu His Val Asn Leu Ile Glu Lys Val Met Val 1 5 10 15 ggt cca agc cca cct ttg ccg aag aca cta caa cta tcc tca atc 96 Gly Pro Ser Pro Pro Leu Pro Lys Thr Thr Leu Gln Leu Ser Ser Ile 20 25 30 gat aac cta cct gtt gtt aga ggc tcg atc ttt aat gcc ttg tta ata 144 Asp Asn Leu Pro Gly Val Arg Gly Ser Ile Phe Asn Ala Leu Leu Ile 35 40 45 tat aat gct tca ccg tct ccc acg atg atc tcc gct gat cca gct aaa Tyr Asn Ala Ser Pro Ser Pro Thr Met Ile Ser Ala Asp Pro Ala Lys 50 55 60 cct atc aga gaa gct ttg gcc aaa atc ctg gtt tac tac cca cct ttc 240 Pro Ile Arg Glu Ala Leu Ala Lys Ile Leu Val Tyr Tyr Pro Pro Phe 65 70 75 80 gct ggc agg cta cgt gag act gag aat ggc gat cta gag gta gag tgc 288 Ala Gly Arg Leu Arg Glu Thr Glu Asn Gly Asp Leu Glu Val Glu Cys 85 90 95 acg gga gag ggt gcg atg ttt ctt gaa gcg atg gcc gat aat gaa tta 336 Thr Gly Glu Gly Ala Met Phe Leu Glu Ala Met Ala Asp Asn Glu Leu 100 105 110 agt gtc tta ggg gat ttc gac gac agt aac cct agc ttc cag caa ttg 384 Ser Val Leu Gly Asp Phe Asp Asp Ser Asn Pro Ser Phe Gln Gln Leu 115 120 125 ttg ttc tcc ctt cca ctg gac act aac ttc aag gat cta tcc ctg tta 432 Leu Phe Ser Leu Pro Leu Asp Thr Asn Phe Lys Asp Leu Ser Leu Leu 130 135 140 gtc gtg cag gtg aca agg ttt aca tgc ggc ggg ttc gtc gtt ggg gtt 480 Val Val Gln Val Thr Arg Phe Thr Cys Gly Gly Phe Val Val Gly Val 145 150 155 160 tca ttt cac cac ggt gta tgc gat ggg aga gga gct gca caa ttt ctg 528 Ser Phe His His Gly Val Cys Asp Gly Arg Gly Ala Ala Gln Phe Leu 165 170 175 aag gga cta gcc gaa atg gca agg gga gaa gtt aag ttg tcg ctg gag 576 Lys Gly Leu Ala Glu Met Ala Arg Gly Glu Val Lys Leu Ser Leu Glu 180 185 190 ccg atc tgg aat cgt gaa cta gtt aag ctg gac gat ccc aag tat ttg 624 Pro Ile Trp Asn Arg Glu Leu Val Lys Leu Asp Asp Pro Lys Tyr Leu 195 200 205 caa ttc ttt cac ttc gaa ttc ttc aga gca cca tca atc gtc gaa aag 672 Gln Phe Phe His Phe Glu Phe Leu Arg Ala Pro Ser Ile Val Glu Lys 210 215 220 at gtt caa acc tac ttc atc atc gat ttc gaa act at aac tac ata 720 Val Gln Thr Tyr Phe and Asp P1 Glu Thr and Asn Tyr Phe 225 230 235 240 aag cag tca gta atg gaa gaa tgt aaa gaa ttc tgc agc tct ttt gaa Lys Gln Ser Val Met Glu Glu Cys Lys Glu Phe Cys Ser Ser Phe Glu 245 250 255 gtt gct tct gca atg acg tgg ata gct agg acc agg gcc ttt caa ata 816 Val Ala Ser Ala Met Thr Trp Ile Ala Arg Thr Arg Ala Phe Gln Ile 260 265 270 ccc gag agc gag tac gtg aaa atc cta ttt ggt atg gac atg agg aac 864 Pro Glu Ser Glu Tyr Val Lys Ile Leu Phe Gly Met Asp Met Arg Asn 275 280 285 tct ttt aac ccg cct ctg ccg tca gt tat tat gga aac tca att ggt Ser Phe Asn Pro Pro Leu Pro Ser Gly Tyr Tyr Gly Asn Ser Ile Gly 290,295,300 acg gct tgt gca gtg gac aat gtt caa gac ttg tg agt ggt tca cta 960 Thr Ala Cys Ala Val Asp Val Gln Asp Leu Leu Ser Gly Ser Leu 305 310 315 320 ctg agg gca ata atg ata atc aag aaa tca aag gta tca ctt aac gac 1008 Leu Arg Ala Ile Met Ile Il Lys Lys Ser Lys Val Ser Leu Asn Asp 325 330 335 aac ttt aag agc cgt gct gtc gtt aag cct tca gaa ctt gac gta aac 1056 Asn Phe Lys Ser Arg Ala Val Val Lys Pro Ser Glu Leu Asp Val Asn 340 345 350 atg aac cat gag aat gtg gtg gca ttt gct gac tgg tca agg ctg ggg 1104 Met Asn His Glu Asn Val Val Ala Phe Ala Asp Trp Ser Arg Leu Gly 355 360 365 ttc gac gaa gtc gat ttt ggc tgg gga aac gcg gtg tct gtt tcc ccg 1152 Phe Asp Glu Val Asp Phe Gly Trp Gly Asn Ala Val Ser Val Ser Pro 370 375 380 gta cag caa cag tcg gca ctt gca atg cag aat tac ttc ctg ttc ttg 1200 Val Gln Gln Gln Ser Ala Leu Ala Met Gln Asn Tyr Phe Leu Phe Leu 385 390 395 400 aag cca agc aag aac aag ccc gat gga att aag att cta atg ttc cta 1248 Lys Pro Ser Lys Asn Lys Pro Asp Gly Ile Lys Ile Leu Met Phe Leu 405 410 415 cca ttg tcc aag atg aaa tcc ttc aaa att gaa atg gaa gcg atg atg atg Pro Leu Ser Lys Met Lys Ser Phe Lys Ile Glu Met Glu Ala Met Met 420 425 430 aag aag tac gtc gcc aag gta taa 1320 Lys Lys Tyr Val Ala Lys Val 435 <210> 11 <211> 439 <212> PRT <213> TcTAT, codon-optimized for expression in Saccharomyces cerevisiae <400> 11 Met Glu Lys Thr Asp Leu His Val Asn Leu Ile Glu Lys Val Met Val 1 5 10 15 Gly Pro Ser Pro Pro Leu Pro Lys Thr Thr Leu Gln Leu Ser Ser Ile 20 25 30 Asp Asn Leu Pro Gly Val Arg Gly Ser Ile Phe Asn Ala Leu Leu Ile 35 40 45 Tyr Asn Ala Ser Pro Ser Pro Thr Met Ile Ser Ala Asp Pro Ala Lys 50 55 60 Pro Ile Arg Glu Ala Leu Ala Lys Ile Leu Val Tyr Tyr Pro Pro Phe 65 70 75 80 Ala Gly Arg Leu Arg Glu Thr Glu Asn Gly Asp Leu Glu Val Glu Cys 85 90 95 Thr Gly Glu Gly Ala Met Phe Leu Glu Ala Met Ala Asp Asn Glu Leu 100 105 110 Ser Val Leu Gly Asp Phe Asp Asp Ser Asn Pro Ser Phe Gln Gln Leu 115 120 125 Leu Phe Ser Leu Pro Leu Asp Thr Asn Phe Lys Asp Leu Ser Leu Leu 130 135 140 Val Val Gln Val Thr Arg Phe Thr Cys Gly Gly Phe Val Val Gly Val 145 150 155 160 Ser Phe His His Gly Val Cys Asp Gly Arg Gly Ala Ala Gln Phe Leu 165 170 175 Lys Gly Leu Ala Glu Met Ala Arg Gly Glu Val Lys Leu Ser Leu Glu 180 185 190 Pro Ile Trp Asn Arg Glu Leu Val Lys Leu Asp Asp Pro Lys Tyr Leu 195 200 205 Gln Phe Phe His Phe Glu Phe Leu Arg Ala Pro Ser Ile Val Glu Lys 210 215 220 Ile Val Gln Thr Tyr Phe Ile Ile Asp Phe Glu Thr Ile Asn Tyr Ile 225 230 235 240 Lys Gln Ser Val Met Glu Glu Cys Lys Glu Phe Cys Ser Ser Phe Glu 245 250 255 Val Ala Ser Ala Met Thr Trp Ile Ala Arg Thr Arg Ala Phe Gln Ile 260 265 270 Pro Glu Ser Glu Tyr Val Lys Ile Leu Phe Gly Met Asp Met Arg Asn 275 280 285 Ser Phe Asn Pro Pro Leu Pro Ser Gly Tyr Tyr Gly Asn Ser Ile Gly 290 295 300 Thr Ala Cys Ala Val Asp Asn Val Gln Asp Leu Leu Ser Gly Ser Leu 305 310 315 320 Leu Arg Ala Ile Met Ile Ile Lys Lys Ser Lys Val Ser Leu Asn Asp 325 330 335 Asn Phe Lys Ser Arg Ala Val Val Lys Pro Ser Glu Leu Asp Val Asn 340 345 350 Met Asn His Glu Asn Val Val Ala Phe Ala Asp Trp Ser Arg Leu Gly 355 360 365 Phe Asp Glu Val Asp Phe Gly Trp Gly Asn Ala Val Ser Val Ser Pro 370 375 380 Val Gln Gln Gln Ser Ala Leu Ala Met Gln Asn Tyr Phe Leu Phe Leu 385 390 395 400 Lys Pro Ser Lys Asn Lys Pro Asp Gly Ile Lys Ile Leu Met Phe Leu 405 410 415 Pro Leu Ser Lys Met Lys Ser Phe Lys Ile Glu Met Glu Ala Met Met 420 425 430 Light Light Tyr Val Ala Light Val 435 <210> 12 <211> 1332 <212> DNA <213> CrMAT, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1332) <400> 12 atg gat tct att act atg gtt gaa acc gag aca tta tcg aag aca ttg 48 Met Asp Ser Ile Thr Met Val Glu Thr Glu Thr Leu Ser Lys Thr Leu 1 5 10 15 att aag cca tct agc cca acc cca cag agt ctg tca cac tac aac ctg 96 Ile Lys Pro Ser Ser Pro Thr Pro Gln Ser Leu Ser His Tyr Asn Leu 20 25 30 tct tac aac gat cag aat ata tat cca gag tat ata ttt gca ggc ttc 144 Ser Tyr Asn Asp Gln Asn Ile Tyr Pro Glu Tyr Ile Phe Ala Gly Phe 35 40 45 ttc tac agc aac ccg gac gga cac gag atc tcg act att aga gag cag 192 Phe Tyr Ser Asn Pro Asp Gly His Glu Ile Ser Thr Ile Arg Glu Gln 50 55 60 ctg cag aac tct ctt agc aag aca tta gta tct tat tat cca ttc gct 240 Leu Gln Asn Ser Leu Ser Lys Thr Leu Val Ser Tyr Tyr Pro Phe Ala 65 70 75 80 ggt aaa gtg gtc aag aac gat tac att cac tgc at gac gac gga ata 288 Gly Lys Val Val Lys Asn Asp Tyr Ile His Cys Asn Asp Asp Gly Ile 85 90 95 gaa ttc gta gac gtc aga atc cac tgc agg atg aac gat att ctt aag 336 Glu Phe Val Asp Val Arg Has Cys Arg With Asp Leu Lys 100 105 110 cct gaa ttg agg tct tac gct tcc gag ctt att cgt ccg aat aga agt 384 Pro Glu Leu Arg Ser Tyr Ala Ser Glu Leu Ile Arg Pro Asn Arg Ser 115 120 125 aca gtg ggg tca gag gac agt act gcg ctt gtc cag tta tct cac ttt 432 Thr Val Gly Ser Glu Asp Served Thr Ala Leu Val Gln Leu Served His Phe 130 135 140 gac tgt ggc ggg gta gct gtc gca ttc ggt ata tct cac aaa gtc gca 480 Asp Cys Gly Gly Val Ala Val Ala Phe Gly Ile Ser His Lys Val Ala 145 150 155 160 gac gca gcg act att ctg tcg ttt ata aag gat tgg gcc gct tct acg 528 Asp Only Thr I Leu Ser Phe I Lys Asp Trp Only Ser Thr 165 170 175 tgt gac ttg tca agt agt cac gat gtg tct aca cca gta cta gta tcc 576 Cys Asp Leu Ser Ser Ser Ser His Asp Will Ser Thr Pro Val Leu Val Ser 180 185 190 gat tcc ata ttc ccc cgt caa gat aac atc atc tgt ggc cag ttc cct 624 Asp Ser Ile Phe Pro Arg Gln Asp Asn Ile Ile Cys Gly Gln Phe Pro 195 200 205 gct tca ccg aac tgc gtg agg aag cgt ttc tta ttc agc ccg gaa gct 672 Ala To Be Pro Asn Cys Val Arg Lys Arg Phe Leu Phe To Be Pro Glu Ala 210 215 220 atc gaa aga cta aaa tcg aaa gcc att gaa ttt ggg atc gag aag cca 720 Ile Glu Arg Leu Lys Ser Lys Ala Ile Glu Phe Gly Ile Glu Lys Pro 225 230 235 240 acg agg gta gag gtc ctg aca gca ttc ttg tgc cgt tgc gct acc gtt 768 Thr Arg Val Glu Val Leu Thr Ala Phe Leu Cys Arg Cys Ala Thr Val 245 250 255 gca ggt aaa tct gcg gcc aag aac aac aat tgt gga cag tca ctg cct Ala Gly Lys Ser Ala Ala Lys Asn Asn Asn Cys Gly Gln Ser Leu Pro 260 265 270 ttc gct gtt att ca gca gtc aac ctg agg ccc tta cta gaa ctg cca 864 Phe Wing Val Ile Gln Wing Val Asn Leu Arg Pro Leu Leu Glu Leu Pro 275 280 285 aag aat tcc gtc ggc aac ctt ata tca atc tac ttt tct aca atc aaa 912 Lys Asn Ser Val Gly Asn Leu Ile Ser Ile Tyr Phe Ser Thr Ile Lys 290,295,300 gaa aac gac acg gtg aac atc gaa cag gag ttc aca aaa tta gtg atc 960 Glu Asn Asp Thr Val Asn Ile Glu Gln Glu Phe Thr Lys Leu Val Ile 305 310 315 320 gga gag ttg agg aag gct aag gat aag tta aag aac ctg tcg caa gag 1008 Gly Glu Leu Arg Lys Ala Lys Asp Lys Leu Lys Asn Leu Ser Gln Glu 325 330 335 aag ctg aat tac gta gct aga atg caa gat ttc gcg aat tgc ctg aag 1056 Lys Leu Asn Tyr Val Ala Arg Met Gln Asp Phe Ala Asn Cys Leu Lys 340 345 350 gaa ttg gac ata agt tca ttc ttc gac atg gaa aac gtg gac ata gac 1104 Glu Leu Asp Ser Ser Phe Phe Asp Met Glu Asn Val Asp Ile Asp 355 360 365 gct tat tta ttt tcg agc tgg tgc agg ttc ccc ttc tac gac atc gat 1152 Ala Tyr Leu Phe Ser Ser Trp Cys Arg Phe Pro Phe Tyr Asp Ile Asp 370 375 380 ttc ggt ctg ggg aag cca ata tgg gtc tgc atg ttt cag cct cac ttt 1200 Phe Gly Leu Gly Lys Pro Ile Trp Val Cys Met Phe Gln Pro His Phe 385 390 395 400 aag aat tgt ata att tta atg gat tat ccc ttt ggt gac gat tac ggc 1248 Lys Asn Cys Ile Ile Leu Met Asp Tyr Pro Phe Gly Asp Asp Tyr Gly 405 410 415 atc gaa gcc cta att acg tg gaa caa gag aag atc ccc gcc ttc gaa 1296 Ile Glu Ala Leu Ile Thr Leu Glu Gln Glu Lys Met Pro Ala Phe Glu 420 425 430 aac aac gag ctg ctg cta agc ttc gcc agc aac taa 1332 Asn Asn Glu Leu Leu Leu Ser Phe Ala Ser Asn 435 440 <210> 13 <211> 443 <212> PRT <213> CrMAT, codon-optimized for expression in Saccharomyces cerevisiae <400> 13 Met Asp Ser Ile Thr Met Val Glu Thr Glu Thr Leu Ser Lys Thr Leu 1 5 10 15 Ile Lys Pro Ser Ser Pro Thr Pro Gln Ser Leu Ser His Tyr Asn Leu 20 25 30 Ser Tyr Asn Asp Gln Asn Ile Tyr Pro Glu Tyr Ile Phe Ala Gly Phe 35 40 45 Phe Tyr Ser Asn Pro Asp Gly His Glu Ile Ser Thr Ile Arg Glu Gln 50 55 60 Leu Gln Asn Ser Leu Ser Lys Thr Leu Val Ser Tyr Tyr Pro Phe Ala 65 70 75 80 Gly Lys Val Val Lys Asn Asp Tyr Ile His Cys Asn Asp Asp Gly Ile 85 90 95 Glu Phe Val Asp Val Arg Ile His Cys Arg Met Asn Asp Ile Leu Lys 100 105 110 Pro Glu Leu Arg Ser Tyr Ala Ser Glu Leu Ile Arg Pro Asn Arg Ser 115 120 125 Thr Val Gly Ser Glu Asp Ser Thr Ala Leu Val Gln Leu Ser His Phe 130 135 140 Asp Cys Gly Gly Val Ala Val Ala Phe Gly Ile Ser His Lys Val Ala 145 150 155 160 Asp Ala Ala Thr Ile Leu Ser Phe Ile Lys Asp Trp Ala Ala Ser Thr 165 170 175 Cys Asp Leu Ser Ser Ser His Asp Val Ser Thr Pro Val Leu Val Ser 180 185 190 Asp Ser Ile Phe Pro Arg Gln Asp Asn Ile Ile Cys Gly Gln Phe Pro 195 200 205 Ala Ser Pro Asn Cys Val Arg Lys Arg Phe Leu Phe Ser Pro Glu Ala 210 215 220 Ile Glu Arg Leu Lys Ser Lys Ala Ile Glu Phe Gly Ile Glu Lys Pro 225 230 235 240 Thr Arg Val Glu Val Leu Thr Ala Phe Leu Cys Arg Cys Ala Thr Val 245 250 255 Ala Gly Lys Ser Ala Ala Lys Asn Asn Asn Cys Gly Gln Ser Leu Pro 260 265 270 Phe Ala Val Ile Gln Ala Val Asn Leu Arg Pro Leu Leu Glu Leu Pro 275 280 285 Lys Asn Ser Val Gly Asn Leu Ile Ser Ile Tyr Phe Ser Thr Ile Lys 290 295 300 Glu Asn Asp Thr Val Asn Ile Glu Gln Glu Phe Thr Lys Leu Val Ile 305 310 315 320 Gly Glu Leu Arg Lys Ala Lys Asp Lys Leu Lys Asn Leu Ser Gln Glu 325 330 335 Lys Leu Asn Tyr Val Ala Arg Met Gln Asp Phe Ala Asn Cys Leu Lys 340 345 350 Glu Leu Asp Ile Ser Ser Phe Phe Asp Met Glu Asn Val Asp Ile Asp 355 360 365 Ala Tyr Leu Phe Ser Ser Trp Cys Arg Phe Pro Phe Tyr Asp Ile Asp 370 375 380 Phe Gly Leu Gly Lys Pro Ile Trp Val Cys Met Phe Gln Pro His Phe 385 390 395 400 Lys Asn Cys Ile Ile Leu Met Asp Tyr Pro Phe Gly Asp Asp Tyr Gly 405 410 415 Ile Glu Ala Leu Ile Thr Leu Glu Gln Glu Lys Met Pro Ala Phe Glu 420 425 430 Asn Asn Glu Leu Leu Leu Ser Phe Ala Ser Asn 435 440 <210> 14 <211> 1254 <212> DNA <213> LiAAT-4 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1254) <400> 14 atg gcc atg ata atc acg aag caa ata tta aga cct agt tcc ccg acg 48 Met Ala Met Ile Ile Thr Lys Gln Ile Leu Arg Pro Ser Ser Pro Thr 1 5 10 15 ccc caa gcc ttt aag aat cac aag ctg tcc tac tta gac caa ata cag 96 Pro Gln Ala Phe Lys Asn His Lys Leu Ser Tyr Leu Asp Gln Ile Gln 20 25 30 gcg cct att tac ata cct ttg ttg ttc ttc tat aag aac gag gag tca 144 Ala Pro Ile Tyr Ile Pro Leu Leu Phe Phe Tyr Lys Asn Glu Glu Ser 35 40 45 aaa tac cca gac cag atc tcg caa aga ttt aag cag agt ttg tcc gaa 192 Lys Tyr Pro Asp Gln Ile Ser Gln Arg Phe Lys Gln Ser Leu Ser Glu 50 55 60 att ttg aca ata ttc tac cct ttg gct ggt acg atg agg cat aac tcg 240 Ile Leu Thr Ile Phe Tyr Pro Leu Ala Gly Thr Met Arg His Asn Ser 65 70 75 80 ttc gtg gac tgc aat gac agg ggt gtc gaa ttt gta gag gtc agg gtc 288 Phe Val Asp Cys Asn Asp Arg Gly Val Glu Phe Val Glu Val Arg Val 85 90 95 cat gcg aga cta gcc cag ttc att caa gat cct aag atg gaa gag ctt 336 Histology of Arg Leu Ala Gln Phe Ile Gln Asp Pro Lys Met Glu Glu Leu 100 105 110 aag caa ttg ata cct gtg gat tgt ata tct cac act gac gat gat ttc 384 Lys Gln Leu Ile Pro Val Asp Cys Ile Ser His Thr Asp Asp Phe 115 120 125 tta ttg cta gtc aag att agc tat ttt gac tgc ggt gag gtc gtc gtt 432 Leu Leu Leu Val Lys Ile Ser Tyr Phe Asp Cys Gly Glu Val Val Val 130 135 140 gga gtc tgc atg tcg cac aaa att ggt gac gga att agt ctg gca gcg 480 Gly Val Cys Met Ser His Lys Ile Gly Asp Gly Ser Leu Ala Ala Ala 145 150 155 160 ttt atg aac gct tgg gca gca acg tgt agg gga gaa tcg tct agt gag 528 Phe Met Asn Ala Trp Ala Ala Thr Cys Arg Gly Glu Ser Ser Ser Glu 165 170 175 atc att cac cca tct tt gat ctt gct tta cac ttt ccg cct aaa gac 576 Ile Ile His Pro Ser Phe Asp Leu Ala Leu His Phe Pro Pro Lys Asp 180 185 190 cac ttg tct tca gca tcc tca ttc cgt gtg gcc ata gcc cag gag aac 624 His Leu To Be To Be Ala To Be Phe Arg Val Ala Ile Ala Gln Glu Asn 195 200 205 atc atg acc aag agg cta gta ttt gat aga gaa aag ttg gag aag ctg 672 It Met Thr Lys Arg Leu Val Phe Asp Arg Glu Lys Leu Glu Lys Leu 210 215 220 cgt aag aga atc gct gcc agt tct gat ggg gtg aga gac cct agc aga 720 Arg Lys Arg Ile Ala Ala Ser Ser Asp Gly Val Arg Asp Pro Ser Arg 225 230 235 240 gtt gaa gct gta tct gtc ttt att tgg aaa agc tta att gaa gcc cac 768 Val Glu Ala Val Ser Val Phe Ile Trp Lys Ser Leu Ile Glu Ala His 245 250 255 aag gcc gag tca cac atg act gag aca cca gcc gtt tct att gct agc 816 Lys Ala Glu Ser His Met Thr Glu Thr Pro Ala Val Ser Ile Ala Ser 260 265 270 cac gcc gtg aac tta agg cct aga aca gtc cca caa atg gac caa act 864 His Ala Val Asn Leu Arg Pro Arg Thr Val Pro Gln Met Asp Gln Thr 275 280 285 ttc ggt aac tgc tac gct ccc gct tcg gcc gtt gtc tcc tgg gat gaa 912 Phe Gly Asn Cys Tyr Ala Pro Ala Ser Ala Val Val Ser Trp Asp Glu 290,295,300 gac tac gta cat cac agt cgt ttg agg gcg gcc ctt aga gaa atc gac 960 Asp Tyr Val His His Ser Arg Leu Arg Ala Ala Leu Arg Glu Ile Asp 305 310 315 320 gac gac tac att aat aag gtc ttg aaa gcc gac aat aat tat tta acg 1008 Asp Asp Tyr Ile Asn Lys Val Leu Lys Ala Asp Asn Asn Tyr Leu Thr 325 330 335 cag gat caa att ggt gac ttg ttt aaa cca gaa aac tca gtt cta agt 1056 Gln Asp Gln Ile Gly Asp Leu Phe Lys Pro Glu Asn Ser Val Leu Ser 340 345 350 tcg tgg tgg cgt ttc cca gtt tac aag gta gac ttt gga tgg ggt aag 1104 Ser Trp Trp Arg Phe Pro Val Tyr Lys Val Asp Phe Gly Trp Gly Lys 355 360 365 cca gtt tgg gtt tct acg acg acc atc caa tac atg aac ttg att ata 1152 Pro Val Trp Val Ser Thr Thr Thr Ile Gln Tyr Met Asn Leu Ile Ile 370 375 380 ttt act tcg acg ccc tca gaa gac ggc ata gag gcg tgg gta act act 1200 Phe Thr Ser Thr Pro Ser Glu Asp Gly Ile Glu Ala Trp Val Thr Thr 385 390 395 400 act cac aat ttc ttc caa gtt ctg cag gca aac tat aat aaa ctt gac 1248 Thr His Asn Phe Phe Gln Val Leu Gln Ala Asn Tyr Asn Lys Leu Asp 405 410 415 acg taa 1254 Thr <210> 15 <211> 417 <212> PRT <213> LiAAT-4 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae <400> 15 Met Ala Met Ile Ile Thr Lys Gln Ile Leu Arg Pro Ser Ser Pro Thr 1 5 10 15 Pro Gln Ala Phe Lys Asn His Lys Leu Ser Tyr Leu Asp Gln Ile Gln 20 25 30 Ala Pro Ile Tyr Ile Pro Leu Leu Phe Phe Tyr Lys Asn Glu Glu Ser 35 40 45 Lys Tyr Pro Asp Gln Ile Ser Gln Arg Phe Lys Gln Ser Leu Ser Glu 50 55 60 Ile Leu Thr Ile Phe Tyr Pro Leu Ala Gly Thr Met Arg His Asn Ser 65 70 75 80 Phe Val Asp Cys Asn Asp Arg Gly Val Glu Phe Val Glu Val Arg Val 85 90 95 His Ala Arg Leu Ala Gln Phe Ile Gln Asp Pro Lys Met Glu Glu Leu 100 105 110 Lys Gln Leu Ile Pro Val Asp Cys Ile Ser His Thr Asp Asp Asp Phe 115 120 125 Leu Leu Leu Val Lys Ile Ser Tyr Phe Asp Cys Gly Glu Val Val Val 130 135 140 Gly Val Cys Met Ser His Lys Ile Gly Asp Gly Ile Ser Leu Ala Ala 145 150 155 160 Phe Met Asn Ala Trp Ala Ala Thr Cys Arg Gly Glu Ser Ser Ser Glu 165 170 175 Ile Ile His Pro Ser Phe Asp Leu Ala Leu His Phe Pro Pro Lys Asp 180 185 190 His Leu Ser Ser Ala Ser Ser Phe Arg Val Ala Ile Ala Gln Glu Asn 195 200 205 Ile Met Thr Lys Arg Leu Val Phe Asp Arg Glu Lys Leu Glu Lys Leu 210 215 220 Arg Lys Arg Ile Ala Ala Ser Ser Asp Gly Val Arg Asp Pro Ser Arg 225 230 235 240 Val Glu Ala Val Ser Val Phe Ile Trp Lys Ser Leu Ile Glu Ala His 245 250 255 Lys Ala Glu Ser His Met Thr Glu Thr Pro Ala Val Ser Ile Ala Ser 260 265 270 His Ala Val Asn Leu Arg Pro Arg Thr Val Pro Gln Met Asp Gln Thr 275 280 285 Phe Gly Asn Cys Tyr Ala Pro Ala Ser Ala Val Val Ser Trp Asp Glu 290 295 300 Asp Tyr Val His His Ser Arg Leu Arg Ala Ala Leu Arg Glu Ile Asp 305 310 315 320 Asp Asp Tyr Ile Asn Lys Val Leu Lys Ala Asp Asn Asn Tyr Leu Thr 325 330 335 Gln Asp Gln Ile Gly Asp Leu Phe Lys Pro Glu Asn Ser Val Leu Ser 340 345 350 Ser Trp Trp Arg Phe Pro Val Tyr Lys Val Asp Phe Gly Trp Gly Lys 355 360 365 Pro Val Trp Val Ser Thr Thr Thr Ile Gln Tyr Met Asn Leu Ile Ile 370 375 380 Phe Thr Ser Thr Pro Ser Glu Asp Gly Ile Glu Ala Trp Val Thr Thr 385 390 395 400 Thr His Asn Phe Phe Gln Val Leu Gln Ala Asn Tyr Asn Lys Leu Asp 405 410 415 Thr <210> 16 <211> 1485 <212> DNA <213> FgaAT, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1485) <400> 16 atg aag aag cag gtc act ttt aaa cct ttc aga ttg tca cca gtc gat 48 Met Lys Lys Gln Val Thr Phe Lys Pro Phe Arg Leu Ser Pro Val Asp 1 5 10 15 cat agt tta cct aag gtt tac atc ttc aag tct cta tat ttc aga ggg 96 His Ser Leu Pro Lys Val Tyr Ile Phe Lys Ser Leu Tyr Phe Arg Gly 20 25 30 gta gat gac act ggt tct ctt agt aga cta cag gat ggc att gat cgt 144 Val Asp Asp Thr Gly Ser Leu Ser Arg Leu Gln Asp Gly Ile Asp Arg 35 40 45 ttg ata tct tgt ctg cct ttc ctg tca ggc gag gtg gtt cca tgt gca 192 Leu Ile Ser Cys Leu Pro Phe Leu Ser Gly Glu Val Val Pro Cys Ala 50 55 60 gac ata cca gat aag gtc ggt gta ctt caa gtt cag atg cct tgc cct 240 Asp Ile Pro Asp Lys Val Gly Val Leu Gln Val Gln Met Pro Cys Pro 65 70 75 80 tcc ttg caa gaa att cca atg ctg cta gtc aaa agt tat cca aac cat 288 Ser Leu Gln Glu Ile Pro Met Leu Leu Val Lys Ser Tyr Pro Asn His 85 90 95 aca tgg cca gca gct tct acc tcg gaa aga tgg aga aac acc gct ttg 336 Thr Trp Pro Ala Ala Ser Thr Ser Glu Arg Trp Arg Asn Thr Ala Leu 100 105 110 cta gat cag tcg tat agg cca ttg ccg gat ttt ata ccc cca tca aag 384 Leu Asp Gln Ser Tyr Arg Pro Leu Pro Asp Phe Ile Pro Pro Pro Ser Lys 115 120 125 cct aga cct gtt ttg aga ttt cag gcg aac ttc ctg gct gat ggt tta 432 Pro Arg Pro Val Leu Arg Phe Gln Ala Asn Phe Leu Ala Asp Gly Leu 130 135 140 atg cta tgt atg gga tat aat cat tct gta ttc gac gga aca ggt gcg 480 Met Leu Cys Met Gly Tyr Asn His Ser Val Phe Asp Gly Thr Gly Ala 145 150 155 160 ggg aac att ctg gaa atg ttg gct gat tgt tgt aga gct aat cca aac 528 Gly Asn Ile Leu Glu Met Leu Ala Asp Cys Cys Arg Ala Asn Pro Asn 165 170 175 tcc atc tta gca ctg cca aca aac ggt gac ata gag agc gag ttg aga 576 Ser Ile Leu Ala Leu Pro Thr Asn Gly Asp Ile Glu Ser Glu Leu Arg 180 185 190 ggt tta ctg tcc agt cca ggt gta gca gtt gca aat gcc tct cag gaa 624 Gly Leu Leu Ser Ser Pro Gly Val Ala Val Ala Asn Ala Ser Gln Glu 195 200 205 gcc tac gca att aat tgt gca cac acg gaa gta gaa ccc gaa ccc agt 672 Ala Tyr Ala Ile Asn Cys Ala His Thr Glu Val Glu Pro Glu Pro Ser 210 215 220 tca gct atg ctt tac tgt tgg cct ttc ttg ctg agt tct gag aag att 720 Ser Ala Met Leu Tyr Cys Trp Pro Phe Leu Leu Ser Ser Glu Lys Ile 225 230 235 240 gaa tgt tta cag gaa gca tgt aat agt tta cta cca cat atc gtt cgt 768 Glu Cys Leu Gln Glu Ala Cys Asn Ser Leu Leu Pro His Ile Val Arg 245 250 255 ttg tac tct ggt acg cag agt tcg ctt ata aac caa gat acg aac tgg 816 Leu Tyr Ser Gly Thr Gln Ser Ser Leu Ile Asn Gln Asp Thr Asn Trp 260 265 270 cca cat att ctt tca tca aac gac gtg cta acc gct ctt tta gct gtt 864 Pro His Ile Leu Ser Ser Asn Asp Val Leu Thr Ala Leu Leu Ala Val 275 280 285 tca att gaa aag gct agg gaa gca aca ggt gcc ctt ggt cat atg agc 912 Ser Ile Glu Lys Ala Arg Glu Ala Thr Gly Ala Leu Gly His Met Ser 290 295 300 aga tca ttg gct atg gct gtt aac cta cgt gag cgt tta aag cct atg 960 Arg Ser Leu Ala Met Ala Val Asn Leu Arg Glu Arg Leu Lys Pro Met 305 310 315 320 cca aga cac tat ttg ggt aac cta gtt acc act gtg tgg gta tca cat 1008 Pro Arg His Tyr Leu Gly Asn Leu Val Thr Thr Val Trp Val Ser His 325 330 335 cac cgt cct gcc gtt aag gac ctt gaa aca atg gtt tta cca gtg cca 1056 His Arg Pro Ala Val Lys Asp Leu Glu Thr Met Val Leu Pro Val Pro 340 345 350 gca tgc aat agg cac gaa ata gac aga gac gac ttg ttg tgg ata acc 1104 Ala Cys Asn Arg His Glu Ile Asp Arg Asp Asp Leu Leu Trp Ile Thr 355 360 365 cac gtg gca ttc cgt att aga tta ggg ctg aac gca ata aac gaa gaa 1152 His Val Ala Phe Arg Ile Arg Leu Gly Leu Asn Ala Ile Asn Glu Glu 370 375 380 cat tot aga ggt ctg atc cac tac ttg cat tcc caa gac gat tgg gaa 1200 His Ile Arg Gly Leu Ile His Tyr Leu His Ser Gln Asp Asp Trp Glu 385 390 395 400 cag att gga ata cat ttc acc gat cca att ttc att tct tcc tgg cgt 1248 Gln Ile Gly Ile His Phe Thr Asp Pro Ile Phe Ile Ser Ser Trp Arg 405 410 415 cac ctt aag gtc tat gaa cta gac ttc gga cct act atc ggt cat gct 1296 His Leu Lys Val Tyr Glu Leu Asp Phe Gly Pro Thr Ile Gly His Ala 420 425 430 gaa cac ttt gag atg gat gtc ggc acc acc gat ggt gtg tgt gtt gtt 1344 Glu His Phe Glu Met Asp Val Gly Thr Thr Asp Gly Val Cys Val Val 435 440 445 atg cct gct aac acc aga gcc gtc ggc aag act aag aag gct cct tgg 1392 Met Pro Ala Asn Thr Arg Ala Val Gly Lys Thr Lys Lys Ala Pro Trp 450 455 460 gac att aga atc gtg tta aac ccc gaa gtg tta cag gca cta ata gct 1440 Asp Ile Arg Ile Val Leu Asn Pro Glu Val Leu Gln Ala Leu Ile Ala 465 470 475 480 agt gcc atc ttt ggt tgg gct atg gtc aag gac gct tcg aca taa 1485 Ser Ala Ile Phe Gly Trp Ala Met Val Lys Asp Ala Ser Thr 485 490 <210> 17 <211> 494 <212> PRT <213> FgaAT, codon-optimized for expression in Saccharomyces cerevisiae <400> 17 Met Lys Lys Gln Val Thr Phe Lys Pro Phe Arg Leu Ser Pro Val Asp 1 5 10 15 His Ser Leu Pro Lys Val Tyr Ile Phe Lys Ser Leu Tyr Phe Arg Gly 20 25 30 Val Asp Asp Thr Gly Ser Leu Ser Arg Leu Gln Asp Gly Ile Asp Arg 35 40 45 Leu Ile Ser Cys Leu Pro Phe Leu Ser Gly Glu Val Val Pro Cys Ala 50 55 60 Asp Ile Pro Asp Lys Val Gly Val Leu Gln Val Gln Met Pro Cys Pro 65 70 75 80 Ser Leu Gln Glu Ile Pro Met Leu Leu Val Lys Ser Tyr Pro Asn His 85 90 95 Thr Trp Pro Ala Ala Ser Thr Ser Glu Arg Trp Arg Asn Thr Ala Leu 100 105 110 Leu Asp Gln Ser Tyr Arg Pro Leu Pro Asp Phe Ile Pro Pro Ser Lys 115 120 125 Pro Arg Pro Val Leu Arg Phe Gln Ala Asn Phe Leu Ala Asp Gly Leu 130 135 140 Met Leu Cys Met Gly Tyr Asn His Ser Val Phe Asp Gly Thr Gly Ala 145 150 155 160 Gly Asn Ile Leu Glu Met Leu Ala Asp Cys Cys Arg Ala Asn Pro Asn 165 170 175 Ser Ile Leu Ala Leu Pro Thr Asn Gly Asp Ile Glu Ser Glu Leu Arg 180 185 190 Gly Leu Leu Ser Ser Pro Gly Val Ala Val Ala Asn Ala Ser Gln Glu 195 200 205 Ala Tyr Ala Ile Asn Cys Ala His Thr Glu Val Glu Pro Glu Pro Ser 210 215 220 Ser Ala Met Leu Tyr Cys Trp Pro Phe Leu Leu Ser Ser Glu Lys Ile 225 230 235 240 Glu Cys Leu Gln Glu Ala Cys Asn Ser Leu Leu Pro His Ile Val Arg 245 250 255 Leu Tyr Ser Gly Thr Gln Ser Ser Leu Ile Asn Gln Asp Thr Asn Trp 260 265 270 Pro His Ile Leu Ser Ser Asn Asp Val Leu Thr Ala Leu Leu Ala Val 275 280 285 Ser Ile Glu Lys Ala Arg Glu Ala Thr Gly Ala Leu Gly His Met Ser 290 295 300 Arg Ser Leu Ala Met Ala Val Asn Leu Arg Glu Arg Leu Lys Pro Met 305 310 315 320 Pro Arg His Tyr Leu Gly Asn Leu Val Thr Thr Val Trp Val Ser His 325 330 335 His Arg Pro Ala Val Lys Asp Leu Glu Thr Met Val Leu Pro Val Pro 340 345 350 Ala Cys Asn Arg His Glu Ile Asp Arg Asp Asp Leu Leu Trp Ile Thr 355 360 365 His Val Ala Phe Arg Ile Arg Leu Gly Leu Asn Ala Ile Asn Glu Glu 370 375 380 His Ile Arg Gly Leu Ile His Tyr Leu His Ser Gln Asp Asp Trp Glu 385 390 395 400 Gln Ile Gly Ile His Phe Thr Asp Pro Ile Phe Ile Ser Ser Trp Arg 405 410 415 His Leu Lys Val Tyr Glu Leu Asp Phe Gly Pro Thr Ile Gly His Ala 420 425 430 Glu His Phe Glu Met Asp Val Gly Thr Thr Asp Gly Val Cys Val Val 435 440 445 Met Pro Ala Asn Thr Arg Ala Val Gly Lys Thr Lys Lys Ala Pro Trp 450 455 460 Asp Ile Arg Ile Val Leu Asn Pro Glu Val Leu Gln Ala Leu Ile Ala 465 470 475 480 Ser Ala Ile Phe Gly Trp Ala Met Val Lys Asp Ala Ser Thr 485 490 <210> 18 <211> 1548 <212> DNA <213> GAO81666.1, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1548) <400> 18 atg gaa gaa cat acc aga tcc ttt gag cca ttt gac ctg gcc tgc tta 48 Met Glu Glu His Thr Arg Ser Phe Glu Pro Phe Asp Leu Ala Cys Leu 1 5 10 15 gat cat act gtg ggg ccg gtt ttc atg aat ttc ttc tta agt ttc aag 96 Asp His Thr Val Gly Pro Val Phe Met Asn Phe Phe Leu Ser Phe Lys 20 25 30 cct gcc aag atc gaa gag agt ctt atc tca att gaa gaa ggt gta act 144 Pro Ala Lys Ile Glu Glu Ser Leu Ile Ser Ile Glu Glu Gly Val Thr 35 40 45 agg tta gtc aac aga ctg cca ttc ctg gcc ggt gac gtt gtt aat tct 192 Arg Leu Val Asn Arg Leu Pro Phe Leu Ala Gly Asp Val Val Asn Ser 50 55 60 gaa aac gta gac ggt cgt gtt aat gta atg agg att cag cca agc tcg 240 Glu Asn Val Asp Gly Arg Val Asn Val Met Arg Ile Gln Pro Ser Ser 65 70 75 80 aca ttg att aga gag att ccc atg cta cac aca aag cac cat cct cat 288 Thr Leu Ile Arg Glu Ile Pro Met Leu His Thr Lys His His Pro His 85 90 95 cat att ttg ccg aat aca cct aga cag att aac cca ggg tcc gac cag 336 His Ile Leu Pro Asn Thr Pro Arg Gln Ile Asn Pro Gly Ser Asp Gln 100 105 110 gat caa agg ttt gct ccc ttg gac gat tcg tac gta cca cca gtg tct 384 Asp Gln Arg Phe Ala Pro Leu Asp Asp Ser Tyr Val Pro Pro Val Ser 115 120 125 tta tta cct ctt gct ccg ggc cca agg ccc gta gta aga ttc caa act 432 Leu Leu Pro Leu Ala Pro Gly Pro Arg Pro Val Val Arg Phe Gln Thr 130 135 140 aat gtt gta att gac ggg att gtg ctt gca ctt ggg ttc cac cac tca 480 Asn Val Val Ile Asp Gly Ile Val Leu Ala Leu Gly Phe His His Ser 145 150 155 160 gta ttt gat gct acc gga gtg ggt ttg ttg atc gaa atg ttg gcc aca 528 Val Phe Asp Ala Thr Gly Val Gly Leu Leu Ile Glu Met Leu Ala Thr 165 170 175 tgt tgt tca agc gat tgt cct gcc cta tca tcc cat att gaa ctg gaa 576 Cys Cys Ser Ser Asp Cys Pro Ala Leu Ser Ser His Ile Glu Leu Glu 180 185 190 gaa gaa ata agg cta agg cgt tct gtg gac aag ata ggt aac ggc gct 624 Glu Glu Ile Arg Leu Arg Arg Ser Val Asp Lys Ile Gly Asn Gly Ala 195 200 205 act gat tta gca tcc caa aga gat gaa gtt cag gac cca aat ggc agt 672 Thr Asp Leu Ala Ser Gln Arg Asp Glu Val Gln Asp Pro Asn Gly Ser 210 215 220 atc act gag tcc cca gct cat gtg cct atg ggt gac agt agc tgg gta 720 Ile Thr Glu Ser Pro Ala His Val Pro Met Gly Asp Ser Ser Trp Val 225 230 235 240 ccc cct aaa cta tct gtt tac tcc ttt aat tta tcg gct gcc ggt ttg 768 Pro Pro Lys Leu Ser Val Tyr Ser Phe Asn Leu Ser Ala Ala Gly Leu 245 250 255 gct cat ttg aag aca gcc tgt aac aag tta ttg ccc gct atc cat gcg 816 Ala His Leu Lys Thr Ala Cys Asn Lys Leu Leu Pro Ala Ile His Ala 260 265 270 agt caa aat ggt tca cca caa agt gcg gaa tca gaa ggt gag aaa tta 864 Ser Gln Asn Gly Ser Pro Gln Ser Ala Glu Ser Glu Gly Glu Lys Leu 275 280 285 cag caa gaa ttc gtt tcg acg aat gat gtt cta acg gct ttg ttg gct 912 Gln Gln Glu Phe Val Ser Thr Asn Asp Val Leu Thr Ala Leu Leu Ala 290 295 300 act tcc att cac caa gcg agg tct aga gtt act gaa acg gaa tta gtt 960 Thr Ser Ile His Gln Ala Arg Ser Arg Val Thr Glu Thr Glu Leu Val 305 310 315 320 ccg aca aaa gcg aaa ctt gcg atg gcc gtt aat ttg agg gaa agg gcc 1008 Pro Thr Lys Ala Lys Leu Ala Met Ala Val Asn Leu Arg Glu Arg Ala 325 330 335 agt tcg tta ccc aag act tat ttg ggg aac tcg cta aca gtt aca gaa 1056 Ser Ser Leu Pro Lys Thr Tyr Leu Gly Asn Ser Leu Thr Val Thr Glu 340 345 350 gct ttt gtg tat tct tta gct gct acc gac ggt ttc gat ggt gtc ccc 1104 Ala Phe Val Tyr Ser Leu Ala Ala Thr Asp Gly Phe Asp Gly Val Pro 355 360 365 gag aga cat tat cat cct gac ttg cgt aac gcc ttg cta tta gaa att 1152 Glu Arg His Tyr His Pro Asp Leu Arg Asn Ala Leu Leu Leu Glu Ile 370 375 380 gct aga gtt gca ttg caa ttg aga aaa ggg ctg gca gcg ata gat gac 1200 Ala Arg Val Ala Leu Gln Leu Arg Lys Gly Leu Ala Ala Ile Asp Asp 385 390 395 400 gcg tat ttt agg caa ttt gtg tct aga ttg agg gct aat cta gac tgg 1248 Ala Tyr Phe Arg Gln Phe Val Ser Arg Leu Arg Ala Asn Leu Asp Trp 405 410 415 tca cag tta ggt gca aac ctg cct gac act atg gtg tca agc tgg aga 1296 Ser Gln Leu Gly Ala Asn Leu Pro Asp Thr Met Val Ser Ser Trp Arg 420 425 430 cat ttg aaa gta tat cgt tta gac ttc ggt gct aga ttg ggg aga gtt 1344 His Leu Lys Val Tyr Arg Leu Asp Phe Gly Ala Arg Leu Gly Arg Val 435 440 445 gta gag ttc cat cca caa acc gct ttg gtt gac ggt att tgt atc atc 1392 Val Glu Phe His Pro Gln Thr Ala Leu Val Asp Gly Ile Cys Ile Ile 450 455 460 caa cct gaa agg ata gcc cat gag gat gat tca gct gat atg gct cca 1440 Gln Pro Glu Arg Ile Ala His Glu Asp Asp Ser Ala Asp Met Ala Pro 465 470 475 480 gaa tct ggg tgg gaa gtt tgt gta aca tta caa agc gat gcc atg gag 1488 Glu Ser Gly Trp Glu Val Cys Val Thr Leu Gln Ser Asp Ala Met Glu 485 490 495 tgc ttc tta aga ggt ggg ttg ttc aca agt ctt tct caa ggt gca att 1536 Cys Phe Leu Arg Gly Gly Leu Phe Thr Ser Leu Ser Gln Gly Ala Ile 500 505 510 aga aga gtt taa 1548 Arg Arg Val 515 <210> 19 <211> 515 <212> PRT <213> GAO81666.1, codon-optimized for expression in Saccharomyces cerevisiae <400> 19 Met Glu Glu His Thr Arg Ser Phe Glu Pro Phe Asp Leu Ala Cys Leu 1 5 10 15 Asp His Thr Val Gly Pro Val Phe Met Asn Phe Phe Leu Ser Phe Lys 20 25 30 Pro Ala Lys Ile Glu Glu Ser Leu Ile Ser Ile Glu Glu Gly Val Thr 35 40 45 Arg Leu Val Asn Arg Leu Pro Phe Leu Ala Gly Asp Val Val Asn Ser 50 55 60 Glu Asn Val Asp Gly Arg Val Asn Val Met Arg Ile Gln Pro Ser Ser 65 70 75 80 Thr Leu Ile Arg Glu Ile Pro Met Leu His Thr Lys His His Pro His 85 90 95 His Ile Leu Pro Asn Thr Pro Arg Gln Ile Asn Pro Gly Ser Asp Gln 100 105 110 Asp Gln Arg Phe Ala Pro Leu Asp Asp Ser Tyr Val Pro Pro Val Ser 115 120 125 Leu Leu Pro Leu Ala Pro Gly Pro Arg Pro Val Val Arg Phe Gln Thr 130 135 140 Asn Val Val Ile Asp Gly Ile Val Leu Ala Leu Gly Phe His His Ser 145 150 155 160 Val Phe Asp Ala Thr Gly Val Gly Leu Leu Ile Glu Met Leu Ala Thr 165 170 175 Cys Cys Ser Ser Asp Cys Pro Ala Leu Ser Ser His Ile Glu Leu Glu 180 185 190 Glu Glu Ile Arg Leu Arg Arg Ser Val Asp Lys Ile Gly Asn Gly Ala 195 200 205 Thr Asp Leu Ala Ser Gln Arg Asp Glu Val Gln Asp Pro Asn Gly Ser 210 215 220 Ile Thr Glu Ser Pro Ala His Val Pro Met Gly Asp Ser Ser Trp Val 225 230 235 240 Pro Pro Lys Leu Ser Val Tyr Ser Phe Asn Leu Ser Ala Ala Gly Leu 245 250 255 Ala His Leu Lys Thr Ala Cys Asn Lys Leu Leu Pro Ala Ile His Ala 260 265 270 Ser Gln Asn Gly Ser Pro Gln Ser Ala Glu Ser Glu Gly Glu Lys Leu 275 280 285 Gln Gln Glu Phe Val Ser Thr Asn Asp Val Leu Thr Ala Leu Leu Ala 290 295 300 Thr Ser Ile His Gln Ala Arg Ser Arg Val Thr Glu Thr Glu Leu Val 305 310 315 320 Pro Thr Lys Ala Lys Leu Ala Met Ala Val Asn Leu Arg Glu Arg Ala 325 330 335 Ser Ser Leu Pro Lys Thr Tyr Leu Gly Asn Ser Leu Thr Val Thr Glu 340 345 350 Ala Phe Val Tyr Ser Leu Ala Ala Thr Asp Gly Phe Asp Gly Val Pro 355 360 365 Glu Arg His Tyr His Pro Asp Leu Arg Asn Ala Leu Leu Leu Glu Ile 370 375 380 Ala Arg Val Ala Leu Gln Leu Arg Lys Gly Leu Ala Ala Ile Asp Asp 385 390 395 400 Ala Tyr Phe Arg Gln Phe Val Ser Arg Leu Arg Ala Asn Leu Asp Trp 405 410 415 Ser Gln Leu Gly Ala Asn Leu Pro Asp Thr Met Val Ser Ser Trp Arg 420 425 430 His Leu Lys Val Tyr Arg Leu Asp Phe Gly Ala Arg Leu Gly Arg Val 435 440 445 Val Glu Phe His Pro Gln Thr Ala Leu Val Asp Gly Ile Cys Ile Ile 450 455 460 Gln Pro Glu Arg Ile Ala His Glu Asp Asp Ser Ala Asp Met Ala Pro 465 470 475 480 Glu Ser Gly Trp Glu Val Cys Val Thr Leu Gln Ser Asp Ala Met Glu 485 490 495 Cys Phe Leu Arg Gly Gly Leu Phe Thr Ser Leu Ser Gln Gly Ala Ile 500 505 510 Arg Arg Val 515 <210> 20 <211> 1284 <212> DNA <213> CfACT1-6 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1284) <400> 20 atg aag gta gaa cgt ttc tca aga aag ttg ata aaa ccc cac acg cct 48 Met Lys Val Glu Arg Phe Ser Arg Lys Leu Ile Lys Pro His Thr Pro 1 5 10 15 act ccc gag aac tta aag aaa tat aaa ttg tct cta tg gac aaa tgc 96 Thr Pro Glu Asn With Lys Tyr Lys Ser With Asp Lys Cys 20 25 30 ctt gga cac gac aac ttc gcg atc gtg ttg ttt tac gaa tct aaa cca 144 Leu Gly His Asp Asn Phe Ala Ile Val Leu Phe Tyr Glu Ser Lys Pro 35 40 45 aga aat aag agt gag ctt gag gaa tcg tta gag aag gtc ttg gta gac 192 Arg Asn Lys Ser Glu Leu Glu Glu Ser Leu Glu Lys Val Leu Val Asp 50 55 60 ttt tat ccc ttg gct ggg cgt cac acg atg aac gac cat att gtc gac 240 Phe Tyr Pro Leu Ala Gly Arg His Thr Met Asn Asp His Ile Val Asp 65 70 75 80 tgc tcg gat gtc ggc gct gtc ttt gta gaa gcc gag gct tta gat gta 288 Cys Ser Asp Val Gly Ala Val Phe Val Glu Ala Glu Ala Leu Asp Val 85 90 95 gag ttg act atg gat gag tta gtc aag aac atg gaa gct caa act ata 336 Glu Leu Thr Met Asp Glu Leu Val Lys Asn Met Glu Ala Gln Thr Ile 100 105 110 cac cac ttg ttg cca aat cag tac ttc agt gca gat gct ccg aac ccg 384 His His Leu Leu Pro Asn Gln Tyr Phe Ser Ala Asp Ala Pro Asn Pro 115 120 125 ctg ctt tcc atc caa gtt acg cac ttt cct tcc ggt ggt ttg gct atc 432 Leu Leu Ser Ile Gln Val Thr His Phe Pro Ser Gly Gly Leu Ala Ile 130 135 140 gga atc gca gtc tcg cac gct gta ttt gat ggt ttc tct ttg ggc gtg 480 Gly Ile Ala Val Ser His Ala Val Phe Asp Gly Phe Ser Leu Gly Val 145 150 155 160 ttc gta gca gca tgg tca aag gcg acc atg aac ccg gat agg aaa atc 528 Phe Val Ala Ala Trp Ser Lys Ala Thr Met Asn Pro Asp Arg Lys Ile 165 170 175 aaa ata aca ccg tca ttc gac tta cca tca ctt ctg ccc tac aaa gac 576 Lys Ile Thr Pro Ser Phe Asp Leu Pro Ser Leu Leu Pro Tyr Lys Asp 180 185 190 gac aac ttt gtt ttg act gct gct gaa att gtc agc cag agc gag gac 624 Asp Asn Phe Gly Leu Thr Ala Ala Glu Ile Val Ser Gln Ser Glu Asp 195 200 205 atc gta gtt aag aga ttt atc ttc ggc aag gaa gcc atc acg agg ttg 672 Ile Val Val Lys Arg Phe Ile Phe Gly Lys Glu Ala Ile Thr Arg Leu 210 215 220 aga agt aag ctt agt cca aat agg aac ggg aag aaa ata tcc agg gtt 720 Arg Ser Lys Leu Ser Pro Asn Arg Asn Gly Lys Lys Ile Ser Arg Val 225 230 235 240 agg gtc gtt tgt gca gtc att gta aag gcc ttg atg gga ttg gag cgt 768 Arg Val Val Cys Ala Val Ile Val Lys Ala Leu Met Gly Leu Glu Arg 245 250 255 gcc aaa cac ggt aag acg cgt gat ttc tta att act caa tca att aac 816 Ala Lys His Gly Lys Thr Arg Asp Phe Leu Ile Thr Gln Ser Ile Asn 260 265 270 atg agg gag aga act aag gcg ccg ctg cag aaa cac gcc tgc gggc aac 864 Met Arg Glu Arg Thr Lys Ala Pro Leu Gln Lys His Ala Cys Gly Asn 275 280 285 tta gca gtc ttg agt tgc acg aga gta gag gcc gag gag atg atg atg 912 Leu Ala Val Leu Ser Cys Thr Arg Arg Val Glu Ala Glu Glu Met Met 290,295,300 gag tta cag aac cta gtt aat ttg atc ggc gac agt acc gaa aag gac 960 Leu Glu Gln Asp Val Asn With Gly Asp Ser Thr Glu Lys Asp 305 310 315 320 atc gcc gac ttt gca gaa tta tta tca cca gat caa gtg ggc aga gac 1008 Pro Asp Gln Val Gly Arg Asp 325 330 335 att ata atc aag atg atg aag tca ttc atg cag ttc ttg gac aat gac 1056 Ile Ile Lys With Met Lys Ser Phe Met Gln Phe Leu Asp Asn Asp 340 345 350 att tac agc gtg tgc ttt acc gat tgg tca aag ttt gaa ttt tac gaa 1104 Ile Tyr Ser Val Cys Phe Thr Asp Trp Ser Lys Phe Glu Phe Tyr Glu 355 360 365 gcg gac ttc ggc ttc ggg aag ccg gtt tgg atg gca gca ggc cca cag 1152 Ala Asp Phe Gly Phe Gly Lys Pro Val Trp Met Ala Ala Gly Pro Gln 370 375 380 aga ccc att atc tct act gca ata ttg atg tca gac agg gaa ggc gac 1200 Arg Pro Ile Ile Ser Thr Ala Ile Leu Met Ser Asp Arg Glu Gly Asp 385 390 395 400 ggt atc gag gct tgg tta cat ttg aat aag aac gac atg ttg att ttc 1248 Gly Ile Glu Ala Trp Leu His Leu Asn Lys Asn Asp Met Leu Ile Phe 405 410 415 gaa caa gac gag gaa atc aag tta ttc act aca taa 1284 Glu Gln Asp Glu Glu Ile Lys Leu Phe Thr Thr 420 425 <210> twenty one <211> 427 <212> PRT <213> CfACT1-6 DNA sequence, codon-optimized for expression in Saccharomyces cerevisiae <400> twenty one Met Lys Val Glu Arg Phe Ser Arg Lys Leu Ile Lys Pro His Thr Pro 1 5 10 15 Thr Pro Glu Asn Leu Lys Lys Tyr Lys Leu Ser Leu Leu Asp Lys Cys 20 25 30 Leu Gly His Asp Asn Phe Ala Ile Val Leu Phe Tyr Glu Ser Lys Pro 35 40 45 Arg Asn Lys Ser Glu Leu Glu Glu Ser Leu Glu Lys Val Leu Val Asp 50 55 60 Phe Tyr Pro Leu Ala Gly Arg His Thr Met Asn Asp His Ile Val Asp 65 70 75 80 Cys Ser Asp Val Gly Ala Val Phe Val Glu Ala Glu Ala Leu Asp Val 85 90 95 Glu Leu Thr Met Asp Glu Leu Val Lys Asn Met Glu Ala Gln Thr Ile 100 105 110 His His Leu Leu Pro Asn Gln Tyr Phe Ser Ala Asp Ala Pro Asn Pro 115 120 125 Leu Leu Ser Ile Gln Val Thr His Phe Pro Ser Gly Gly Leu Ala Ile 130 135 140 Gly Ile Ala Val Ser His Ala Val Phe Asp Gly Phe Ser Leu Gly Val 145 150 155 160 Phe Val Ala Ala Trp Ser Lys Ala Thr Met Asn Pro Asp Arg Lys Ile 165 170 175 Lys Ile Thr Pro Ser Phe Asp Leu Pro Ser Leu Leu Pro Tyr Lys Asp 180 185 190 Asp Asn Phe Gly Leu Thr Ala Ala Glu Ile Val Ser Gln Ser Glu Asp 195 200 205 Ile Val Val Lys Arg Phe Ile Phe Gly Lys Glu Ala Ile Thr Arg Leu 210 215 220 Arg Ser Lys Leu Ser Pro Asn Arg Asn Gly Lys Lys Ile Ser Arg Val 225 230 235 240 Arg Val Val Cys Ala Val Ile Val Lys Ala Leu Met Gly Leu Glu Arg 245 250 255 Ala Lys His Gly Lys Thr Arg Asp Phe Leu Ile Thr Gln Ser Ile Asn 260 265 270 Met Arg Glu Arg Thr Lys Ala Pro Leu Gln Lys His Ala Cys Gly Asn 275 280 285 Leu Ala Val Leu Ser Cys Thr Arg Arg Val Glu Ala Glu Glu Met Met 290 295 300 Glu Leu Gln Asn Leu Val Asn Leu Ile Gly Asp Ser Thr Glu Lys Asp 305 310 315 320 Ile Ala Asp Phe Ala Glu Leu Leu Ser Pro Asp Gln Val Gly Arg Asp 325 330 335 Ile Ile Ile Lys Met Met Lys Ser Phe Met Gln Phe Leu Asp Asn Asp 340 345 350 Ile Tyr Ser Val Cys Phe Thr Asp Trp Ser Lys Phe Glu Phe Tyr Glu 355 360 365 Ala Asp Phe Gly Phe Gly Lys Pro Val Trp Met Ala Ala Gly Pro Gln 370 375 380 Arg Pro Ile Ile Ser Thr Ala Ile Leu Met Ser Asp Arg Glu Gly Asp 385 390 395 400 Gly Ile Glu Ala Trp Leu His Leu Asn Lys Asn Asp Met Leu Ile Phe 405 410 415 Glu Gln Asp Glu Glu Ile Lys Leu Phe Thr Thr 420 425 <210> twenty two <211> 1272 <212> DNA <213> CfACT1-8, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(1272) <400> twenty two atg aaa gtc gaa agg att tca cgt aaa ttc atc aag cca tat aca cct 48 Met Lys Val Glu Arg Ile Ser Arg Lys Phe Ile Lys Pro Tyr Thr Pro 1 5 10 15 aca cca cag aac ctt aag aag tac aag cta tcc ttg ctg gat aaa tgc 96 Thr Pro Gln Asn With Lys Lys Tyr Lys Ser With Asp Lys Cys 20 25 30 atg gga cac atg gac ttc gct gta gta ttg ttg tac gaa tca aag cca 144 Met Gly His Met Asp Phe Ala Val Val Leu Phe Tyr Glu Ser Lys Pro 35 40 45 aga aac aag at gag ctg gaa gaa tca cta gag aaa gtg tta gtc gat 192 Arg Asn Lys Asn Glu Leu Glu Glu Ser Leu Glu Lys Val Leu Val Asp 50 55 60 ttc tat cca ttg gca ggc agg tat acc atg aac gac cac att gtc gat 240 Phe Tyr Pro Leu Ala Gly Arg Tyr Thr Met Asn Asp His Ile Val Asp 65 70 75 80 tgc agc gat gag ggc gcc gtt ttc gtt gag gca gag gcc cct aat gtt 288 Cys Ser Asp Glu Gly Ala Val Phe Val Glu Ala Glu Ala Pro Asn Val 85 90 95 gag ctt aca gtg gac cag tg gtt aag aac atg gaa gcc cag aca atc 336 Glu Thr Val Asp Gln Leu Val Lys Asn Met Glu Ala Gln Thr Ile 100 105 110 cac gac ttc tta cca gac caa tat ttt cct gct gac gca cca aat ccg 384 His Asp Phe Leu Pro Asp Gln Tyr Phe Pro Ala Asp Ala Pro Asn Pro 115 120 125 ttg cta agt att caa gta acg cac ttc cct tgt ggt ggt tta gct atc 432 His Phe Pro Cys Gly Gly Leu Ala Ile 130 135 140 ggg att gtt gtt agt cac gcg gtc ttt gat gga ttc tca ttg ggc gta 480 Gly Ile Val Val Ser His Ala Val Phe Asp Gly Phe Ser Leu Gly Val 145 150 155 160 ttc tta gcc gcc tgg agc aaa gct acc atg aac cct gag agg aag atc 528 Phe Leu Ala Trp Ser Lys Ala Thr Met Asn Pro Glu Arg Lys Ile 165 170 175 gaa atc acc cct tcc ttc gat ttg cct agt ctt ctg ccc tac aag gat 576 Glu Ile Thr Pro Ser Phe Asp Leu Pro Ser Leu Leu Pro Tyr Lys Asp 180 185 190 gaa tct ttc ggt tta aat ttt agc gaa att gtc aaa gct gag aat atc 624 Glu Ser Phe Gly Leu Asn Phe Ser Glu Ile Val Lys Ala Glu Asn Ile 195 200 205 gta gtt aaa cgt tg aat ttc ggg aaa gag gct att acg cgt tg agg 672 Val Val Lys Arg Leu Asn Phe Gly Lys Glu Ala Ile Thr Arg Leu Arg 210 215 220 tcc aag ctg tct cct aac cag aat gt aaa acc att tcc aga gtg agg Ser Lys Leu Ser Pro Asn Gln Asn Gly Lys Thr Ile Ser Arg Val Arg 225 230 235 240 gta gtc tgc gcg gtg ata gtt aag gcg ttg atg gga ctg gag aga gca 768 Val Val Cys Ala Val Ile Val Lys Ala Leu Met Gly Leu Glu Arg Ala 245 250 255 aag act aga gac ttt atg ata tgt cag ggg atc aac atg aga gag agg 816 Lys Thr Arg Asp Phe Met With Cys Gln Gly And Asn Met Arg Glu Arg 260 265 270 acg aag gcg ccc ctg cag aag cat gcg tgt ggc aac cta gca gtt tcg 864 Thr Lys Ala Pro Leu Gln Lys His Ala Cys Gly Asn Leu Ala Val Ser 275 280 285 tct tac act aga gta gcg gca gcg gaa gca gaa gaa ctg cag tcc 912 Ser Tyr Thr Arg Arg Val Ala Ala Ala Glu Ala Glu Glu Leu Gln Ser 290,295,300 tta gtg aat ttg atc ggg gac tct atc gaa aag tca atc gca gac tac 960 Lion Val Asn Lion With Gly Asp Ser With Glu Lys Ser With Ala Asp Tyr 305 310 315 320 gct gat ata ctt tcg agt gat caa gat ggg aga cac atc att tcc act Only Asp Served Asp Gln Asp Gly Arg His Served Thr 325 330 335 atg atg aag agc ttt atg cag ttt gct gca cct gat ata aaa gcc att 1056 Met Met Lys Ser Phe Met Gln Phe Ala Ala Pro Asp Ile Lys Ala Ile 340 345 350 tca ttt acc gac tgg tca aag ttc ggc ttt tac caa gta gat ttt ggt 1104 Ser Phe Thr Asp Trp Ser Lys Phe Gly Phe Tyr Gln Val Asp Phe Gly 355 360 365 ttt ggt aaa cca gtt tgg acc ggc gtc cgt cca gaa cgt cca atc ttc 1152 Phe Gly Lys Pro Val Trp Thr Gly Val Arg Pro Glu Arg Pro Ile Phe 370 375 380 tca gcc gcg ata ttg atg agt aac agg gaa ggc gat ggc atc gag gct 1200 Ser Ala Ala Ile Leu Met Ser Asn Arg Glu Gly Asp Gly Ile Glu Ala 385 390 395 400 tgg ctt cat ttg gac aag aac gat atg cta ata ttt gag caa gac gaa 1248 Trp Leu His Leu Asp Lys Asn Asp Met Leu Ile Phe Glu Gln Asp Glu 405 410 415 gaa att aag ttg ttg ata acg taa 1272 Glu Ile Lys Leu Leu Ile Thr 420 <210> twenty three <211> 423 <212> PRT <213> CfACT1-8, codon-optimized for expression in Saccharomyces cerevisiae <400> twenty three Met Lys Val Glu Arg Ile Ser Arg Lys Phe Ile Lys Pro Tyr Thr Pro 1 5 10 15 Thr Pro Gln Asn Leu Lys Lys Tyr Lys Leu Ser Leu Leu Asp Lys Cys 20 25 30 Met Gly His Met Asp Phe Ala Val Val Leu Phe Tyr Glu Ser Lys Pro 35 40 45 Arg Asn Lys Asn Glu Leu Glu Glu Ser Leu Glu Lys Val Leu Val Asp 50 55 60 Phe Tyr Pro Leu Ala Gly Arg Tyr Thr Met Asn Asp His Ile Val Asp 65 70 75 80 Cys Ser Asp Glu Gly Ala Val Phe Val Glu Ala Glu Ala Pro Asn Val 85 90 95 Glu Leu Thr Val Asp Gln Leu Val Lys Asn Met Glu Ala Gln Thr Ile 100 105 110 His Asp Phe Leu Pro Asp Gln Tyr Phe Pro Ala Asp Ala Pro Asn Pro 115 120 125 Leu Leu Ser Ile Gln Val Thr His Phe Pro Cys Gly Gly Leu Ala Ile 130 135 140 Gly Ile Val Val Ser His Ala Val Phe Asp Gly Phe Ser Leu Gly Val 145 150 155 160 Phe Leu Ala Ala Trp Ser Lys Ala Thr Met Asn Pro Glu Arg Lys Ile 165 170 175 Glu Ile Thr Pro Ser Phe Asp Leu Pro Ser Leu Leu Pro Tyr Lys Asp 180 185 190 Glu Ser Phe Gly Leu Asn Phe Ser Glu Ile Val Lys Ala Glu Asn Ile 195 200 205 Val Val Lys Arg Leu Asn Phe Gly Lys Glu Ala Ile Thr Arg Leu Arg 210 215 220 Ser Lys Leu Ser Pro Asn Gln Asn Gly Lys Thr Ile Ser Arg Val Arg 225 230 235 240 Val Val Cys Ala Val Ile Val Lys Ala Leu Met Gly Leu Glu Arg Ala 245 250 255 Lys Thr Arg Asp Phe Met Ile Cys Gln Gly Ile Asn Met Arg Glu Arg 260 265 270 Thr Lys Ala Pro Leu Gln Lys His Ala Cys Gly Asn Leu Ala Val Ser 275 280 285 Ser Tyr Thr Arg Arg Val Ala Ala Ala Glu Ala Glu Glu Leu Gln Ser 290 295 300 Leu Val Asn Leu Ile Gly Asp Ser Ile Glu Lys Ser Ile Ala Asp Tyr 305 310 315 320 Ala Asp Ile Leu Ser Ser Asp Gln Asp Gly Arg His Ile Ile Ser Thr 325 330 335 Met Met Lys Ser Phe Met Gln Phe Ala Ala Pro Asp Ile Lys Ala Ile 340 345 350 Ser Phe Thr Asp Trp Ser Lys Phe Gly Phe Tyr Gln Val Asp Phe Gly 355 360 365 Phe Gly Lys Pro Val Trp Thr Gly Val Arg Pro Glu Arg Pro Ile Phe 370 375 380 Ser Ala Ala Ile Leu Met Ser Asn Arg Glu Gly Asp Gly Ile Glu Ala 385 390 395 400 Trp Leu His Leu Asp Lys Asn Asp Met Leu Ile Phe Glu Gln Asp Glu 405 410 415 Glu Ile Lys Leu Leu Ile Thr 420 <210> twenty four <211> 654 <212> DNA <213> OAH94415.1, codon-optimized for expression in Saccharomyces cerevisiae <220> <221> CDS <222> (1)..(654) <400> twenty four atg gat acc aag agg gtc ggt tat aca gtc gtt gat ttg agt cag tgg 48 Met Asp Thr Lys Arg Val Gly Tyr Thr Val Val Asp Leu Ser Gln Trp 1 5 10 15 ggc aga aaa gaa cac ttc gaa gca ttc cag agc ttc gcc cag tgc acc 96 Gly Arg Lys Glu His Phe Glu Ala Phe Gln Ser Phe Ala Gln Cys Thr 20 25 30 ttt tcc cag act gtt caa tta gac ata act tcc ctg ctg aag act gtc 144 Phe Ser Gln Thr Val Gln Leu Asp Ile Thr Ser Leu Leu Lys Thr Val 35 40 45 aag cag aac gga tat aaa ttc tac ccg acc ttt atc tac ata ata agc 192 Lys Gln Asn Gly Tyr Lys Phe Tyr Pro Thr Phe Ile Tyr Ile Ser 50 55 60 cgt tta gtg aac aag cat gcc gaa ttc cgt atg gcc atg aag gat ggt 240 Arg Leu Val Asn Lys His Ala Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 gaa ctg gta att tgg gac tcc gta aac cct ggt tac aca atc ttt cac 288 Glu Leu Val Ile Trp Asp Ser Val Asn Pro Gly Tyr Thr Ile Phe His 85 90 95 gaa cag acc gaa aca ttt tca tct ctg tgg agc tat tac cac aag gac 336 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Tyr Tyr His Lys Asp 100 105 110 atc aat cag ttt ctt aaa acg tat tct gaa gac atc gct cag tac ggg 384 With Gln Phe Leu Lys Thr Tyr Ser Glu Asp With Gln Tyr Gly 115 120 125 gac gat ctg gcg tac ttc ccc aag gag ttt att gaa aat atg ttc ttc 432 Asp Asp Leu Ala Tyr Phe Pro Lys Glu Phe Ile Glu Asn Met Phe Phe 130 135 140 gtg tca gcg aac cca tgg gtg agc ttc aca agt ttc aac tta aac gtg 480 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asn Leu Asn Val 145 150 155 160 gcc aat att aat aac ttc gca ccg gtc ttt aca atc ggt aaa tac 528 Ala Asn Ile Asn Asn Phe Ala Pro Val Phe Thr Ile Gly Lys Tyr 165 170 175 tac acg cag ggc gac aag gtg ttg atg ccg tta gct att cag gtc cat 576 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 cat gca gtc tgc gac ggg ttt cat gtc ggc agg tta ttg aac gaa att 624 His Ala Val Cys Asp Gly Phe His Val Gly Arg Leu Leu Asn Glu Ile 195 200 205 cag cag tac tgc gat gag gga tgc aag taa 654 Gln Gln Tyr Cys Asp Glu Gly Cys Lys 210 215 <210> 25 <211> 217 <212> PRT <213> OAH94415.1, codon-optimized for expression in Saccharomyces cerevisiae <400> 25 Met Asp Thr Lys Arg Val Gly Tyr Thr Val Val Asp Leu Ser Gln Trp 1 5 10 15 Gly Arg Lys Glu His Phe Glu Ala Phe Gln Ser Phe Ala Gln Cys Thr 20 25 30 Phe Ser Gln Thr Val Gln Leu Asp Ile Thr Ser Leu Leu Lys Thr Val 35 40 45 Lys Gln Asn Gly Tyr Lys Phe Tyr Pro Thr Phe Ile Tyr Ile Ile Ser 50 55 60 Arg Leu Val Asn Lys His Ala Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 Glu Leu Val Ile Trp Asp Ser Val Asn Pro Gly Tyr Thr Ile Phe His 85 90 95 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Tyr Tyr His Lys Asp 100 105 110 Ile Asn Gln Phe Leu Lys Thr Tyr Ser Glu Asp Ile Ala Gln Tyr Gly 115 120 125 Asp Asp Leu Ala Tyr Phe Pro Lys Glu Phe Ile Glu Asn Met Phe Phe 130 135 140 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asn Leu Asn Val 145 150 155 160 Ala Asn Ile Asn Asn Phe Phe Ala Pro Val Phe Thr Ile Gly Lys Tyr 165 170 175 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 His Ala Val Cys Asp Gly Phe His Val Gly Arg Leu Leu Asn Glu Ile 195 200 205 Gln Gln Tyr Cys Asp Glu Gly Cys Lys 210 215 <210> 26 <211> 1755 <212> DNA <213> Dryopteris fragrans <220> <221> CDS <222> (1)..(1755) <400> 26 atg gag ttc tct gcc tct gct cct cct cct agg cta gcc agt gtc ata 48 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 ata ttg gag cct ctc ggc ttc ctc ctc aca cca cac tac tcc tct cag 96 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 ctt ccc aaa aag ctg ctc cgt cgc ctg ttg tgc act aga atc tgg cac 144 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 agg tat cag cga ggc cgc ctt cgc ctg cgt gac gct gct atg ctg ctc 192 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 gcc cag ctc cca ttc cta gct gtg tct gat cac ccc tgg gct ctg gac 240 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 aat ctc gca agc ctg ctc cgc ccc aca gct gtg cgt gcg gtg cca tgg 288 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 atg ctg ctg ctg ctc gac ttc cta cga gac gag ctc cat ctg aag gta 336 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 gtc tgc gcg acc aac tcc tcc cca gaa gag ctg caa gag ctg cgc cac 384 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 cag ttt ccg gcc ctc ttt gcc aag gtc gat gcc acc gtt tct tca ggc 432 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 gag gag ggc gtg ggc aag ccg tcc gtg cgc ttc ctg cag gct gcg ttg 480 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 gac aaa gcc ggt gtc cac gcg cag caa acc ttg tat ctt gac tct ttt 528 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 gac agc ttg gag acc atc atg gct gca cgc tct ctt ggc atg cat gca 576 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 cta tct gta gag cca tgc cac att gat gag ctc acc gcc agg gcc tct 624 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 tcc ggc cag cta aga gat gca cag ctt ata agg cgt att gtg tgc gcc 672 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Arg Ile Val Cys Ala 210 215 220 atg cac ggg cca gca gta tct gca gtt gtg tcg ggc agt atc aca tcg 720 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 tcc ggc cca cag aca gca aag atc gag gaa ttg cca aca gct gct gat 768 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 agt cat ctc cgc agc gca gct ctc act tct gct cag cag ttt ttc ctc 816 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 aaa gtt att gct cat cgt cct gag aag cca ttc gtc cag ctt ca 864 Lys Val Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 tct ctc acc tcg gag ggc atc cga ata tac gac acc ttt gca cag ttt 912 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290,295,300 gtc ata gcc gac ctg ctc gac gac acc cgc ttc cta ccc atg caa tct 960 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 cct cct ccc aat ggg ctc atc acc ttt gtt aac cca agc gcg tac ctt 1008 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 gct gat gat ata aag aat ggc aac agc cat att gtc ccg ggt gtg caa 1056 Only Asp Asp Ile Lys Asn Gly Asn Served His Ile Val Pro Gly Val Gln 340 345 350 ttt tac gca tcc gat gcg tgc act ctc atc gac atc cca cat gac cta 1104 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 gac acc acc tcc gtt ggc ttg tca gta ctg cac aag ttt gga aag gtg 1152 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 gac aag gac aca ctc aac aaa gtg cta gac aga atg ctc gag caa gtg 1200 Asp Lys Asp Thr Leu Asn Lys Val Leu Asp Arg Met Leu Glu Gln Val 385 390 395 400 agt gaa gac gac ggc att ctg cag gtg tat ttt gat gtg gag cgt ccg 1248 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 cgc atc gat cca gtt gtg gtg gca aac acg gtg ttt ctg ttc cac ttg 1296 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 gga aag aga ggg cat gag gtg gcg agg agt gag aag ttt gtg gag agt 1344 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 gtg ctg ctg cag agg gca tac gaa gaa ggg acg ttg tat tac aac ctg 1392 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 ggg gaa gca ttt ttg gtg agt gtg gcg agg ctg gtg cac gag ttt aag 1440 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 gag cac ttt aca agg agc ggc atg agg agg gca ctg gag gag agg cta 1488 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 aga gag cgg gca agg gcg ggc atg caa gag agg gat gat gcg ctg gcg 1536 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 cta gcc atg cgc att cgt gca tgc gct ttg tgt ggc ctg gcc gga gag 1584 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 ggc ctc aca aaa gca gca gag cag gag ctt ttg cgc ctg cag tgc aag 1632 Gly Leu Thr Lys Ala Ala Glu Gln Glu Leu Leu Arg Leu Gln Cys Lys 530 535 540 tcc aag ggc tgt tgg ggg tgc cac cct ttc tat cgc aat ggc agt aat 1680 Ser Lys Gly Cys Trp Gly Cys His Pro Phe Tyr Arg Asn Gly Ser Asn 545 550 555 560 gtg ctc agc tgg atc ggc agt gag gcc ctt acc act gct tac gct att 1728 Val Leu Ser Trp Ile Gly Ser Glu Ala Leu Thr Thr Ala Tyr Ala Ile 565 570 575 gct gcg cta cag ccc att gat att taa 1755 Ala Ala Leu Gln Pro Ile Asp Ile 580 <210> 27 <211> 584 <212> PRT <213> Dryopteris fragrans <400> 27 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Arg Ile Val Cys Ala 210 215 220 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 Lys Val Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290 295 300 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 Ala Asp Asp Ile Lys Asn Gly Asn Ser His Ile Val Pro Gly Val Gln 340 345 350 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 Asp Lys Asp Thr Leu Asn Lys Val Leu Asp Arg Met Leu Glu Gln Val 385 390 395 400 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 Gly Leu Thr Lys Ala Ala Glu Gln Glu Leu Leu Arg Leu Gln Cys Lys 530 535 540 Ser Lys Gly Cys Trp Gly Cys His Pro Phe Tyr Arg Asn Gly Ser Asn 545 550 555 560 Val Leu Ser Trp Ile Gly Ser Glu Ala Leu Thr Thr Ala Tyr Ala Ile 565 570 575 Ala Ala Leu Gln Pro Ile Asp Ile 580 <210> 28 <211> 1755 <212> DNA <213> DfHAD-8(K�32R)_Dryopteris fragrans <220> <221> CDS <�22> (1)..(1755) <400> 28 atg gag ttc tct gcc tct gct cct cct cct agg cta gcc agt gtc ata 48 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 ata ttg gag cct ctc ggc ttc ctc ctc aca cca cac tac tcc tct cag 96 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 It should be noted that there seems to be an encoding issue with the "K�32R" in tag . It might be a special symbol that needs to be further clarified or corrected depending on the original format. If it's a misrepresentation, it should be adjusted to the correct form for an accurate translation.ctt ccc aaa aag ctg ctc cgt cgc ctg ttg tgc act aga atc tgg cac 144 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 agg tat cag cga ggc cgc ctt cgc ctg cgt gac gct gct atg ctg ctc 192 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 gcc cag ctc cca ttc cta gct gtg tct gat cac ccc tgg gct ctg gac 240 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 aat ctc gca agc ctg ctc cgc ccc aca gct gtg cgt gcg gtg cca tgg 288 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 atg ctg ctg ctg ctc gac ttc cta cga gac gag ctc cat ctg aag gta 336 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 gtc tgc gcg acc aac tcc tcc cca gaa gag ctg caa gag ctg cgc cac 384 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 cag ttt ccg gcc ctc ttt gcc aag gtc gat gcc acc gtt tct tca ggc 432 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 gag gag ggc gtg ggc aag ccg tcc gtg cgc ttc ctg cag gct gcg ttg 480 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 gac aaa gcc ggt gtc cac gcg cag caa acc ttg tat ctt gac tct ttt 528 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 gac agc ttg gag acc atc atg gct gca cgc tct ctt ggc atg cat gca 576 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 cta tct gta gag cca tgc cac att gat gag ctc acc gcc agg gcc tct 624 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 tcc gcc cag cta aga gat gca cag ctt ata agg cgt att gtg tgc gcc 672 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Ile Val Cys Ala 210 215 220 atg cac ggg cca gca gta tct gca gtt gtg tcg ggc agt atc aca tcg 720 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 tcc ggc cca cag aca gca aag atc gag gaa ttg cca aca gct gct gat 768 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 agt cat ctc cgc agc gca gct ctc act tct gct cag cag ttt ttc ctc 816 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 aaa gtt att gct cat cgt cct gag aag cca ttc gtc cag ctt ca 864 Lys Val Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 tct ctc acc tcg gag ggc atc cga ata tac gac acc ttt gca cag ttt 912 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290 295 300 gtc ata gcc gac ctg ctc gac gac acc cgc ttc cta ccc atg caa tct 960 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 cct cct ccc aat ggg ctc atc acc ttt gtt aac cca agc gcg tac ctt 1008 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 gct gat gat ata aag aat ggc aac agc cat att gtc ccg ggt gtg caa 1056 Ala Asp Asp Ile Lys Asn Gly Asn Ser His Ile Val Pro Gly Val Gln 340 345 350 ttt tac gca tcc gat gcg tgc act ctc atc gac atc cca cat gac cta 1104 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 gac acc acc tcc gtt ggc ttg tca gta ctg cac aag ttt gga aag gtg 1152 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 gac aag gac aca ctc aac aaa gtg cta gac aga atg ctc gag caa gtg 1200 Asp Lys Asp Thr Leu Asn Lys Val Leu Asp Arg Met Leu Glu Gln Val 385 390 395 400 agt gaa gac gac ggc att ctg cag gtg tat ttt gat gtg gag cgt ccg 1248 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 cgc atc gat cca gtt gtg gtg gca aac acg gtg ttt ctg ttc cac ttg 1296 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 gga aag aga ggg cat gag gtg gcg agg agt gag aag ttt gtg gag agt 1344 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 gtg ctg ctg cag agg gca tac gaa gaa ggg acg ttg tat tac aac ctg 1392 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 ggg gaa gca ttt ttg gtg agt gtg gcg agg ctg gtg cac gag ttt aag 1440 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 gag cac ttt aca agg agc ggc atg agg agg gca ctg gag gag agg cta 1488 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 aga gag cgg gca agg gcg ggc atg caa gag agg gat gat gcg ctg gcg 1536 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 ctg gcc atg cgc att cgt gca tgc gct ttg tgt ggc ctg gcc gga gag 1584 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 ggc ctc aca aga gca gca gag cag gag cta ctg cgc ctg cag tgc aag 1632 Gly Leu Thr Arg Ala Ala Glu Gln Glu Leu Leu Arg Leu Gln Cys Lys 530 535 540 tcc aag ggc tgt tgg ggg tgc cac cct ttc tat cgc aat ggc agt aat 1680 Ser Lys Gly Cys Trp Gly Cys His Pro Phe Tyr Arg Asn Gly Ser Asn 545 550 555 560 gtg ctc agc tgg atc ggc agt gag gcc ctt acc act gct tac gct att 1728 Val Leu Ser Trp Ile Gly Ser Glu Ala Leu Thr Thr Ala Tyr Ala Ile 565 570 575 gct gcg cta cag ccc att gat att taa 1755 Ala Ala Leu Gln Pro Ile Asp Ile 580 <210> 29 <211> 584 <212> PRT <213> DfHAD-8(K532R)_Dryopteris fragrans <400> 29 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Arg Ile Val Cys Ala 210 215 220 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 Lys Val Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290 295 300 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 Ala Asp Asp Ile Lys Asn Gly Asn Ser His Ile Val Pro Gly Val Gln 340 345 350 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 Asp Lys Asp Thr Leu Asn Lys Val Leu Asp Arg Met Leu Glu Gln Val 385 390 395 400 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 Gly Leu Thr Arg Ala Ala Glu Gln Glu Leu Leu Arg Leu Gln Cys Lys 530 535 540 Ser Lys Gly Cys Trp Gly Cys His Pro Phe Tyr Arg Asn Gly Ser Asn 545 550 555 560 Val Leu Ser Trp Ile Gly Ser Glu Ala Leu Thr Thr Ala Tyr Ala Ile 565 570 575 Ala Ala Leu Gln Pro Ile Asp Ile 580 <210> 30 <211> 1755 <212> DNA <213> DfHAD-9(V274A)_Dryopteris fragrans <220> <221> CDS <222> (1)..(1755) <400> 30 atg gag ttc tct gcc tct gct cct cct cct agg cta gcc agt gtc ata 48 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 ata ttg gag cct ctc ggc ttc ctc ctc aca cca cac tac tcc tct cag 96 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 ctt ccc aaa aag ctg ctc cgt cgc ctg ttg tgc act aga atc tgg cac 144 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 agg tat cag cga ggc cgc ctt cgc ctg cgt gac gct gct atg ctg ctc 192 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 gcc cag ctc cca ttc cta gct gtg tct gat cac ccc tgg gct ctg gac 240 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 aat ctc gca agc ctg ctc cgc ccc aca gct gtg cgt gcg gtg cca tgg 288 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 atg ctg ctg ctg ctc gac ttc cta cga gac gag ctc cat ctg aag gta 336 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 gtc tgc gcg acc aac tcc tcc cca gaa gag ctg caa gag ctg cgc cac 384 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 cag ttt ccg gcc ctc ttt gcc aag gtc gat gcc acc gtt tct tca ggc 432 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 gag gag ggc gtg ggc aag ccg tcc gtg cgc ttc ctg cag gct gcg ttg 480 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 gac aaa gcc ggt gtc cac gcg cag caa acc ttg tat ctt gac tct ttt 528 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 gac agc ttg gag acc atc atg gct gca cgc tct ctt ggc atg cat gca 576 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 cta tct gta gag cca tgc cac att gat gag ctc acc gcc agg gcc tct 624 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 tcc ggc cag cta aga gat gca cag ctt ata agg cgt att gtg tgc gcc 672 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Arg Ile Val Cys Ala 210 215 220 atg cac ggg cca gca gta tct gca gtt gtg tcg ggc agt atc aca tcg 720 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 tcc ggc cca cag aca gca aag atc gag gaa ttg cca aca gct gct gat 768 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 agt cat ctc cgc agc gca gct ctc act tct gct cag cag ttt ttc ctc 816 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 aaa gct att gct cca cat cgt cct gag aag cca ttc gtc cag ctt cca 864 Lys Ala Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 tct ctc acc tcg gag ggc atc cga ata tac gac acc ttt gca cag ttt 912 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290 295 300 gtc ata gcc gac ctg ctc gac gac acc cgc ttc cta ccc atg caa tct 960 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 cct cct ccc aat ggg ctc atc acc ttt gtt aac cca agc gcg tac ctt 1008 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 gct gat gat ata aag aat ggc aac agc cat att gtc ccg ggt gtg caa 1056 Only Asp Asp Ile Lys Asn Gly Asn Served His Ile Val Pro Gly Val Gln 340 345 350 ttt tac gca tct gat gcg tgc act ctc atc gac atc cca cat gac cta 1104 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 gac acc acc tcc gtt gc tg tca gta ctg cac aag ttt gga aag gtg 1152 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 gac aag gac aca ctc aac aaa gtg cta gac aga atg ctg gag caa gtg 1200 Asp Lys Asp Thr With Asn Lys Val With Asp Arg With Glu Gln Val 385 390 395 400 agt gaa gac gac ggc att ctc cag gtg tat ttt gat gtg gag cgt ccg 1248 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 cgc atc gat cca gtt gtg gtg gca aac acg gtg ttt ctg ttc cac ttg 1296 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 gga aag aga ggg cat gag gtg gcg agg agt gag aag ttt gtg gag agt 1344 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 gtg ctg ctg cag agg gca tac gaa gaa ggg acg ttg tat tac aac ctg 1392 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 ggg gaa gca ttt ttg gtg agt gtg gcg agg ctg gtg cac gag ttt aag 1440 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 gag cac ttt aca agg agc ggc atg agg agg gca ctg gag gag agg cta 1488 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 aga gag cgg gca agg gcg ggc atg caa gag agg gat gat gcg ctg gcg 1536 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 ctg gcc atg cgc att cgt gca tgc gct ttg tgt ggc ctg gcc gga gag 1584 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 ggc ctc aca aaa gca gca gag cag gag cta ctg cgc ctg cag tgc aag 1632 Gly Leu Thr Lys Ala Ala Glu Gln Glu Leu Leu Arg Leu Gln Cys Lys 530 535 540 tcc aag ggc tgt tgg ggg tgc cac cct ttc tat cgc aat ggc agt aat 1680 Ser Lys Gly Cys Trp Gly Cys His Pro Phe Tyr Arg Asn Gly Ser Asn 545 550 555 560 gtg ctc agc tgg atc ggc agt gag gcc ctt acc act gct tac gct att 1728 Val Leu Ser Trp Ile Gly Ser Glu Ala Leu Thr Thr Ala Tyr Ala Ile 565 570 575 gct gcg cta cag ccc att gat att taa 1755 Ala Ala Leu Gln Pro Ile Asp Ile 580 <210> 31 <211> 584 <212> PRT <213> DfHAD-9(V274A)_Dryopteris fragrans <400> 31 Met Glu Phe Ser Ala Ser Ala Pro Pro Pro Arg Leu Ala Ser Val Ile 1 5 10 15 Ile Leu Glu Pro Leu Gly Phe Leu Leu Thr Pro His Tyr Ser Ser Gln 20 25 30 Leu Pro Lys Lys Leu Leu Arg Arg Leu Leu Cys Thr Arg Ile Trp His 35 40 45 Arg Tyr Gln Arg Gly Arg Leu Arg Leu Arg Asp Ala Ala Met Leu Leu 50 55 60 Ala Gln Leu Pro Phe Leu Ala Val Ser Asp His Pro Trp Ala Leu Asp 65 70 75 80 Asn Leu Ala Ser Leu Leu Arg Pro Thr Ala Val Arg Ala Val Pro Trp 85 90 95 Met Leu Leu Leu Leu Asp Phe Leu Arg Asp Glu Leu His Leu Lys Val 100 105 110 Val Cys Ala Thr Asn Ser Ser Pro Glu Glu Leu Gln Glu Leu Arg His 115 120 125 Gln Phe Pro Ala Leu Phe Ala Lys Val Asp Ala Thr Val Ser Ser Gly 130 135 140 Glu Glu Gly Val Gly Lys Pro Ser Val Arg Phe Leu Gln Ala Ala Leu 145 150 155 160 Asp Lys Ala Gly Val His Ala Gln Gln Thr Leu Tyr Leu Asp Ser Phe 165 170 175 Asp Ser Leu Glu Thr Ile Met Ala Ala Arg Ser Leu Gly Met His Ala 180 185 190 Leu Ser Val Glu Pro Cys His Ile Asp Glu Leu Thr Ala Arg Ala Ser 195 200 205 Ser Gly Gln Leu Arg Asp Ala Gln Leu Ile Arg Arg Ile Val Cys Ala 210 215 220 Met His Gly Pro Ala Val Ser Ala Val Val Ser Gly Ser Ile Thr Ser 225 230 235 240 Ser Gly Pro Gln Thr Ala Lys Ile Glu Glu Leu Pro Thr Ala Ala Asp 245 250 255 Ser His Leu Arg Ser Ala Ala Leu Thr Ser Ala Gln Gln Phe Phe Leu 260 265 270 Lys Ala Ile Ala Pro His Arg Pro Glu Lys Pro Phe Val Gln Leu Pro 275 280 285 Ser Leu Thr Ser Glu Gly Ile Arg Ile Tyr Asp Thr Phe Ala Gln Phe 290 295 300 Val Ile Ala Asp Leu Leu Asp Asp Thr Arg Phe Leu Pro Met Gln Ser 305 310 315 320 Pro Pro Pro Asn Gly Leu Ile Thr Phe Val Asn Pro Ser Ala Tyr Leu 325 330 335 Ala Asp Asp Ile Lys Asn Gly Asn Ser His Ile Val Pro Gly Val Gln 340 345 350 Phe Tyr Ala Ser Asp Ala Cys Thr Leu Ile Asp Ile Pro His Asp Leu 355 360 365 Asp Thr Thr Ser Val Gly Leu Ser Val Leu His Lys Phe Gly Lys Val 370 375 380 Asp Lys Asp Thr Leu Asn Lys Val Leu Asp Arg Met Leu Glu Gln Val 385 390 395 400 Ser Glu Asp Asp Gly Ile Leu Gln Val Tyr Phe Asp Val Glu Arg Pro 405 410 415 Arg Ile Asp Pro Val Val Val Ala Asn Thr Val Phe Leu Phe His Leu 420 425 430 Gly Lys Arg Gly His Glu Val Ala Arg Ser Glu Lys Phe Val Glu Ser 435 440 445 Val Leu Leu Gln Arg Ala Tyr Glu Glu Gly Thr Leu Tyr Tyr Asn Leu 450 455 460 Gly Glu Ala Phe Leu Val Ser Val Ala Arg Leu Val His Glu Phe Lys 465 470 475 480 Glu His Phe Thr Arg Ser Gly Met Arg Arg Ala Leu Glu Glu Arg Leu 485 490 495 Arg Glu Arg Ala Arg Ala Gly Met Gln Glu Arg Asp Asp Ala Leu Ala 500 505 510 Leu Ala Met Arg Ile Arg Ala Cys Ala Leu Cys Gly Leu Ala Gly Glu 515 520 525 Gly Leu Thr Lys Pathway Glu G...
Claims
1. A biocatalytic method for producing alkyl acetate compounds, The following steps are involved: (1) contacting alkyl alcohol with a polypeptide in the presence of an acetyl donor, the polypeptide having an acetyltransferase activity of an enzyme of class EC 2.3.1 capable of transferring an acetyl group from the acetyl donor to the alkyl alcohol, thereby obtaining alkyl acetate; wherein the acetyl donor is acetyl coenzyme A (acetyl-CoA), and Wherein the acetyltransferase is selected from: a) a polypeptide having an amino acid sequence selected from SEQ ID NO: 9, 17, 118, 124, 144, 23, 21, 11, 19, 13, 15, 25, 121, 143, 127, 130, 133 or 136.
2. The method according to claim 1, wherein the method further comprises the following steps: (2) Separating an alkyl acetate compound from the reaction product of step (1).
3. The method according to claim 1, wherein the alkyl acetate compound is selected from the group consisting of fennel acetate, fennel acetate, and bicyclofarnesyl acetate, each of which is in stereoisomerically pure form or as a mixture of at least two stereoisomers thereof, or a combination thereof comprising at least two members of the group.
4. The method according to claim 1 or 3, wherein the thiazolinyl alcohol is selected from the group consisting of thiazolin, thiazolin and bicyclic farnesol, each in stereoisomerically pure form or as a mixture of at least two stereoisomers thereof, or a combination thereof comprising at least two members of the group.
5. The method according to claim 1, further comprising, before step 1), biocatalytic formation of the alkyl alcohol compound.
6. The method according to claim 5, wherein the biocatalytic formation is an enzymatic synthesis from an acyclic sesquiterpene precursor.
7. The method according to claim 6, wherein the acyclic sesquiterpene precursor is farnesyl pyrophosphate (FPP).
8. The method of claim 6, wherein the enzymatic synthesis of the succinic acid ester is catalyzed by one or more polypeptides having the ability to convert the acyclic sesquiterpene precursor to at least one succinic acid ester in one or more enzymatic steps.
9. The method of claim 8, wherein the at least one alkyl alcohol is produced from FPP in a single or multiple enzymatic steps.
10. The method of claim 9, wherein the at least one alkyl alcohol is produced by enzymatic conversion of FPP, catalyzed by: a) a polypeptide having a terpene synthase activity for forming the terpene alcohol; or b) A combination of a polypeptide having an aminoalkyl phosphate synthase activity that forms at least one aminoalkyl phosphate intermediate and a polypeptide having a phosphatase activity that converts the at least one aminoalkyl phosphate intermediate into at least one aminoalkyl alcohol.
11. The method according to claim 10, wherein: a) the polypeptide having silymarin synthase activity is selected from polypeptides having silymarin synthase activity, silymarin synthase activity, bicyclofarnesol synthase activity or any combination of these activities; and b) The combination of polypeptides comprises an alkyl diphosphate synthase activity and a phosphatase.
12. The method according to claim 11, wherein the alkyl diphosphate synthase activity is pyrrolyl diphosphate synthase activity.
13. The method according to claim 11, wherein the terpene synthase is selected from: a) a polypeptide having zygophyll synthase activity and an amino acid sequence of SEQ ID NO: 5; or b) a polypeptide having safflower oil synthase activity and an amino acid sequence of SEQ ID NO:
7.
14. The method of claim 1, which is performed in vivo in cell culture or in vitro in a liquid reaction medium, each under conditions favorable for the production of at least one alkyl acetate.
15. The method according to claim 14, which is carried out in a recombinant host cell or a recombinant non-human host organism capable of functionally expressing: a) at least one acetyltransferase as defined in claim 1; b) at least one polypeptide having the ability to convert an acyclic sesquiterpene precursor FPP into at least one succinic acid alkyl alcohol as defined in any one of claims 8 to 13; and / or c) at least one enzyme selected from enzymes involved in the mevalonate pathway.
16. The method of claim 15, wherein the non-human host cell or host organism is selected from a prokaryotic or eukaryotic microorganism.
17. The method of claim 16, wherein the non-human host cell or host organism is selected from bacteria, fungi and plant cells or plants.
18. The method according to claim 1, further comprising, as step (3), treating the alkyl acetate of step (1) or step (2) using chemical or biocatalytic synthesis or a combination of both to obtain a derivative.
19. The method of claim 1, comprising providing to a non-human host organism or host cell: a) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide having acetyltransferase activity, which polypeptide is capable of transferring an acetyl group from an acetyl donor to an alkyl alcohol; b) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide having safranol synthase activity, which polypeptide is capable of producing safranol from an acyclic sesquiterpene precursor; and / or c) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide involved in a biosynthetic pathway for producing said acyclic sesquiterpene precursor.
20. The method of claim 19, wherein the nucleic acid in a), b) or c) is stably integrated into the genome.
21. The method of claim 1, comprising transforming a non-human host organism or host cell with: a) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide having acetyltransferase activity, which polypeptide is capable of transferring an acetyl group from an acetyl donor to an alkyl alcohol; b) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide having safranol synthase activity, which polypeptide is capable of producing safranol from an acyclic sesquiterpene precursor; and / or c) at least one nucleic acid comprising a nucleic acid sequence encoding at least one polypeptide involved in a biosynthetic pathway for producing said acyclic sesquiterpene precursor.
22. The method of claim 21, wherein the nucleic acid in a), b) or c) is stably integrated into the genome.
